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Introduction: Oral cancer has a poor prognosis due to late detection and the high risk 
of recurrence and development of secondary tumours at distant sites. This may be 
attributed to the fact that conventional anticancer therapy does not eradicate the 
cancer stem cells which are a subset of the tumour cell population characterised by 
unique properties including their capability for indefinite self-renewal, proliferation 
and differentiation to diverse heterogeneous cell lineages that form the bulk of the 
tumour. Moreover, they are highly tumourigenic, play a crucial role in invasion and 
metastasis and also have the ability to resist anticancer therapy. Identifying and 
isolating CSCs is considered an important step in order to study their biological 
characteristics accurately with the aim of subsequently targeting and eradicating them. 
CSCs isolation has previously been mainly based on the expression of specific 
markers or clonogenicity as well as the rapid adherence of such cells to ECM 
proteins.  
Aims: The purpose of this study to develop functional assays (adhesion and 
chemoresistance) to isolate CSCs from OSCC cell lines and investigate the stem cell 
characteristics of the sorted cells compared to unsorted cells. Additionally, we aimed 
to investigate the stability of the isolated phenotypes and determine whether the CSCs 
signal differently from non-CSCs to stromal cells (fibroblasts).  
Methods: Cancer stem cells were isolated from 2 different oral squamous cell 
carcinoma cell lines (H357 and SCC4) using 2 different functional assays on the basis 
of their rapid adherence to fibronectin (75µg/mL, 10 mins) and their resistance to 
conventional chemotherapy (15µM cisplatin for 24 hours). The stability of the early 
adherent phenotype was investigated by repeating the adhesion assay after incubation 
of the early adherent phenotype in culture for 48 hours. For the chemoresistant cells 
phenotype cells were treated with same dose of cisplatin for second time. The isolated 
cells by both functional assays were characterised by molecular assays (flow 
cytometry and qPCR) as well as functional assays (proliferation and colony forming 
assays). Moreover, the effects of CSCs on activation of normal oral fibroblasts 
(NOFs) into cancer associated fibroblasts (CAFs) was assessed by incubation of 
NOFs in low serum conditioned medium collected from both sorted and unsorted cells 
for 48 hours. The gene and protein expression of the activation markers alpha smooth 




immunofluorescence. In addition, an immunohistochemical study was performed to 
investigate the in vivo correlation between CSC markers (CD24 and CD44) and 
stromal marker (α-SMA) in patient samples of oral squamous cell carcinoma. 
Results: The isolated cells from both cell lines using both functional methods 
expressed highly significant levels of stem cell markers and stem associated genes 
(CD24, CD44 and CD29) compared to unsorted cells. In addition, the isolated cells 
showed low growth rate and high colony forming efficiency compared with unsorted 
cells. Moreover, the early adherent phenotype of the both tested oral cancer cell lines 
showed a continuation of rapid adherence to fibronectin after incubation in culture for 
48 hours. Similarly, chemoresistant cells showed higher significant growth rate 
compared to unsorted cells following a second exposure to chemotherapeutic drug. 
The early adherent cells showed chemoresistance levels significantly higher than 
unsorted as well as chemoresistant cells being more rapidly adherent to fibronectin 
than unsorted cells. Expression of both α-SMA and IL-6 genes was increased in NOFs 
by 2-3 fold as a result of exposure to either H357 or SCC4 CSCs conditioned medium 
when compared to unsorted OSCC cells. Increased levels of α-SMA protein staining 
were also observed. Furthermore, immunohistochemical analysis revealed a positive 
correlation between the expression of CSC markers (CD24 and CD44) and an 
activated fibroblast marker (α-SMA) in the tumour microenvironment of oral 
squamous cell carcinoma patient samples.  
Conclusions: Our data suggests that rapid adherence to fibronectin and chemo-
resistance to cisplatin effectively isolate the same sub-population of cells from cell 
lines which show stem cell like characteristics. Factors released by CSCs can 
specifically activate fibroblasts and the in vivo correlation between CSCs and 
activated stromal fibroblasts in oral squamous cell carcinoma suggests that one of the 
mechanisms by which CSCs drive tumour progression is through their activation to 
the fibroblasts in the tumour microenvironment. 
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1.1 Normal stem cells (SCs) 
Stem cells are uncommon, immortal cells that have the capability to preserve 
themselves by self-renewal as well as differentiation to specialized cells of a specific 
tissue (Reya et al., 2001). They are present in various somatic tissues and are 
considered crucial contributors to the physiology of these tissues and the maintenance  
of homeostasis (Jordan, Guzman and Noble, 2006), through cell repair (Soltysova, 
Altanerova and Altaner, 2005). 
 
1.1.1 Characteristics of stem cells 
Stem cells have 3 distinguishing features that make them unique, which are: 
1. The ability of self-renewal (in other words, during cell division at least one of 
daughter cells maintains the same biological properties of the parent cell). 
2. The ability to differentiate to diverse cell lineages. 
3. The capability to proliferate continuously (Jordan, Guzman and Noble, 2006). 
 
1.1.2 Patterns of spatial ordering of stem cells and their progeny in 
oral epithelium 
Tissue renewal of the epithelial layer that covers the oral mucosa depends mainly on 
the epithelial stem cells (Iglesias-Bartolome, Callejas-Valera and Gutkind, 2013) 
which are located chiefly in the basal cell layer of the stratified squamous epithelium. 
Therefore, cell division occurs primarily in this layer (Baccelli and Trumpp, 2012). 
The function of stem cells in preserving the structure of the epithelium requires a 
proliferative hierarchy with a specific spatial ordering. In this hierarchal model the 
stem cell situated at the apex divide either asymmetrically or symmetrically 
(González-Moles et al., 2013), as shown in figure (1.1). Asymmetrical division of 
stem cell will give rise to one stem cell and one transit amplifying cell (TAC), which 
has the ability to divide 3-5 times until all daughter cells terminally differentiate. The 
main function of the TACs is to increase the number of differentiated cells due to the 
limited self-renewal capacity of these cells in comparison with stem cells (González-
Moles et al., 2013). 
On the other hand, symmetrical division of stem cells generates either two TACs 
accompanied by loss of the parent stem cell or two stem cells which retain properties 
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of the parent cell. However, symmetrical division only occurs during recovery of lost 
basal stem cells populations as a result of disease or trauma (Mackenzie, 2006) or in 
early embryonic development (Soltysova, Altanerova and Altaner, 2005). 
 
 
Figure 1.1: Concept of stem cell hierarchy in human oral mucosa. 
 
1.1.3 Types of stem cell 
Embryonic stem cells (ESC): are omnipotent cells which are derived from the inner 
cell mass of the blastocyst. They are considered to be original source of all cells in an 
organism. Furthermore, they can differentiate to all cell types and generate cells 
which produce different organs through the differentiation process (Thomson et al., 
1998). 
Somatic adult stem cells: are immortal cells that reside in various adult tissues. 
These cells are pluripotent and they continue their biological function throughout the 
organism lifespan with a more restricted and regulated process of self-renewing. 
Moreover, there are different types of somatic stem cells that vary in their 
proliferation and differentiation potential according to the type host tissue. The main 
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function of these cells are in the renewal of aged tissue and repair of damaged tissues 
as well as their ability to differentiate into various lineages (Soltysova, Altanerova 
and Altaner, 2005).  
Germinal stem cells: The main function of these specialized cells in adult are 
production of sperms and eggs (Soltysova, Altanerova and Altaner, 2005). 
 
1.1.4 Normal stem cell niche  
The stem cell niche is a specialized microenvironment that forms an indefinite home 
for one or more stem cells. It is composed of tissue cells and extracellular substrates 
that regulate the function of these stem cells in maintaining tissue homeostasis and 
repairing of damaged tissue (Spradling, Drummond-Barbosa and Kai, 2001), as 
shown in the figure (1.2). 
Adult stem cells rely on their niche in supporting and supplying them with the 
required signals to control their proliferation and differentiation processes. There is a 
critical balance between these two opposing processes which play a crucial role in 
prevention of tumourigenesis or depletion of the stem cell pool (Li and Neaves, 
2006). 
 
Figure 1.2: Stem cell niche structure, adapted from (Spradling, Drummond-   
Barbosa and Kai, 2001). 
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1.2 Cancer stem cells (CSCs)    
A small subpopulation of tumour cells have some properties of normal stem cells of 
the tissue from which the tumour originated from (Maccalli et al., 2014) which 
include their capability for indefinite self-renewal and differentiation to diverse 
heterogeneous cell lineages that form the bulk of the tumour (Reya et al., 2001). In 
addition, cancer stem cells have unique features such as tumourigenicity and have 
ability to initiate a tumour similar to the original one when they are transplanted to 
immune deficient animals (Prince and Ailles, 2008). CSCs are considered the most 
resistant cells in a tumour to conventional anticancer therapy which kill most of the 
differentiated cancer cells causing shrinkage of tumour except these cells that remain 
survive and resume growth after cessation of treatment causing subsequent tumour 
relapse (Vermeulen et al., 2012). Moreover, these cells play a significant role in 
invasion and metastasis (Campbell and Polyak, 2007).  
 
1.2.1 Cancer stem cells theories  
 
There are two contradictory theories which attempt to explain the initiation and 
formation of a tumour:  
1. The stochastic or clonal theory is the oldest theory and proposes that a tumour 
arises from mutation of a single normal stem cell giving rise to a neoplastic 
clone and subsequent a tumour that composed of a homogeneous population 
of neoplastic cells that all have the same tumourigenic potential (Wang and 
Dick, 2005).   
2. The hierarchical model theory is considered as the most recent theory and 
proposes that the tumour consists of heterogeneous cell lineages and only a 
minor subset of cells within it have the ability of tumour initiation and driving 
the growth of the tumour. These are referred to as cancer stem cells or tumour 
initiating cells (Wang and Dick, 2005). However, the majority of tumour mass 
consists of transit amplifying cells which are rapidly proliferating and post 
mitotic differentiating cells. Both TACs and differentiated cells are derived 
from cancer stem cells and can not themselves initiate of tumour 
(Krishnamurthy and Nor, 2012). 
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1.2.2 Origin of cancer stem cells 
 
The precise origin of CSCs until now remain unclear but there are 3 hypotheses 
(figure 1.3) that could explain the origin of cancer stem cells: 
1. Malignant transformation of normal adult somatic stem cells to cancer stem 
cells due to accretion of epigenetic and genetic changes (mutations) that lead 
to loss of their self-regulation of cell proliferation (Smalley and Ashworth, 
2003). This hypothesis is supported by the fact that normal stem cells have the 
longest life-span among all body cells and mutations that lead to 
transformation of cells is a very slow process requiring a prolonged time, often 
decades. On the other hand, it is known that cancer stem cells share 
characteristics of normal stem cells such as self-renewal and differentiation. 
Whereas, other somatic cells require further mutations to acquire these 
properties (Islam, Qiao, et al., 2015). 
2. Cellular de-differentiation of progenitor cells or fully differentiated mature 
tumour cells due to mutations that leads to the reacquisition of cancer stem 
cell properties (Krivtsov et al., 2006). The de-differentiation process is 
directly linked to epithelial-mesenchymal transition (EMT) (Mani et al., 
2008). EMT provides differentiated mature cancer cells with stemness 
characteristics such as self-renewal and tumourigenicity capabilities that 
allowing them to generate a tumour at a distant site by metastasis (Qian et al., 
2012). Furthermore, invasive cancer cells express both EMT and stemness 
associated genes (Spaderna et al., 2007). 
3. Recently, it has been shown that pluripotent stem cells can be induced from 
non-pluripotent somatic cells in vitro leading to expression of specific genes 
which subsequently cause reprogramming of these cells via transduction of 
specific transcriptional factors such as OCT3/4, Sox2, c-Myc and Klf4 
(Takahashi and Yamanaka, 2006). The reprograming process that leads to 
induced pluripotency and formation of iPS cells similar to the oncogenic 
transformation process which leads to transformation of somatic stem cells to 
CSCs (Nishi et al., 2014). 
 
 




Figure 1.3: Origins of cancer stem cell 
 
 
1.2.3 Regulation of cancer stem cells 
  
1. Signalling pathways  
 
Self-renewal and differentiation of normal stem cells maintain tissue homeostasis via 
strictly controlled signalling pathways. However, CSCs share normal stem cells 
pathways but with aberrant activation or dysregulation that leads to tumourigenesis. 
These signalling pathways are: Wnt /β-catenin, Notch and the hedgehog pathway 
(Reya et al., 2001) (figure 1.4) that initiate multiple regulatory networks involved in 
cytokine production in cancer stem cell niche which controls the self-renewal and 
differentiation of cancer stem cells and subsequent tumour progression (Reya and 
Clevers, 2005).  
The Wnt signalling pathway has a significant role in control of stem cell function 
through regulation of self-renewal and driving of their symmetrical division (Le 
Grand et al., 2009). Furthermore, it has been reported that overexpression of this 
pathway results in de-differentiation of terminally differentiated cells as well as 
mature cancer cells (Radulescu et al., 2013). 
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Wnt-target gene activation is mediated by β-catenin. This process involves entrance of 
β-catenin to the nucleus from the cytoplasm. It then cooperates with the transcription 
factor TCF/LEF leading to activation of Wnt-target genes such as: c-Myc, cyclin D1 
and c-Jun (Katoh and Katoh, 2007). On the other hand, it has been identified that 
aberrant activation of the Wnt signalling pathway has a crucial role in resistance to 
anticancer therapy resistant. Subsequently, inhibition of β-catenin transcriptional 
activity is considered an important target in cancer treatment that results in 
suppressing of tumour growth (Dean, Fojo, and Bates, 2005).  
The Notch signalling pathway has been considered as one of key pathways controlling 
proliferation and differentiation of embryonic and normal adult somatic stem cells 
(Bray, 2006). However, deregulation of this pathway results in expansion of early 
progenitor cells and various stem cells (Chiba, 2006). There are 4 types of Notch 
receptors (Notch 1-4) that have been identified, each one is a non-covalent 
heterodimer composed of intracellular, transmembrane and extracellular domains. 
Notch ligands are 2 families: Jagged-like (JLL1/2) and Delta-like (DLL1/3/4). 
Conformational change in the Notch receptor as a result of binding to its ligand leads 
to access of a disintegrin and metalloproteinase (ADAM) protein resulting in Notch 
cleavage followed by another cleavage by γ-secretase which results in release of the 
Notch intracellular domain (NICD) from the cell membrane which translocates to the 
nucleus. In the nucleus Notch target gene transcription is induced as a result of an 
interaction of the NICD with DNA binding proteins (the transcriptional regulators 
include CSL and the Mastermind-like (MAML) family) (Bray, 2006). HES and HERP 
gene families are considered the most common primary target genes of Notch 
signalling pathways (Iso, Kedes and Hamamori, 2003). 
The Hedgehog pathway organises development of organisms through regulation of 
embryonic stem cells (ESCs), as well as control of the expansion of progenitor and 
stem cells (Zhao, Li and Guan, 2010). Activation of this pathway is initiated via 
binding of the Shh ligand to the Patched receptor, which activates the receptor (SMO) 
leading to induction of a signalling cascade which in turn activates the GLI 
transcription factors. As a result, Shh target gene expression is initiated which 
influences cellular proliferation and angiogenesis (Merchant and Matsui, 2010).   
 
 













Figure 1.4: Diagrams illustrating signalling pathways regulating CSCs (A) Wnt/ 
β-catenin (B) Notch (C) Hodgehog pathways. 
 
2. miRNA regulation of cancer stem cells  
MicroRNAs (miRNAs) are short non-coding RNA molecules which regulate gene 
expression by targeting the mRNAs either through translational repression or 
controlled cleavage (Bartel, 2004). MiRNAs are considered as epigenetic factors that 
participate in tumour progression, anticancer therapy resistance and acquisition of 
CSCs characteristics (Ji et al., 2009), as well as induction of EMT and subsequent 
promotion of metastasis (Song et al., 2013). Furthermore, miRNAs play an important 
role in the control of CSCs functions such as self-renewal, differentiation and 
tumourigenesis and stimulate expansion of cancer stem cells through regulation of 
cytokines and chemokines which are produced by cells of the cancer 
microenvironment (niche) (Yu et al., 2012). Literature suggested that miR-21 and 
miR-205 are common putative oncogenes that are overexpressed and play important 
roles in progression of oral cancer (Jiang et al., 2005; Tran et al., 2007; Chang et al., 
2008; Carolina, Gomes and Gomez, 2008).  
 
3. Telomerase reactivation 
Telomerase is a reverse transcriptase enzyme which is responsible for the addition of 
terminal repeats to the 3’ end of telomeres which are required for cell division 
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(Allsopp et al., 2003). Shortening of telomeres causes instability of chromosome, 
fusion and finally senescence (Counter et al., 1992). Therefore, it has been reported 
that the capacity of cancer stem cells for prolonged self-renewal can be partly 
attributed to the reactivation of telomerase (Allsopp et al., 2003). 
 
 
1.2.4 Cancer stem cells and treatment resistance  
 
CSCs play an important role in initiation of cancer when transplanted to immune 
deficient animals; they are also responsible for recurrence and the relapse of the 
tumour after chemo or radiotherapy due to their crucial role in resistance to anticancer 
treatment (Yu et al., 2012). It has been identified that CSCs have an endogenous 
intrinsic resistance against all conventional anticancer therapies (Bao et al., 2006), i.e. 
CSCs possess resistance even if the medications have never been applied against a 
specific tumour previously (Schmidt and Efferth, 2016). As a result, conventional 
therapies eradicate all cells within a tumour except CSCs (Dallas et al., 2009) (figure 
1.5).  
CSCs have many mechanisms to protect themselves against destruction and making 
them resistant to therapeutic chemicals (Takaishi et al., 2009), which include:  
  
1. Aberrations in apoptotic mechanisms  
It has been reported that CSCs can avoid the programmed cell death that is normally 
initiated by conventional anticancer therapy by many mechanisms, such as elevation 
of the apoptosis induction threshold through increase in the expression of anti-
apoptotic proteins, such as the Bcl-2 family of proteins (Madjd et al., 2009). In 
addition, mutation or inactivation of genes that induce apoptosis as well as cell cycle-
regulating genes, for instance p53 gene and its isoforms p63 and p73. Therefore, when 
the function of p53 gene is lost this promotes EMT via Snail expression and as a 
consequence increases the therapy resistance (Kim et al., 2011). 
 
2. Elevated expression or high activity of cell membrane transporters (ABC 
transporters)  
CSCs express increased levels of ATP-binding cassette transporter proteins (ABC 
transporters) which utilize ATP in the translocation of substances such as fat, drugs 
and metabolic products across the cell membrane. Therefore, they decrease the 
intracellular levels of the chemotherapeutic agents in CSCs via efflux of drugs outside 
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the cell membrane (Fletcher et al., 2010). Although the family of ABC transporters 
involves 49 proteins, only 3 of them are well-characterised as multi-drug resistance 
regulators in tumours which include ABCB1, ABCC1 and ABCG2 (Vasiliou, 
Vasiliou and Nebert, 2009). 
 
3. Intracellular detoxification enzymes  
The aldehyde dehydrogenase enzyme family are considered the most important 
detoxification enzymes in CSCs and oxidise intracellular aldehydes to carboxylic 
acids leading to synthesis of γ-amino butyric acid and retinoic acid that have an 
important roles in maintaining and differentiating of CSCs (Ma and Allan, 2011). In 
addition, high activity of ALDH enzymes allow CSCs to metabolize and detoxify 
various chemotherapeutic agents and their intermediate products, such as 
cyclophosphamide, ifosfamide, and mafosfamide (Parajuli, Fishel and Hurley, 2014). 
The detoxification process of chemotherapeutic drugs involves 3 stages. The first 
stage consists of removing OH and free radical species following transformation to 
create low toxin metabolites. In the last stage the drug or toxin is pumped outside the 
cell via membrane channels (Signore, Ricci-Vitiani and De Maria, 2013). It has been 
reported that high expression of the aldehyde dehydrogenase enzyme ALDH1 in a 
tumour is a predictor of poor prognosis (Ginestier et al., 2007).  
 
 
4. Cancer stem cell quiescence  
Quiescence is a physiological mechanism by which normal stem cells protect 
themselves from harmful insults by preventing the exhaustion of their division 
potential (Maugeri-Saccà, Zeuner and De Maria, 2011). Cancer stem cell quiescence 
has a significant role in their resistant to treatment based on the fact that the highly 
proliferating cells within a tumour are targeted mainly by conventional anticancer 
therapy as a selective mechanism to avoid the non-proliferating normal cells in the 
body. Whereas, CSCs are usually dormant and proliferate slowly and thus are largely 
resistant to such therapies (Roesch et al., 2010).  
 
5. Enhanced DNA repair response 
Many anticancer therapies induce tumour cell death by causing DNA damage through 
mechanisms such as: crosslinking of DNA, inhibition of DNA synthesis and 
inhibition of topoisomerase. If the DNA damage is not repaired, it will be fatal to the 
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cells (Cheung-Ong, Giaever and Nislow, 2013). However, the highly active DNA 
repair pathways of CSCs allow them to repair DNA damage effectively. 
Subsequently, they survive and avoid the effects of therapy (Colak and Medema 
2014). The DNA repair process of CSCs include over expression of  genes that are 
involved in  DNA damage response systems such as Brca1, Nek1, Hus1, Chek1, Ung, 
Sfpq, Uhrf1and Xrcc5 (Zhang et al., 2008). Moreover, activation of cell cycle 
checkpoints (kinase signalling pathways) which inhibit progression of the cell cycle 
that allows DNA compensation (Niida and Nakanishi, 2006). 
 
6. Autophagy 
Autophagy is a mechanism by which CSCs resist insults from the microenvironment 
such as starvation, treatment or hypoxia by using energy from alternative sources 
through activation of catabolic processes that preserve cell viability and metabolic 
homeostasis. This mechanism involves intracellular degradation and recycling. 
Proteins and organelles are sequestrated in autophagosomes which fuse with 
lysosomes forming an autolysosome the contents of which are then degraded by 
lysosomal enzymes resulting in delivery of amino acids and energy (Kroemer, Mariño 
and Levine, 2010). Recently, it has been reported that CSCs utilise the cytoprotective 
influences of autophagy in inducing resistance to anticancer therapies in many types 
of tumour (Ma et al., 2014).   
 
7. Reactive oxygen species (ROS) scavenging  
Reactive oxygen species (ROS) are normal metabolism by-products of oxygen and 
are considered to be a major cause of apoptosis triggered by chemo and radiotherapy 
(Shi et al., 2012). Radiotherapy leads to extensive production of intracellular ROS 
that cause toxicity through modification of vital cellular components like DNA, 
protein and lipid resulting in cell death (Cook et al., 2004). CSCs have high activity of 
ROS scavengers. Therefore, they are able to keep lower intracellular levels of ROS 
than non-CSCs (Phillips, McBride and Pajonk, 2006). The ROS scavenging system of 
CSCs include increased expression of antioxidant enzymes, for instance peroxidase, 
catalase and superoxide dismutase (Chang et al., 2014). 
 
 




It has been identified that the usual location of CSCs in a tumour is near to hypoxic 
zones (Simon and Keith, 2008). Therefore, hypoxia is thought to participate in  
maintaining CSCs self-renewal as well as inducing of EMT (Das et al., 2008). At low 
levels of oxygen, the hypoxia response is initiated through activation of hypoxia –
inducible factor 1 alpha (HIF1α), which is then translocated into the nucleus and 
dimerizes with HIF1β leading to activation of transcription of hypoxia response genes 
(Semenza, 2004). More than 60 response genes have been identified which activate 
survival signalling pathways for proliferation as well as promotion of angiogenesis to 
provide oxygen (Michiels, 2004). The role of hypoxia in therapy resistance is 
attributed to activation of stem related signalling pathways and promotion of 
quiescence. Therefore, expression of both Wnt, Notch and Hedgehog signalling 
pathways and stemness markers such as c-MET, NANOG and SOX2 are induced via 
activation of HIF1α (Majmundar, Wong and Simon, 2010). However, CSC 
quiescence is induced as a result of unfavourable conditions for cell proliferation such 
as limitations of nutrients and reduction of oxygen that occurs during hypoxia 
(Almog, 2010).   
 
9. Epithelial mesenchymal transition (EMT).  
EMT is a process of changing of the polarity and epithelial phenotype of epithelial 
tumour cells to a mesenchymal, fibroblast-like phenotype, which results in the loss of 
epithelial integrity and increased of migration and subsequent local invasion and 
metastasis (Thiery, 2002). It has been reported that anticancer resistance is enhanced 
in CSCs undergoing EMT at the same time in response to specific pathways such as 
the TGF-β pathway (Sarrio et al., 2012). 
 
10. MicroRNA deregulation  
It has been reported that deregulation of specific microRNAs have a role in promoting 
the CSCs phenotype and acquiring resistance to anticancer therapy as a consequence 
(MacDonagh et al., 2015).   
  




Figure 1.5: Effects of conventional anticancer therapy on tumour progression. 
 
1.2.5 Cancer therapy targets 
1. Signalling pathways inhibition 
Inhibiting CSC self-renewal and proliferation signalling pathways,  such as Wnt, 
Notch and Hedghog  pathways are considered to be one way to target CSCs (Kim, 
Jeon and Kim, 2014). The Wnt pathway can be targeted by blocking the transcription 
of Wnt targeting genes using biological inhibitors or small molecule antagonists (Fujii 
et al., 2007). These include small interfering RNA (siRNA), monoclonal antibodies, 
non-steroidal anti-inflammatory drugs such as Sulindac which target β-catenin (Boon 
et al., 2004), and small molecule antagonists like FJ9 that target Dvl (Fujii et al., 
2007). Moreover, Notch signalling can be directly targeted using γ-secretase 
inhibitors which prevent enzymatic cleavage of Notch and NICD release (Mizugaki et 
al., 2012; Leon et al., 2016). The Hedgehog pathway can also be targeted by 
inhibiting either the SMO receptor or inhibition of the Gli transcription factor (glioma 
associated oncogene homolog) (Ng and Curran, 2013). Although blocking and down-
regulating signalling pathways is considered an effective approach for CSCs 
targeting, they may have negative impacts on normal stem cells. Therefore, these 
approaches should be modified to improve their specificity (Han et al., 2013).  
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2. CSC induced apoptosis 
Another therapeutic approach would be to shift the apoptotic balance towards a more 
pro-apoptotic state by inhibiting anti-apoptotic proteins (Colak et al., 2014). For 
instance,  induction of apoptosis in CSCs in some tumours due to over-expression of 
tumour necrosis factor-related apoptosis (TRAIL) which is a pro-apoptotic protein 
and inhibition of NK-kB which is an anti-apoptotic transcription factor (García et al., 
2012). 
 
3.  Inhibition of ABC transporter 
Targeting ATP-binding cassette transporters and drugs efflux pumps in CSCs would 
subsequently reduce the clearance of chemotherapeutic drugs (Papagerakis et al., 
2014). Verapmil is an example of general inhibitor for ABC transporters that 
increased the chemo-sensitivity of CSCs (Loebinger et al., 2008). 
 
4. Targeting of CSC surface markers 
Although surface markers have been widely used in detection and identification of 
CSCs, they also provide a strategy to target these cells (Leon et al., 2016). Therefore, 
antibody based therapies which include immunotoxins that are directed to CSCs 
markers specifically have been proposed (Swaminathan et al., 2013). 
 
5. Targeting of CSC quiescence 
This was performed by enhancing proliferation in order that they respond to 
conventional therapy (Colak et al., 2014). Sensitivity to anticancer therapies could be 
restored by inducting quiescent CSCs to enter the cell cycle. Cytokines such as 
granulocyte-colony stimulating factor (G-CSF) and interferon-α (IFNα) play a key 
role in the promotion of dormant CSCs cycling (Essers and Trumpp, 2010). 
 
6. Inactivation of DNA damage repair mechanisms 
It has been investigated that a potential therapy was obtained using agents that 
interfere or block the mechanisms of DNA repair such as Poly (ADP-ribose) 
polymerase (PARP) and DNA-dependent protein kinase (Veuger et al., 2003). In 
addition, inhibition of checkpoint kinases (Chk1 and Chk2) by specific inhibitors 
enhanced the blocking of  DNA repair mechanisms (Reinhardt and Yaffe, 2009). 
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7. Targeting of the CSC niche (microenvironment) 
CSCs depend on their interaction with the tumour niche for their survival, self-
renewal, differentiation and tumourigenesis. Therefore, blocking stromal signalling 
systems in the CSCs niche (Ma et al., 2013), as well as disruption and interfering with 
the prevasculature niche may represent other possible cancer therapy routes 
(Krishnamurthy et al., 2010). 
 
8. MicroRNA expression manipulation 
It has been reported in several tumours that miRNAs act as tumour suppresser genes 
which target and down-regulate many oncogenes such as miRNA-34a that target 
Notch-1, Notch-2, c-Met and CDK6 (Guessous et al., 2010). Thus, manipulation of 
miRNA may represent another strategy to target CSCs. 
 
9. Targeting the hypoxic conditions of the tumour microenvironment  
Inhibition and inactivation of hypoxia inducible factor 1-α (HIF1α) is considered a 
key factor in increasing oxygen levels and targeting hypoxia in the tumour 
microenvironment. Furthermore, it has been shown that LY294002 and rapamycin are 
the most common HIF1α inhibitors (Zhong et al., 2000). 
 
10. Inhibiting the activity of detoxification enzymes 
Aldehyde dehydrogenase enzymes (ALDH) can be blocked by specific inhibitors such 
as diethylaminobenzaldehyde (DEAB) and/or all-trans retinoic acid (ATRA) which 
lead to increased sensitization of CSCs to anticancer therapies (Croker and Allan, 
2012). 
 
11. Induction of CSCs differentiation 
This approach of treatment involves forcing CSCs to terminal differentiate and 
therefore lose their ability to self-renewal. Anticancer differentiation treatment 
includes 2 group of drugs: First, retinoic acid (vitamin A and retinoid), and secondly 
drugs that are directed against tumour epigenetic changes such as all-trans retinoic 
acid (ATRA), suberoylanilide hydroxamic acid (SAHA) and Histone deacetylase 
(HDAC) inhibitors (Massard, Deutsch and Soria, 2006). 
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However, several therapeutic approaches have been suggested to target CSCs and 
most of them currently are the research phase. Targeting of self-renewal and 
proliferation signalling pathways of CSCs are entering clinical trial phases followed 
by targeting of stromal signalling pathways in CSCs microenvironment to a lesser 
extent (Liu and Wicha, 2010; Takebe et al., 2015). 
 
1.3 Oral cancer 
1.3.1 Prevalence 
Oral cancer is considered to be the eighth most common around the world (Amit et 
al., 2013). Oral squamous cell carcinoma represents about 90% of oral cancers and 
there are about 300,000 new cases diagnosed worldwide every year (Ferlay et al., 
2015). The tongue is considered as the most common site for oral cancer followed by 
the floor of mouth, while other intra-oral sites such as gingiva, buccal mucosa, labial 
mucosa and hard palate are less common sites (Boffetta et al., 2008). Despite 
advances in diagnosis and treatment methods of oral cancer over the last few decades, 
there has been no significant improvement in patient prognosis. Furthermore, the 
survival rate of patients with oral cancer remains very low with less than 50% survival 
after 5 years because of late detection and the high risk of recurrence and 
development of a second primary tumour. This survival rate has remained largely 
unchanged over the last 50 years (Tanaka et al.,  2011).  
 
1.3.2 Risk factors 
There are many risk factors which play a significant role in oral tumorigenesis either 
independently or synergistically (Tanaka et al.,  2011), which include: 
1. Tobacco 
Tobacco consumption in all its forms whether smoked, chewed or taken as snuff is 
considered an important traditional oral carcinogen in adults (Llewellyn, Johnson and 
Warnakulasuriya,  2001). It has been reported that 1/4 of oral cancer cases due to 
cigarette smoking (Hashibe et al., 2007). Furthermore, it has been identified that 
cigarette smoke contains more than 60 carcinogens. Tobacco-specific nitrosamines, 
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polycyclic aromatic hydrocarbons and aromatic amines are the most important 
carcinogens present in cigarette smoke and are considered causal factors linked with 
oral cancer (Hecht, 2003). The association between oral cancer and cigarette smoking 
is dose dependent, i.e. the risk of developing oral cancer rises proportionally with the 
number of cigarettes smoked daily and duration of smoking (Hashibe et al., 2007). 
 
2. Alcohol 
Heavy alcohol drinking is considered the main cause of about 7-19% of oral cancer 
cases (Hashibe et al., 2007). It has been reported that the incidence of oral cancer 
among heavy drinkers is 2-3 fold higher than non-drinkers (Seitz and Stickel, 2007). 
Alcohol is metabolised by alcohol dehydrogenase (the major alcohol metabolising 
enzyme) which oxidises ethanol to acetaldehyde which is considered an oral 
carcinogen that accumulates in the oral mucosa of heavy drinkers with consequent 
production of DNA adducts (Baan et al., 2007; Seitz and Stickel, 2007). In addition, 
alcohol exerts other carcinogenic effects through several suggested mechanisms. First, 
alcohol may act as solvent to facilitate penetration of other carcinogens through 
cellular membranes of targeted tissues. Second, ethanol may activate carcinogenic 
substances by stimulating liver metabolism. Third, it may alter the intracellular 
metabolism of epithelial cells in the target tissue (Llewellyn, Johnson and 
Warnakulasuriya,  2001). 
 
3. Betal quid  
Chewing of betal quid has damaging effects on the oral mucosa either through direct 
initiation of tumour inducing mutations or by rendering the mucosa susceptible to 
environmental poisons (Merchant et al., 2000). 
 
4. Viral infection 
There are two types of viruses have been implicated in oral carcinogenesis which are 
Human papilloma virus (HPV) and Epstein-Barr virus (EBV) (Llewellyn, Johnson 
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5. Immune deficiency 
As a result of the increased incidence of oral cancer in immune deficient people. It is 
considered a predisposing factor for oral cancer in young individuals. For instance, 
human immune deficiency virus infection (HIV infection), Wiskott-Aldrich 
syndrome, Bloom syndrome, Plummer Vinson syndrome and immunosuppression 
regimes after organ transplantation (Scully et al., 1991; Streilein, 1991; Varga and 
Tyldesley, 1991). 
 
6. Familial and genetic factors  
 It has been increasingly evident that oral cancer development has a familial and 
genetic predisposition especially in young people with no other associated risk 
factors. There is a significant increase in fragility of chromosomes after exposure to 
mutagens in some individuals compared to old people. The chromosomal fragility 
might result in genetic abnormalities (e.g. alterations of DNA repair genes such as 
XRCC1 and XRCC3 repair genes) in tobacco smoking young adults which may 
contribute to the development of head and neck oral cancer (Kostrzewska-Poczekaj et 
al., 2013).  
 
7. Diet 
Several epidemiological studies have been suggested that the diet play a role in the 
development of oral cancer. High levels of vitamins and antioxidants found in  
vegetable and fruits may have a protective role against oral cancer (Negri et al., 
2000). On the contrary, food riche with animal fat, animal protein, cholesterol and 
saturated fatty acids may be increasing the risk of oral cancer (Bravi et al., 2013).  
 
 
1.3.3 Tumorigenic process 
Oral cancer arises as a consequence of many molecular events which may occur due 
to the combined effects of exposure to environmental carcinogens and an individual’s 
genetic predisposition (Califano et al., 1996). These events include damage of 
individual genes and genetic material due to chronic exposure to carcinogens. 
Accumulation of genetic alterations such as mutations, oncogene amplification and 
tumour suppressor genes inactivation will result in the formation of a premalignant 
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lesion and subsequent carcinoma. Therefore, the tumour cells will acquire 
autonomous self-sufficient growth and elude the inhibitory growth signals leading to 
immortalization due to telomere lengthening and subsequently result in uncontrolled 
progression of tumour. In addition, endothelial cells are stimulated to create new 
blood vessels (angiogenesis) which have an essential role in progression of solid 
tumour (Hanahan and Weinberg, 2000).  
 
1. Acquisition of self-sufficient growth 
Proliferation of normal cells requires exogenous signals provided by growth factors. 
These factors usually interact with the extracellular matrix (ECM) and cytokines 
(Hanahan and Weinberg, 2000). These signals are transduced from cell surface-
receptors leading to activation of many intracellular pathways and subsequent 
stimulation of cell proliferation (Todd et al., 1991). In oral carcinogenesis, there is a 
dysregulation of growth factor signalling due to increased levels of receptor and/or 
growth factors ligands, which enhances autocrine stimulation in the absence of 
exogenous factors and results in tumour progression (Grandis and Tweardy, 1993). 
The growth factors include: epidermal growth factor (EGF), hepatocyte growth factor 
(HGF) and activating protein-1 (AP-1) (Choi and Myers, 2008). 
 
2. Abnormalities in growth-inhibitory signals 
During oral carcinogenesis, the expression of cell cycle inhibitory proteins encoded 
by tumour suppresser genes is lost. In normal cells, there is tight regulation of the 
growth inhibitory signals by the interaction of cyclin-dependent kinases (CDK), 
cyclins, and the product of the retinoblastoma (Rb) gene. In addition, other inhibitors 
of cell-cycle progression are proteins encoded by the tumour suppressor genes p16, 
p15, p21, and p53 (Choi and Myers, 2008). 
 
3. Evasion of Apoptosis 
Apoptosis is a tightly regulated physiologic cellular mechanism for programmed cell 
death to eradicate the altered or senescent cells which become harmful or useless and 
is considered to have crucial role in cell homeostasis (Williams, 1991) . 
In normal cells, apoptosis is controlled by the Bcl-2 family of regulatory proteins 
which consist of about 15 proteins and are divided into anti-apoptotic (Bcl-2, Bcl-XL) 
or pro-apoptotic (Bax, Bak) proteins. In carcinogenesis the expression of Bcl-2 family 
Chapter 1 Review of Literature  
22 
 
proteins is altered and leads to a change in the pro-apoptotic/ anti-apoptotic protein 
ratio. As a consequence, inhibition of apoptosis occurs resulting in promotion of 
tumour growth (Kroemer, 1997). Moreover, Popović et al., (1996) reported an 
enhance expression of anti-apoptotic proteins Bcl-2 and Bcl-XL in oral squamous cell 
carcinoma and oral dysplastic lesions. 
 
4. Immortalization 
Normal cells have a finite replication capacity and after certain number of cell 
divisions, they terminate proliferation and become senescent. On the contrary, the 
capacity of replication of tumour cells is unlimited and they become immortalized due 
to lengthening of their telomeres through expression of telomerase (Stewart and 
Weinberg, 2000). Several oral cancer studies have identified the overexpression of 
human telomerase reverse transcriptase (the protein catalytic subunit of telomerase) is 
an early event in oral carcinogenesis (Lee et al., 2001; Chen et al., 2007). 
 
5. Angiogenesis 
Growth of tumours beyond a certain size requires the formation of new blood vessels 
from pre-existing ones, which is achieved by shifting the balance of pro-angiogenic / 
anti-angiogenic factors (Folkman, 1990). The factors that regulate the angiogenic 
process are divided into pro-angiogenic signals such as vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), acidic and basic fibroblast 
growth factors (FGF1 and  FGF2), and IL-8 and the inhibitory signals which are the 
interferons, proteolytic fragments such as angiostatin and endostatin, and 
thrombospondin-1 (Choi and Myers, 2008). In addition, Tanigaki et al., (2004) found 
a significant correlation between overexpression of pro-angiogenic VEGF-C with 
local recurrence and distant metastasis in oral squamouse cell carcinoma.  
 
1.3.4 Invasion and metastasis 
Oral cancer is characterised by invasion of adjacent tissues as well as dissemination to 
cervical lymph nodes and distant sites (figure 1.6). Invasion and metastasis are 
considered a complex process involving many steps such as adhesion of cells, re-
organisation of the cell cytoskeleton, migration of cells, basement membrane 
dissolution, intravasation, survival of cells in the blood stream, extravasation and 
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growth at the distant site accompanied by neo-angiogenesis  (Chambers, Groom and 
MacDonald, 2002). In the first step of invasion, the motility and invasiveness of 
tumour cells will be increased, and it has been assumed that these events may be 
related to epithelial mesenchymal transition (EMT). Furthermore, polarity loss and 
motility acquisition require loss of cell to cell adhesion, cytoskeletal rearrangements 
and organelle redistribution including changes in gene expression profiles of tumour 
cells (Thiery, 2002). Alterations in expression of E-cadherin and integrins play a 
significant role in EMT and tumour invasion.  E-cadherin is cell adhesion molecule 
that maintains epithelial cell integrity through mediating cell to cell adhesions 
between normal mucosal cells. Therefore, changes in E-cadherin expression or 
activity leads to an alteration in the shape of cells and an increase their motility and 
invasiveness. Integrins are cell-surface receptors that binds the epithelial cells to the 
extracellular matrix (ECM). Alterations in integrin expression will alter cell 
attachment making cells more motile and invasive. In addition, local invasion requires 
dissolution and disintegration of basement membrane and modification of the ECM 




     Figure 1.6: Cancer invasion to adjacent tissue and distant metastasis.  
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1.3.5 Tumour microenvironment 
The tumour microenvironment is a complex system resulting from a crosstalk 
between various cell types and it plays a crucial role in cancer progression because it 
is considered as an essential regulator of carcinogenesis and angiogenesis. It is 
composed of invasive tumour cells and stromal elements which include fibroblasts of 
different phenotypes, ECM and inflammatory and immune cells as well as blood 
vessels, lymph vessels and nerves (Albini and Sporn, 2007) (figure 1.7). 
The most important stromal element is cancer associated fibroblast (CAF) which has a 
critical role in tumourigenesis and angiogenesis by providing a communication 
network. CAFs secrete chemokines such as CXCL12 which induce angiogenesis and 
also they secrete growth factors that induce altered ECM consequently providing 
further oncogenic signals that stimulate proliferation and invasion of cancer cells  
(Kalluri and Zeisberg, 2006).  Myofibroblasts are another important element which 
are activated when the integrity of tissue is compromised and invasion begins. They 
may increase growth and expansion of tumour via secretion of numerous growth 
factors, chemokines, cytokines, and ECM components (Shao, 2006). Other cellular 
components of tumour microenvironment which take part in tumour growth include: 
endothelial cells, adipocytes, smooth muscle cells, neutrophils, mast cells, 
lymphocytes, macrophages and dendritic cells (Albini and Sporn, 2007).  
There is also a variety of proteins secreted by tumour cells into the microenvironment 
which include growth factors and ECM degrading proteinases. These secreted 
proteins are implicated in cell adhesion, motility, cell-cell communication and 
invasion (Albini and Sporn, 2007). 
The ECM of microenvironment is remodelled and modified extensively by proteases 
particularly matrix metalloproteinases (MMPs) secreted from tumour and non-tumour 
cells which result in changes in cell to cell and cell to ECM interactions and the 
generation of new signals from the cell surface (Nakajima et al., 1987). Furthermore, 
the non–ECM proteins such as cytokines, growth factors and growth factors receptors 
are also targeted by MMPs. Growth factors can be stored in the ECM and released 
and activated by MMPs (Fingleton et al, 2001).  




Figure 1.7: Tumour microenvironment adapted from (Prajapati and Lambert, 
2016), permission obtained to reuse here. 
 
 
1.3.5.1 Fibroblast phenotypes in the tumour microenvironment 
Fibroblasts are non-vascular non-inflammatory mesenchymal cells present in the 
fibrillar matrix of connective tissue that they secrete. The normal functions of these 
cells is maintenance of homeostasis of both the adjacent epithelia through secretion of 
growth factors and of the extracellular matrix ECM through synthesis of collagen I, 
III, V and fibronectin as well as matrix metalloproteinases (the degrading enzymes of 
ECM) (Tomasek et al., 2002). Although fibroblasts usually exist in a dormant state in 
normal conditions, they are triggered and transiently activated during wound healing 
and invade the wound site and acquire a myofibroblast phenotype with enhanced 
expression of alpha-smooth muscle actin (α-SMA) stress fibres (figure 1.8). 
Furthermore, wound contraction and closing are attributed to the effects of 
myofibroblasts laying down of ECM and their contractile properties. Subsequent scar 
formation can be initiated by rearrangement of new ECM by MMPs secreted from the 
activated fibroblast  (Darby et al., 2014). As soon as the wound is repaired, a 
significant reduction the number of activated fibroblasts occurs accompanied by a 
restoration of fibroblast phenotype. To date, it is not known if the activated fibroblasts 
are cleared by apoptosis and replaced from adjacent normal tissue with resting 
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fibroblasts or wether activated fibroblasts return to their normal quiescent phenotype 
that they had before activation  (Tomasek et al., 2002). On the other hand, cancer 
activated fibroblasts (CAFs) are permanently activated in the tumour 
microenvironment, have stable phenotype even in absence of the activation stimuli, 
and are not eliminated by apoptosis nor revert to their original normal phenotype (Li, 
Fan and Houghton, 2007) (figure 1.8). 
 
1.3.5.2 Activation of normal fibroblasts into CAFs 
Transforming growth factor β (TGF-β) is considered as the key pathway that induces 
activation of both cancer associated fibroblasts (CAFs) and physiologically activated 
fibroblasts. Although, there are other growth factors that mediate activation of 
quiescent fibroblasts such as platelet-derived growth factor (PDGF), epidermal 
growth factor (EGF), fibroblast growth factor 2 (FGF2), chemokines like monocyte 
chemotactic protein-1 (MCP1) and ECM-degrading proteases (Kalluri and Zeisberg, 
2006). It has been reported that tumour cells directly trigger the activation and 
transition of normal fibroblasts to CAFs (Vicent et al., 2012). However, some studies 
suggested that the interaction of normal fibroblasts with ECM has an important effect 
on their activation, for instance TGF-β1 induced differentiation of myofibroblast from 
oral and dermal fibroblasts is inhibited by blocking of the α5β1 integrin (Lygoe et al., 
2007). On the other hand, already activated CAFs play a significant role in further 
recruitment of resting quiescent residential fibroblast which acquire a CAF phenotype 
through homotypic interactions (Vicent et al., 2012). In addition, Clayton and his 
colleagues (1998) revealed that leukocytes activate normal fibroblast directly by cell 
to cell communication via adhesion molecules like vascular cell adhesion molecule-1 
(VCAM-1) and/or intercellular adhesion molecule-1 (ICAM-1).  
 




Figure 1.8: Schematic representation illustrating the morphological and 
proprieties differences between normal fibroblast and cancer associated 
fibroblast. Adapted from (Kalluri and Zeisberg, 2006). 
 
1.3.5.3 Transforming growth factor (TGF-β) 
TGF-β is a pleiotropic growth factor that displays dual activities, it has a tumour 
suppression effect in normal cells, whilst acting as tumour promoter in cancer cells 
through induction of an invasive phenotype (Massagué, 2008). In addition, TGF-β 
plays significant roles in metastasis and angiogenesis (Costanza et al., 2017) as well 
as mediation of epithelial- mesenchymal transition (EMT) (Yu et al., 2014) and 
activation of cancer associated fibroblasts (Kalluri and Zeisberg, 2006). Although, 
TGF-β possess four variants, TGF-β1 has received the most experimental attention 
due to its production by a variety of cells such as keratinocytes, macrophages, 
fibroblasts, and platelets (Lee and Eun, 1999; Mani et al., 2002; Eppley, Woodell and 
Higgins, 2004). Moreover, it has been reported that TGF-β1 has other important 
activities such being chemotactic to inflammatory cells, fibroblasts and keratinocytes, 
promotion of inflammatory cell recruitment (Moses, Yang and Pietenpol, 1990) and 
hyperplastic scaring regulation (Russell et al., 1988).  
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1.3.5.4 Cancer associated fibroblasts (CAF) 
CAFs represent the activated phenotype of fibroblasts within the tumour 
microenvironment and are characterised by their high expression of α-SMA. They 
form the most common cells within stroma in most tumour types (Kalluri and 
Zeisberg, 2006). CAFs enhance tumour progression by triggering proliferation of 
tumour cells through secretion of different growth factors, cytokines and hormones. 
For instance, epithelial mitogens like hepatocyte growth factor (HGF), fibroblast 
growth factor (FGF), Wnt family proteins and epidermal growth factor (EGF) as well 
as cytokines such as, interleukin-6 (IL-6) and stromal derived factor (SDF)-1α 
(CXCL12). CAF expression of all these factors is increased in various tumour types 
(Pietras and Östman, 2010). In addition, CAFs secrete many chemokines such as 
monocyte chemotactic protein 1 (MCP1) and cytokines as well as interleukins such as  
(IL-1) to initiate an inflammatory response in tumours (Strieter et al., 1989; Kalluri 
and Zeisberg, 2006). Moreover, CAFs enhance remodelling of ECM through 
secretion of ECM proteins such as collagen I, fibronectin and tenascin C as well as 
ECM degrading proteases such as MMP2, MMP3 and MMP9 (Kalluri and Zeisberg, 
2006). CAFs have an important role in promotion of angiogenesis though secretion of 
factors which stimulate endothelial cells and pericytes (Hanahan and Coussens, 2012). 
For instance, endothelial progenitor cell recruitment is mediated by CXCL12 secreted 
from CAFs (Orimo et al., 2005). It has been reported that CAFs are crucial in 
suppression of immune cells recruitment and modulation of the immune response. 
The immunosuppressive activity of fibroblast activation protein (FAP) expressing 
CAFs was attributed to their excessive secretion of CXCL12 that results in 
elimination  of  programmed cell death ligand 1 (PD-L1) and anti-cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) which is an immunological checkpoint 
antagonists responsible for promotion of T cell function (Feig et al., 2013). 
 
1.3.5.5 Origin of CAFs in tumour microenvironment 
CAFs in tumour stroma vary in their phenotypes, morphology and biological 
properties. This heterogeneity could be explained by the variety of their origins 
(Rønnov-Jessen et al., 1995). CAFs could be derived by activation of local tissue 
resident fibroblasts or could arise from epithelial cancer cells that undergo epithelial- 
Chapter 1 Review of Literature  
29 
 
mesenchymal transition (EMT). Moreover, CAFs might originate from endothelial 
cells and pericytes through endothelial-mesenchymal transition (EndoMT) the process 
by which endothelial cells convert to fibroblast-like cells (Orimo and Weinberg, 
2007). In addition, recruitment and activation of cell populations from distant tissues 
such as bone marrow progenitor cells and circulating fibrocytes is considered another 
possible source of CAFs within the tumour microenvironment (Ishii et al., 2003). 
 
 1.3.5.6 CAF markers 
Previously α-SMA, fibroblast activated protein (FAP), platelet derived growth factor 
receptor-α or β (PDGFR-α or β), neuron glial antigen (NG2), podoplanin, and thy-1 
(CD90) were considered as specific markers for identification of CAFs (Sugimoto et 
al., 2006, Polanska and Orimo, 2013). Currently, it has been widely identified that 
there is no specific marker expressed by CAFs that is not expressed by other type of 
cells, for example: vascular smooth muscle cells expressed high levels of α-SMA. 
Neuron glial 2 (NG2) and platelet derived growth factor receptor-β (PDGFR-β) are 
well known to be found in normal pericytes, while podoplanin is expressed by 
lymphatic endothelial cells (Augsten, 2014). This fact could be attributed to several 
causes which are: the variety of origins of CAFs, tumour microenvironment 
heterogeneity and the resemblance of CAFs to normal host fibroblasts (Bussard et al., 
2016). Therefore, currently the most reliable methods to identify CAFs are dependent 
on a combination of both marker expression and morphological appearance (Ishii et 
al., 2016). 
 
1.3.5.7 Heterogeneity of CAFs 
It has been reported that CAFs do not have a unique phenotype, genotype and 
secretory potential within tumour stroma, even in stroma of a specific tumour (Lewis 
et al., 2004; Rosenthal et al., 2004; Sugimoto et al., 2006; Tchou et al., 2012). 
Recently, it has been found that CAF diversity and the cooperation between various 
cell subpopulations play a pivotal role in tumourigenesis (Kiskowski et al., 2011). In 
oral squamous cell carcinoma (OSCC), two different subtypes of CAF have been 
identified. CAF-N which is close to normal fibroblasts in their secretary profile and 
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gene expression and CAF-D which has divergent gene expression with increased 
levels of TGF-β1 secretion. A high percentage of cells are CAF-N and exhibit 
intrinsic motility and their migration potential is increased in response to TGF-β1. 
However, CAF-D involves only a few motile cells and their motility capacity is 
largely unaltered in response to TGF-β1. The authors assumed that the various 
detected phenotypes (CAF-N and CAF-D) are not actually distinct phenotypes, but 
they represent different stages of CAF progression in OSCC, where CAF-N exist in 
early stage which later on change to CAF-D. Moreover, this changing process is 
regulated and controlled by the levels of TGF-β (Costea et al., 2013). 
 
1.3.5.8 Senescent fibroblasts  
 
Cellular senescence can be defined as a state of permanent growth arrest of cells due 
to loss of their ability to proliferate. However, cells maintain their viability as well as 
metabolic and transcription activities. Senescent cells differ from quiescent cells by 
the elevated levels of pINK4A  (Hayflick, 1965). The main cause of cellular senescence 
is irreparable DNA damage. This damage may be induced by telomeres shortening 
due to excessive replication or mutations (Crabbe et al., 2004) as well as oxidative 
stress that result from mitochondrial dysfunction, oncogene overexpression and 
anticancer therapies (Di Micco et al., 2006).  The p53 or p16/Rb pathway stimulate 
the G1-S checkpoint to arrest the growth of cells and initiate cellular senescence 
(Coppé et al., 2008; Demehri, Turkoz and Kopan, 2009; Pazolli et al., 2009). 
Evidence suggests that fibroblast activation and senescence represents various stages 
of the same pathway (Hassona et al., 2013). Support of this theory comes from the 
fact that activated fibroblasts (TGF-β treated) possess a gene expression profile which 
significantly overlaps with senescent fibroblasts (radiation-treated fibroblasts). Also, 
when oral fibroblasts treated with TGF-β result are activated this is followed by 
senescence. An α-SMA positive phenotype is expressed by activated and senescent 
CAFs and finally both activated and senescent CAFs have the same tumour promoting 
activities which are mediated through the same signalling pathways (Demehri, Turkoz 
and Kopan, 2009; Alspach et al., 2014., Procopio et al., 2015). Senescent CAFs are 
characterised by developing a senescence-activated-secretory-phenotype (SASP) 
(Kuilman and Peeper, 2009), with secretion of various growth factors, inflammatory 
Chapter 1 Review of Literature  
31 
 
factors, interleukins, cytokines, ECM proteins and proteases (Coppé et al., 2008, 
Pazolli et al., 2009). In addition, senescent CAFs play a significant role in promotion 
of tumour invasion and metastasis as well as resistance of anticancer therapies (Coppé 
et al., 2008). Furthermore, it has been suggested that senescent CAFs induce EMT in 
tumours mediated by TGF-β in conjunction with MMP2 that results in down 
regulation of different cell adhesion molecules (Hassona et al., 2014).    
  
 
1.3.6 Extracellular vesicles (EVs) 
Extracellular vesicles are highly heterogeneous subsets of membrane vesicles secreted 
by almost all cell types including tumour cells and released in the extracellular spaces. 
These vesicles vary in their subcellular origin, size and components (figure 1.9). They 
are considered crucial for regulation of cell to cell communication as well as 
mediation of extracellular pathways. Many functional molecules are transferred by 
EVs such as mRNA, miRNA, DNA, proteins, transcriptional factors and lipid, which 
have the ability to influence the biological functions of recipient cells (Raposo and 
Stoorvogel, 2013). Furthermore, EVs are categorised according to their biogenesis 
into 3 groups (Colombo, Raposo and Théry, 2014). Exosomes are the smallest EV 
type, about 50-150nm in diameter. They form from the release of multivesicular 
bodies (MVB) containing intraluminal vesicles by exocytosis (Fujita et al., 2015). 
Microvesicles are larger than exosomes with a diameter ranging from 100-1000nm 
and are produced by budding or shedding from the plasma membrane (Raposo and 
Stoorvogel, 2013). Apoptotic bodies are the largest type of EVs about 500-4000nm in 
diameter (Fujita, Yoshioka and Ochiya, 2016), which contain nuclear fragments 
(DNA and RNA fragments) as well as cell organelles (Holmgren et al., 1999). They 
are cleared by macrophages by phagocytosis (Elmore, 2007). It has reported that 
apoptotic bodies contribute to intercellular communication in the tumour 
microenvironment (Bergsmedh et al., 2001). 
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1.3.6.1 Roles of extracellular vesicles (EVs) in the interactions 
between cancer cells and stromal fibroblasts 
EVs have the potential to influence the crosstalk between cancer cells and 
surrounding fibroblasts in the tumour stroma to enhance tumour progression (Naito et 
al., 2017). TGF-β enriched cancer derived-EVs mediate the induction of CAFs by 
activation of fibroblasts (Webber et al., 2010; Webber et al., 2015). Webber and his 
colleagues (2010) found that cancer derived-EVs were loaded with TGF-β on their 
surface which stimulated TGF-β/SMAD3 signalling in fibroblasts resulting in 
induction of a CAF phenotype with expression of α-SMA and FGF2. Moreover, 
motility and metastasis of cancer cells were enhanced by CAF-derived EVs through 
activation of the Wnt-Planer cell Polarity signalling pathway (Luga et al., 2012). It 
has been reported that CAF derived EVs mediate anticancer therapy resistance in 
cancer cells. For instance, CAF derived EVs that contain non-coding RNA induce 
Notch target genes leading to enhanced treatment resistance of cancer initiated cells 
(Boelens et al., 2014). Josson and his colleagues (2015) revealed that EMT was 
initiated by secretion of miR-409 contained within CAF derived EVs. In addition, the 
metabolic properties of both cancer cells and CAFs were modified due the effects of 
EVs (Chaudhri et al., 2013). For instance, the metabolic properties of cancer cells in 
prostate cancer were modified by CAF derived EVs (Zhao et al., 2016). On the other 
hand, fibroblast consumption of glucose in metastatic sites was altered through the 
influence of cancer derived EVs on pyruvate kinase in breast cancer (Fong et al., 





















Figure 1.9: Schematic representation illustrating the extracellular vesicles types 
and biogenesis. Adapted from (Colombo, Raposo and Théry, 2014). 
 
 
1.3.6.2 Roles of CSC-derived exosomes in the tumour 
microenvironment 
CSC-derived exosomes play pivotal roles in the tumour microenvironment and are 
considered to be potent regulators of many tumour features. CSC-derived exosomes 
mediate the complex interactions between monocytes and T-cells. As a result they 
induce acute tumour immunosuppression through the inhibition of T-cells in the 
presence of monocytes through their specific secretion of IL-10 (Domenis et al., 
2017). CSC-derived exosomes play key roles in mediating and enhancing tumour 
angiogenesis by different ways. Pro-angiogenic factors such VEGF-A and functional 
miRNA were secreted by CSC-derived exosomes that resulted in an increased 
angiogenic potential of endothelial cells as well as promotion of permeability (Treps 
et al., 2017). Grange and his colleagues (2011) revealed in their study that renal CSCs 
with CD105 positive secreted exosomes activated endothelial cells and enhanced the 
formation of vessels and initiating a pre-metastatic niche for cancer cells. In addition, 
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angiogenesis was mediated by increasing levels of VEGFR-1 in endothelial cells 
stimulated by non-coding RNA (lncRNA) H19 release from CSC-derived exosomes 
(Conigliaro et al., 2015). Sanchez and his colleagues (2015) found that tumour stroma 
in prostate cancer was modulated by CSC-derived exosomes enriched with miR-139 
and miR-183 that resulted in promotion of fibroblast proliferation and migration. 
Furthermore, it has been identified that CSC-derived exosomes play an important role 
in tumour stroma remodelling due to their effects on ECM protein synthesis and 
degradation through mediation of receptor –ligand interactions (Mu, Rana and Zöller, 
2013; Sung et al., 2015). On the other hand, CSC-derived exosomes maintain the 
CSC phenotype by exporting CSC specific molecules such as signalling proteins for 
the Wnt pathway (Gong and Huang, 2012; de Sousa e Melo and Vermeulen, 2016; 
Basu, Haase and Ben-Ze’ev, 2016) like β-catenin (Basu, Haase and Ben-Ze’ev, 2016),  
activators of transcription–Notch pathway component like Jagged, functional 
enzymes like ALDH and surface receptors such as CD44 and CD133 (Sharghi-
Namini et al., 2014; Nakamura et al., 2017). 
 
1.4 Cancer stem cell markers 
 CSCs markers are cell surface molecules or intracellular soluble proteins which, 
either alone or in combination have the ability to identify CSCs in various cancers. 
Therefore, these markers can be used in physical detection and isolation of CSC 
subpopulations in a tumour from other heterogeneous tumor cells. These markers, 
whether they are cell-surface or cytoplasmic/nuclear soluble proteins are considered 
as CSC antigens. However, their expression by the corresponding normal adult stem 
cells supports the theory that CSCs originate from normal stem cells (Islam, Gopalan, 
et al., 2015). 
 It is known that the phenotype of CSCs is not identical in all types of tumours. As a 
result, there is no unique or universal marker to CSCs (Clarke et al., 2006). However, 
it has been suggested that a combination of markers may improve the specificity in 
identification of CSCs (Zhang, Filho and Nör, 2012). For instance, Zhang and his 
colleagues (2009) isolated CSCs in head and neck cancer using combination of 
ABCG2, BMi-1, CD44 and Oct4 markers, whereas Han and his colleagues (2014) 
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used CD44 and CD24. In addition, Zhang and his colleagues (2012) isolated CSCs in 
oral cancer by using a combination of CD44, CD133 and ALDH. The most common 
markers used for detection of CSCs of head and neck squamous cell carcinoma are 
listed in the table 1.1, whereas other important CSCs markers in different cancer types 
are listed in table 1.2.  
 
1.4.1 Cancer stem cell markers in oral cancer  
It has become increasingly clear that using of combination markers for detection of 
CSCs is tumour type- dependent (Zhang, Filho and Nör, 2012). Therefore, some CSC 
markers are more relevant to oral cancer than others, which include:  
CD44: This is a cell surface glycoprotein involved in cell adhesion and migration, 
cell-cell interactions, cell signalling and leucocyte attachment and rolling (Ponta, 
Sherman and Herrlich, 2003; Prince et al., 2007; Takaishi et al., 2009). CD44 is 
expressed on epithelial cells, erythrocytes and leukocytes (Kemper, Grandela and 
Medema, 2010) as well as most tumour cells. In normal cells, it has been 
demonstrated to be a specific receptor for hyaluronic acid that promotes cell migration 
(Ponta, Sherman and Herrlich, 2003). CD44 acts as a co-receptor of many 
complimentary receptors on the cell membrane by presenting to them their relevant 
cytokines and chemokines (Naor et al., 2009). Furthermore, it has affinity for 
osteopontin and as a result of their interaction, CD44 controls cellular functions that 
result in tumour progression (Karsten and Goletz, 2013). CD44 is considered one of 
the most common markers that was used first for identification of CSCs in head and 
neck squamous cell carcinoma. It has been found that the subpopulation of cells with 
high expression of CD44 simultaneously overexpressed other specific markers of 
stemness such as Bmi-1 which maintains the state of undifferentiation of the cell 
(Prince et al., 2007). CD44 is incorporated into many complex cell signalling 
cascades which enhance the initiation of tumour through interaction with adjacent 
receptors such as tyrosine kinases (Wong, Herriot and Rae, 2003). It has been 
identified that all physiological functions and activities of the CD44 molecule in 
normal and stem cells were exhibited in cancer cell populations that expressed it 
(Karsten and Goletz, 2013).  
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CD24: is a cell adhesion molecule that is bound to the cell membrane through a 
glycosylphosphatidylinositol (GPI) anchor (Kay, Rosten and Humphries, 1991). In 
normal physiology, it is expressed on certain epithelial cells, neutrophil and pre-B 
lymphocytes but it is lost during plasma cell maturation. Therefore, B cell 
proliferation and maturation was reported as one of the important normal functions of 
CD24 (Lu et al., 1998). On the other hand, cancer cells in haematological 
malignancies and several solid tumours expressed CD24 (Kristiansen et al., 2002; 
Kristiansen et al., 2003) . In head and neck squamous cell carcinoma, it has been 
reported that CD24+/CD44+ cells possessed stemness properties and also demonstrate 
higher invasiveness in vitro (Kristiansen, Sammar and Altevogt, 2004; Zhang et al., 
2011). Moreover, CD24 is considered to be one of the key ligands of the P-selectin 
receptor (the main adhesion receptor expressed by activated platelets and endothelial 
cells) (Nestl et al., 2001).  Therefore, it has been established that CD24 strongly 
related to tumour metastasis due to its role in promotion of adhesion of tumour cells 
by binding to P-selectin receptors on activated platelets and endothelial cells 
(Friederichs et al., 2000). Gao and his colleagues (2010) revealed that the CD24 
positive cancer cell subpopulations exhibit self-renewal ability and stronger resistance 
to anticancer therapies compared to CD24 negative cells population. Many studies 
established CD24 as a marker of CSCs and provide evidence that it plays a crucial 
role in tumour progression and metastasis when its highly expressed along with 
CD29, CD31 and CD44 markers in several tumours ( Visvader and Lindeman, 2008; 
Lee et al., 2010). 
CD29 (integrin-β1): It is a transmembrane receptor which is part of the integrin 
receptor family. Integrin receptors consist of an α subunit and β subunit that 
collaborate in order to bind a specific ECM protein. However, the β1 subunit 
associates with different α subunits forming various heterodimers each binding to a 
specific ECM protein depending on α subunit partner and expressing cell type (Hynes, 
1992; Brakebusch and Fa, 2003). For instance: α2β1 for collagen, α3β1 for laminin 5 , 
α5β1 for fibronectin, α8β1 for tenascin and  α9β1 for tenascin, fibronectin and 
vitronectin (Watt, 2002). Integrin-β1 is normally expressed by epidermal 
keratinocytes with the highest levels in the stem cell of the basal layer than other 
keratinocytes (Watt, 2002; Braun et al. 2003). The normal functions of integrin-β1 
involve mediation of adhesion to ECM and initiation of terminal differentiation (Levy 
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et al., 2000), and motility of cells which is mediated by integrin-mediated adhesion 
(Schwartz and Assoian, 2001). Moreover, keratinocyte-ECM interactions have a key 
role in maintaining cell survival, proliferation and the architecture of epidermal tissue 
(Hynes, 2002). In addition, integrin-β1 has been implicated in the self-renewal 
characteristic of stem cells (Lechler and Fuchs, 2006; Taddei et al., 2008) and 
regulation of their differentiation (Naylor et al., 2001; Watt, 2002). On the other hand, 
it plays significant roles in tumour progression, migration and invasion. The crosstalk 
of integrins with oncogenes and growth factor receptors on cancer cells and their 
associated cells are crucial for tumour growth and invasion. Furthermore, it has been 
established that integrin-β1 provides the necessary traction for motility of cells and 
consequent invasion via its direct binding to ECM proteins as well as its role in 
regulation of activity of ECM proteases (Assoian and Klein, 2008). 
CD133 (prominin-1): Is a glycosylated protein with five transmembrane domains 
and two large extracellular loops. Normally, it has been reported that CD133 
expression is restricted to CD34+ stem cells of the haematopoietic system and plasma 
membrane protrusion of epithelial cells such as microvilli. Although, till now the 
functions of CD133 are relatively unknown (Yin et al., 1997). It is thought that 
CD133 has a role in organization of the topology of plasma membrane (Röper, 
Corbeil and Huttner, 2000). On the other hand, in head and neck squamous cell 
carcinoma, CD133 positive stem-like cells have higher clonogenicity, tumourigenesis, 
invasiveness, and resistance to conventional chemotherapy when compared with 
CD133 negative cells (Zhang et al., 2010).  
Aldehyde dehydrogenase (ALDH) enzymes: ALDH is an intracellular enzyme 
involved in cell differentiation, detoxification and standard chemotherapy resistance 
through intracellular aldehyde oxidation (Magni et al., 1996; Sophos and Vasiliou. 
2003; Chute et al., 2006). ALDH1 enzyme is considered a marker for the 
identification of normal somatic cells and CSCs as well as being a prognostic marker 
to predict tumour prognosis and metastasis (Ginestier et al., 2007; Charafe-Jauffret et 
al., 2010). In addition, Chen and colleagues (2009) found that radio-resistance and 
tumourgenicity in HNSCC were enhanced by cell populations with positive ALDH 
compared to ALDH negative populations.  
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Oct-4, Nanog and Sox2 transcription factors: These factors play significant roles in 
the maintenance of self-renewal and pluripotency of embryonic stem cells. In 
addition, detection of stem cells in the lamina propria of oral mucosa of human adults 
based on their Oct4, Sox2 and Nanog expression has been reported. Although, the fact 
that these factors are not expressed on the cell membrane has hindered the 
effectiveness of CSC sorting by FACS (Boyer et al., 2005; Loh et al., 2006; Chiou et 
al., 2008). Furthermore, Lim and colleagues (2011) revealed that stem-like cancer 
cells isolated from HNSCC expressed significantly higher levels of these transcription 
factors compared to unsorted cells. However, their levels reflect the grade of OSCC, 
i.e. high grade OSCC has elevated levels of Oct4, Sox2 and Nanog expression (Chiou 
et al., 2008). 
ATP-binding cassette transporters (ABC transporters): These are a superfamily of 
efflux pumps in the plasma membrane such as MDR1, ABCG2 that determine the 
side population cell phenotype. They are capable of the efflux of fluorescent DNA 
dyes like Hoechst 33342 and Dye Cycle Violet (Goodell et al., 1996; Hadnagy et al., 
2006). The side population cells in head and neck squamous cell carcinoma that 
overexpressed ABCG2, Bmi-1, CD44 and Oct4 show cancer stem-like properties with 
high invasive and metastatic potential (Zhang et al., 2009; Song et al., 2010) . 
Bmi-1: is polycomb protein and proto-oncogenic chromatin regulator known to 
stimulate the self-renewal of stem cells by negatively regulating the expression of 
Ink4a and Arf tumour suppressors (Chen et al., 2011).  In head and neck squamous 
cell carcinoma Bmi-1is highly enriched in CD133 positive cells, leading to 
suppression of apoptosis of these cells and promotion of proliferation (Chen et al., 
2011).  
Ep-CAM (ESA): Epithelial cell adhesion glycosylated membrane is a protein 
involved in Wnt signalling and a cancer stem cell surface CD antigen (CD326). It has 
been reported that two biologically distinct phenotypes of CSC in head and neck 
squamous cell carcinoma exist based on ESA/CD44 expression: CD44 (high) ESA 
(high) are proliferative with epithelial characteristics and CD44 (high) ESA (low) are 
migratory with mesenchymal traits (Laimer et al., 2008). 
CD117 (KIT): It is a transmembrane tyrosine-kinase receptor which is part of the 
platelet-derived growth-factor/colony stimulator factor 1 receptor subfamily. This 
Chapter 1 Review of Literature  
39 
 
receptor is present in various cell types such as haematopoietic progenitor cells, mast 
cells, germ cells, Cajal cells of the gastrointestinal tract, skin epithelial cells and 
cerebellar neurons as well as their neoplasms. The KIT receptor is activated normally 
by binding to stem cell factor which is considered be its specific ligand. Receptor 
engagement results in activation of signalling cascade leading to activation of 
different transcription factors involved in cell survival, differentiation, adhesion, 
chemotaxis and apoptosis regulation (Miettinen and Lasota, 2005).  
 
Table 1.1: Markers relevant to head and neck carcinoma, adapted from (Islam, 
Gopalan, et al., 2015). 
 
 
Marker name Other cancer type with high 
expression 
References 
CD44 Breast, colon, stomach, liver, 
ovary, pancreas, prostate   
Ponta, Sherman and 
Herrlich, (2003), Takaishi et 




Breast, colon, liver, pancreas, 
skin 
Sophos and Vasiliou, (2003), 
Magni et al., (1996), Chute 
et al., (2006) 
CD 133 (prominin-1) Brain, colon, endometrium, liver, 
lung, ovary, pancreas, prostate, 
breast 
Zhang et al., ( 2010) 
Oct-4, Nanog and Sox2  
Transcription factors 
Bladder, breast, liver Boyer et al., (2005),Loh et 
al., (2006),Chiou et al., 
(2008) 
ABC transporters Brain (glioma), gastrointestinal 
tract, liver, lung, thyroid 
Goodell et al., (1996), 
Hadnagy et al., (2006) 
Bmi-1 Bladder, skin, prostate, ovary, 
breast, colon 
Chen et al., (2011) 
CD24 Breast, stomach, pancreas  Kristiansen, Sammar and 
Altevogt, (2004),Zhang et 
al., (2011) 
Ep-CAM  Colon, pancreas, breast Laimer et al., (2008) 
CD117 (KIT) ovary Sheu et al., (2005) 
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Table 1.2: Other important markers of CSCs in various cancer types with their 
normal functions, adapted from (Islam, Gopalan, et al., 2015). 
Marker name Normal function Reported cancer References 
CD90 Cell adhesion and signal 
transduction in T cells  
Brain, liver, 
breast and lung 
Yang et al., (2008), 
Rege and Hagood, 
(2006), 
He et al., (2012) 
CD38 Signal transduction, calcium 
signalling and cell adhesion  
Haematological Ferrero and Malavasi, 
(1999) 
α6-Integrin Cell adhesion, cell-surface 
mediated signalling  
Breast, prostate, 
brain (glioma) 
Hoogland et al., (2014) 




Wilson et al., (2014) 




Herrmann et al, (2014) 
CD166 Cell adhesion and cell-cell 
interactions  
Colon, lung  Tachezy et al., (2014) 
LGR5/ GPR49 Cell adhesion  Colon Walker et al., (2011) 
CD15 Cell adhesion, migration, 




Kerr and Stocks, 
(1992) 
 
Nestin Remodelling of the cell  Brain (glioma), 
prostate 
Kleeberger et al., 
(2007) 
CD13 Regulate peptides and lipid 
turnover  
Liver Wickström et al., 
(2011) 
ABCG2 Transport various molecules across 
extra and intra-cellular membranes 
Lung, breast, 
brain 
Bertolini et al., (2009) 
CD20 Regulates B cell differentiation  Skin 
(melanoma) 
Chen et al., (2005), 
Fang et al., (2005) 
c-Met Regulates invasive growth  Pancreas, breast Furge, Zhang and 
Vande Woude, (2000) 
CXCR4/CD184 Regulates chemotactic activity of 
lymphocytes  
Lung, ovarian Bertolini et al., (2009) 
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Nodal activity Cell differentiation and signal 
transduction  
Pancreatic Branford and Yost, 
(2004) 
Keratin 5(K5) Structural framework of 
keratinocytes  
Bladder, lung Tokar, Diwan and 
Waalkes, (2010), 
Mulvihill et al., (2013) 
P63 Transactivation, regulates apoptosis Bladder Di Como et al., (2002) 
CD34 Regulation of cell adhesion  Haematological Civin et al., (1984), 
Lin, Finger and 
Gutierrez-Ramos, 
(1995) 
E-Cadherin Cell-cell adhesion Breast, skin Alt-Holland et al., 
(2008), 
Dittmer et al., (2009) 
S100A8 Epithelial migration Colon Duan et al., (2013) 
Cyclin D1 Induces EMT in CSCs and 
Epithelial migration 
Ovarian, Breast Wang et al., (2013) 
Ki67 Cell proliferation Glioblastoma Li et al., (2012) 
 
 
1.4.2 Detection and isolation of CSCs 
Identifying and isolating CSCs is considered an important step in order to study their 
characteristics accurately. There are many methods and techniques used for detection 
of CSCs, which can be classified into: cell sorting, functional, molecular, image 
based, filtration and cell adhesion (Islam, Gopalan, et al., 2015) (table1.3). 
1. Cell sorting  
This approach is characterized by its high specificity and is considered as a reliable 
method for isolation of CSCs from other non-CSCs based on variety of cell surface 
and intracellular molecules (markers) (Kentrou et al., 2011). Furthermore, it is 
subdivided into different techniques: 
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1.A Fluorescence activated cell sorting (FACS) 
FACS is a specialized type of flow cytometry, in which any mixture of heterogeneous 
biological cells can be sorted on the basis that each cell has a specific scattering of 
light based on size and granularity (Julius, Masuda and Herzenberg, 1972). When 
combined with fluorescently labelled antibodies, it can be used to separate and isolate 
cells with various surface marker phenotypes (Shackleton et al., 2009). The first step 
of sorting cells from solid tumour includes preparation of a cell suspension through 
exposing the tumour to enzymes that degrade the cell to cell junctions and 
attachments to the ECM. The cell suspension is placed in the FACS machine and 
flowed through a nozzle of a narrow tunnel leading to disruption of the stream and 
formation of single cell droplets. After that, these droplets are passed through a laser 
beam which directs certain cells into an electrostatic field due to differences in optical 
characteristics among cells. The phenomenon of electrostatic deflection bends the 
flow of charged cells leading to collecting them in the vessel, while the residual 
electrostatically uncharged cells flow vertically down (Shackleton et al., 2009). 
For isolation of certain cells like CSCs, a specific antibody conjugated to fluorescent 
dye for a certain surface antigen (marker) is incubated with the cell suspension. After 
that, cells are flowed through the laser beam when is  adjusted to the wavelength of 
the fluorescent dye used and as a consequence to electrostatic deflection, labelled 
cells can be isolated (Fulawka, Donizy and Halon,  2014). 
 
1.B Magnetic activated cell sorting (MACS).  
 Antibodies to cell surface CSCs markers used in this method and are bound to 
magnetic beads. When the cell suspension is incubated with the beads and then 
exposed to a high magnetic field, the subset of cells that have the specific antigen 
(marker) will stay in the magnetic column, whereas the rest of the cells can be washed 
away. After that, the column is removed from the magnetic field and the remaining 
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2. Functional assays 
CSCs have unique properties, so functional approaches have been developed to isolate 
them from others cells (Podberezin, Wen and Chang, 2012). These methods include: 
2.1 Side population assay 
This approach is based on the ability of CSCs to efflux dyes and drugs to the outside 
due to their high expression of ABC membrane transporter proteins. This method 
includes incubation with Hoechst 33342 dye in suspension followed by FACS sorting 
(Fulawka, Donizy and Halon,  2014). In FACS analysis, excitation of the Hoechst 
33342 dye, result in emission as either Hoechst blue or Hoechst red for non-CSCs 
tumour cells due to their retention of dye. However, CSCs are negative for both dyes 
and are considered as side population cells because of their efflux of all Hoechst dyes 
(Mo et al., 2011). 
 
2.2 Microsphere assay 
This assay has been used to evaluate the clonogenic potential of CSCs on the basis of 
the capability of single CSCs to produce colonies more effectively than their progeny. 
In addition, these colonies will form spheres when they grow in non-adherent culture. 
The technique includes plating single cells on soft agar and after 21 days the derived 
colonies are stained either with crystal violet or nitro-blue-tetrazolium, counting, 
measured and finally compared to the non-CSCs derived colonies. In general, CSCs 
demonstrate a larger colony number and size than non-CSCs (Pastrana, Silva-Vargas 
and Doetsch, 2011).  
 
2.3 ALDH assay 
 Aldehyde dehydrogenase (ALDH) is an intracellular enzyme that oxidises and 
converts retinol into retinoic acid leading to detoxification of intracellular aldehydes 
and is considered important in the resistance of CSCs to chemotherapy (Russo and 
Hilton, 1988). This assay is based on the characteristic of increased expression of 
ALDH by CSCs. Therefore, the Aldefluor flow cytometric assay is used to isolate 
CSCs in various cancer types. It is includes addition of the active reagent boron-
dipyrromethene (BODIPY) - aminoacetaldehyde to the cells, which is converted later 
on to BODIPY- aminoacetate by the action of the ALDH enzyme (Hess et al., 2006). 
 




 Xenotransplantation is considered the gold standard in research of CSCs and depends 
on the tumourigenic features of CSCs and their ability to initiate and develop a 
secondary tumour similar to original one when they are transplanted to immune-
deficient animals (Rosen and Jordan, 2009). In this assay CSCs are isolated using 
FACS analysis, and then injected either subcutaneously or intraperitoneally into mice. 
As soon as a secondary tumour develops, the transplantation procedure is repeated. If 
a tertiary tumour is generated with similar heterogeneous cell population similar to 
that of primary tumour, it is highly suggestive that the cells isolated first are CSCs 
(Clarke et al., 2006). 
 
2.5 PKH retention assay  
 This approach is based on the relative quiescence and slow proliferation features of 
CSCs and it shows the asymmetric division of these cells. The identification 
mechanism of retention assay depends mainly on the activity of PKH26 and PKH6 
dyes which are lipophilic dyes that irreversibly bind and label the cell membrane. In 
addition, these dyes are distributed eventually among daughter cells after subsequent 
cell division. As a consequence, the dye will be diluted through continuous cell 
division. Hence, non-CSCs have rapid proliferation rate, so they will dilute and lose 
their membrane dye. On the other hand, CSCs are more dormant with a slow 
proliferation rate, so they retain PKH dyes for a longer time compared to non-CSC 
differentiated cells (Pece et al., 2010). 
 
2.6 Chemoresistance assay 
 CSCs can be isolated on the basis of their resistance to conventional therapy and their 
survival after treatment. CSCs dose-response curves for chemotherapeutic agents are 
compared to those for  non-CSCs (Tirino et al., 2012). 
 
2.7 Adhesion assay 
In this assay CSCs are isolated from other non-CSCs according to their rapid 
adherence to basement membrane and extracellular matrix molecules such as collagen 
IV and collagen I compared to the adherence rate of non-CSCs. This rapidity of 
adhesion of CSCs is attributed to their expression of high levels of specific adhesion 
molecules like integrins (Jones and Watt, 1993). 
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3. Molecular assays 
Molecular assays have been used to isolate CSCs on the basis of analysis of the 
expression of specific genes such as stemness genes and transcriptional factors like 
OCT4, Sox2, and Nanog (Lianidou and Markou, 2011; Tirino et al., 2012). The most 
sensitive and specific molecular assays are Reverse transcription-polymerase chain 
reaction (RT-PCR) and quantitative reverse transcription-polymerase chain reaction 
(RT-qPCR). These assays detect the CSCs through amplification of complementary 
DNA (cDNA) sequences that identify the target gene depending on the design of 
oligonucleotide primer probes (Loberg et al., 2004). 
 
4. Image- based approaches 
These techniques include: image microscopy, immunocytochemistry and 
immunohistochemistry and identify CSCs on the basis of site and level of protein 
markers expression. Moreover, they involve using of fluorescently labelled antibodies 
against specific antigens in tracked cells, and then the labelled cells are visualized 
using a fluorescence microscope (Lianidou and Markou, 2011). 
 
5. Filtration 
 Filtration methods are new techniques which are used for isolation of CSCs, but they 
need more clinical validation. They include two techniques: micro-filter and micro-
chips. In micro-filter cells are isolated depending on their size using specially 
designed micro-filters (Zheng et al., 2011), while for micro-chips the separation 
procedure depends mainly on the interaction between the antibody-coated chip 
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Table 1.3: advantages and disadvantages of different CSCs isolations methods, 
adapted from (Islam, Gopalan, et al., 2015). 





cell sorting (FACS) 
Able to isolate and 
quantify rare cell, 
multi-parameter 
separation 
Processing may cause 
artefact and bias cell 
analysis, 
limited to cell 
suspension 
Greve et al., 
(2006), Cassens 




Cell Sorting (MACS) 
Easy and fast Isolate the cells on 
basis of single 
parameter, 
suitable for cell 
suspension only 















Microsphere assay Simple and easy Unable to detect 
quiescent CSCs and 






ALDH assay Highly stable Low specificity 
 
Moghbeli et al.,  
( 2014), Yu et 
al., ( 2011) 
SP assay Easy and simple Condition dependent, 
costly, low specificity, 
lack of purity 
Moghbeli et al., 
(2014), Mo et 
al., ( 2011) 




Tirino et al., 
(2012) Pece et 




Fast and simple Low specificity, 
sensitivity 
 
Tirino et al., 





















assay, sample, time 
and cost effective 
 
Does not allow 




Reinholz et al., 
 ( 2005) 



















Time consuming, has 





















Immunohistochemistry Inexpensive, highly 
specific 
Limited to tissue 







Micro-filter Time effective and 
specific 
No morphological 




Lin et al.,                                                         
(2010) 
Zheng et al.,  
( 2011) 
Micro-chips Time and sample 
effective 
Needs more clinical 
validation 
 
Nagrath et al., 
(2007), Stott et 
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1.5 Hypothesis and aims 
1.5.1 Background  
A study by Locke and his colleagues (2005) showed that there is a small subset of 
cells within a tumour that drives the growth and other aggressive behaviours of 
tumour such as tumourigenicity, resistance to therapy, invasion and metastasis. 
Furthermore, identification and targeting of these cells is considered a crucial step to 
eradicate the tumour and prevent its recurrence. The primary focus of this study was 
the morphologic heterogeneity present in different cancerous epithelial cell lines and 
to determine if this heterogeneity is due to the asymmetric division hierarches of 
CSCs or not. (Locke et al., 2005). 
The study showed that all examined cell lines demonstrate obvious clonal 
heterogeneity with a range of colony morphologies of named holoclones, meroclones 
and paraclones of normal keratinocyte cells (Locke et al., 2005). Moreover, they 
found that cell proliferation rate was high in the meroclones and early paraclone 
colonies which may indicate that they contain of early- and late-amplifying cells 
while the holoclones were composed of smaller, rapid adherent and highly clonogenic 
cells. Holoclones have the ability to generate all types of colony and are therefore 
were considered as the source of remaining cells of tumour. In addition, stem cell 
markers like β1 integrin, E-cadherin, B-catenin, CD44 and ESA were expressed at 
higher levels in holoclone cells than meroclone cells (Locke et al., 2005). 
Liang and her colleagues (2014) suggested a method for isolation of CSCs on the 
basis of their adherence properties rather than clonogenicity or defined marker 
expression. They describe a non-invasive, low-cost alternative to isolation of CSCs by 
FACS from oral squamous cell carcinoma. The study involved investigation of 
primary cells derived from patients with oral squamous cell carcinoma as well as 
several cell lines from human head and neck squamous cell carcinoma and oral 
dysplasia. Assays were performed on these cells to allow them adhere to collagen IV 
and classify isolated cells as rapid adherent for the cells that adhere within 10 
minutes, middle adherent cells for that adhered within 30 minutes and finally late 
adherent for the cells that adhere in 4 hours. After that, further investigations on each 
group of cells were done to study their characteristics. Firstly, colony and sphere 
formation assays were used to examine their morphology. Secondly, molecular profile 
assays were used to investigate stem cell properties. Finally, tumourigenic capacity 
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was assessed in a tongue xenotransplantation assay in immune-deficient NOD-SCID 
mice (Liang et al., 2014). The study showed that rapid adherent cells were smaller, 
more homogenous and had a significant higher colony and sphere forming, with 
greater migratory ability and higher expression of stem cell markers such as integrin 
β1 as well as they displaying a higher tumour initiation ability compared to middle 
and late adherent cells (Liang et al., 2014).  
These two studies suggest that CSC populations exist in OSCC cell lines and that they 
can be isolated using adhesion assays. This forms the basis of the project described 
here. 
 
1.5.2 Hypothesis  
We hypothesise that cancer stem cells can be isolated from oral cancer cell lines using 
two different functional assays (cell adhesion and chemoresistance) and that these 
cells have a stable phenotype, may represent the same population and generate 
aberrant signalling to surrounding stromal cells. 
 
1.5.3 Aims 
• Develop functional assays (adhesion and/or chemoresistance) to isolate cells 
from OSCC cell lines and investigate the stem cell characteristics of these cells. 
• Investigate the stability of the isolated adherent and/or chemoresistant 
phenotype.  
• Investigate the chemoresistance of the early adherent population and the 
adhesion rate of chemoresistant cells to determine whether cells with similar 
characteristics are being isolated using the two functional methods. 
• Determine whether soluble factors from the CSCs signal differently to stromal 
cells (fibroblasts) than non-CSCs.  
• Investigate whether expression of CSC and fibroblast activation markers 
correlate in samples of OSCC tissue. 
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2.1 Cell lines 
All cell lines were obtained from the Academic Unit of Oral and Maxillofacial 
Pathology in the School of Clinical Dentistry, University of Sheffield. All reagents 
were from Sigma, UK unless otherwise stated. 
2.1.1 H357 cell line 
Oral keratinocyte H357 cell line originally derived from the tongue of a 74 year old 
male patient who had a well differentiated (grade II) oral squamous cell carcinoma 
(provided by Professor S. Prime, University of Bristol) (Prime et al., 1990). This cell 
line was cultured in keratinocyte growth media (KGM) which consists of: Dulbecco’s 
modified eagles medium (DMEM) and HAMS-F12 medium (3:1), 10% foetal bovine 
serum (FBS), Penicillin (100 IU/mL) and Streptomycin (100 mg/mL), Amphotericin 
B (2.5 µg/mL), all from Invitrogen, UK, L-Glutamine (2 mM), Adenine (0.18 mM), 
Hydrocortisone (5 µg/mL), Cholera toxin (1nM), Insulin (5 µg/mL), and Epidermal 
growth factor (10 ng/mL). 
 
2.1.2 SCC4 cell line 
SCC4 cells are a human squamous cell carcinoma cell line with an epithelial-like 
morphology. It is derived from the tongue of a 55 year old male patient (Rheinwald 
and Beckett, 1981). The growth media that used for SCC4 cell line was Dulbecco’s 
modified eagles medium (DMEM) and HAMS-F12 medium (1:1), 10% FBS, 
Penicillin (100 IU/mL) and Streptomycin (100 mg/mL), Amphotericin B (2.5 µg/mL). 
 
2.1.3 NOF cells    
Primary normal oral fibroblasts were derived from gingival biopsies obtained with 
informed, written consent from patients during elective oral surgery undertaken at the 
Charles Clifford Dental Hospital, Sheffield, UK, under the ethical approval (number 
15/LO/0116) granted by the Sheffield Research Ethics Committee. NOFs were 
cultured in fibroblast growth media (FGM), which consisted of DMEM (Gibco®, UK) 
supplemented with 4.5 g/L D-glucose, 10% (v/v) FBS, Penicillin (100 IU/mL) 
Streptomycin (100 mg/mL) and Amphotericin B (2.5 µg/mL). 
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2.2 Cell culture 
All cell culture procedures were performed in a class II laminar flow hood. Hood 
surfaces were decontaminated before and after work sessions using 70% ethanol. 
The cell lines were routinely grown usually in 12mL of their specific growth media in 
75cm2  flasks with filter caps (Greiner Bio-One Ltd, UK) and were maintained in an 
incubator under controlled conditions at 5% CO2 and 37
oC temperature, until they 
became approximately 80-90% confluent. 
 
2.2.1 Cell thawing from liquid nitrogen  
The cryovial containing the desired cell line was removed from liquid nitrogen 
container and thawed in a water bath at 37oC with appropriate safety protection. The 
cryovial contents were then transferred to a centrifuge tube and 2mL of the respective 
growth media was added. After that, the suspension was centrifuged at 179 g for 5 
minutes, the supernatant was removed and the pellet was re-suspended in 1mL fresh 
respective growth media and transferred to a 75cm2 flask. Afterwards, 12mL media 
was added and the flask incubated in 5% CO2 at 37
oC. 
 
2.2.2 Passaging of cells 
Sub-culturing of cells was performed twice weekly to maintain cell viability. Medium 
was aspirated from the flask using a 10mL serological pipette, then cells were washed 
twice with phosphate buffered saline (PBS) (Sigma-Aldrich, Dorset, UK) without 
Mg2+ or Ca2+.  After that, 1mL of 0.05% (v/v) porcine trypsin / 0.02% (v/v) ethylene 
diamine tetra-acetic acid (EDTA) was added and the flask incubated at 37°C for 10 
minutes. Then, by gentle agitation, the cells were detached from the flask wall and 
this was monitored by microscopic examination. Approximately 3mL of growth 
medium was then added to the flask to neutralize the enzymatic activity of trypsin, 
and the suspension was transferred to a tube and was centrifuged at 179 g for 5 
minutes. The supernatant was discarded and the cell pellet was re-suspended in fresh 
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2.3 Adhesion assay   
The first step of the adhesion assay (figure 2.1) is coating of a 96–well tissue culture 
plate (Greiner Bio-One Ltd, UK) with extracellular matrix (ECM) protein. The ECM 
proteins collagen I and plasma fibronectin (Sigma-Aldrich) were prepared by diluting 
in sterile PBS to the desired concentration (e.g. 10 µg/mL). Then, 100µL of the ECM 
solution was pipetted into the required wells of a 96 well plate and the lid labelled 
accordingly. If there are any uncoated control wells, 100µL PBS alone was added. 
The plate was then incubated for 1hr at 37oC (or at 4oC overnight). After that, the 
ECM was removed from the plate and non-specific binding sites were blocked by 
pipetting 100µL blocking buffer into each well and the plate incubated for 1 hour at 
37oC. The blocking buffer was prepared by mixing serum free medium (DMEM: F12, 
3:1) and 1% (10 mg/mL) bovine serum albumin (BSA) which was filter sterilised to 
allow storage in the fridge for a few weeks. During this incubation time, cells were 
prepared and counted by removing media from the flask, washing the cells with 
phosphate buffered saline (PBS without Ca2+ and Mg2+) and trypsinising as described 
above. Prolonged trypsinisation may damage the protein-related structures of the cell 
i.e. receptors. Other detachment solutions can be used to detach cells such as 
Accutase. The cell suspension was transferred into a tube for centrifugation (179 g, 5 
mins). Cells were re-suspended in 2-5mL serum free medium (SFM) and counted 
manually using a light microscope and haemocytometer slide with Trypan blue 
exclusion (dead cells were stained blue while viable cells did not take-up the dye). 
The counting procedure involved transferring a mixture of 5µL Trypan blue solution 
0.4% (Sigma-Aldrich, UK) and 5µL of cell suspension into the chamber of a 
haemocytometer slide with a cover slip. The number of viable cells per mL = total 
number of cells in four squares of haemocytometer slide × dilution factor × 104 / 4.  
The next step, cells were seeded into wells by removing the blocking buffer from the 
plate. 100µL of a 400,000 cells/mL solution was added and the plate incubated for 
various times up to 1hr at 37oC (this time can be changed). Following the incubation 
period unattached cells were removed from the plate by inversion.  And the wells 
were washed twice with 100µL SFM. Then, 100µL of SFM was added to each well 
followed by 20µL of MTS solution (CellTiter 96® Aqueous One Solution Cell 
Proliferation Reagent in the dark Promega, Southampton, UK). The reagent contains a 
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tetrazolium compound, 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) which is metabolically cleaved by 
viable cells. It is light sensitive so the cell culture hood light was turned off when 
adding the solution. In the final step, the absorbance was measured at 492nm by using 
of an Infinite® M200 Pro Series spectrophotometer (Tecan UK Ltd) and analysed 
using Magellan TM Software (Tecan UK Ltd). The results were saved into an Excel 
sheet document.  
 
 
Figure 2.1: Diagram summarizing the steps of the adhesion assay. 
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2.4 Determination of the stability of the early adherent phenotype  
This experiment consisted of 2 parts performed on separate days. In the first part, a 
T75 cm2 flask was coated with 1ml of (75µg/mL) fibronectin and incubated at 37oC 
for 1 hour. The flask was then washed with PBS and 1mL of the blocking buffer was 
added to the flask to block any remaining non-specific binding sites. After that, cells 
were prepared and seeded densities dependent on the cell line used in the flask which 
was then incubated at 37oC for 10 minutes. The non-adherent cells were washed twice 
with SFM, while the early adherent cells were collected and seeded into 96 well plate 
triplicate (that was previously coated with fibronectin and then incubated with the 
blocking buffer) at density of 40,000 cells per well as well as unsorted cells were 
seeded with same density in triplicate and incubated at 37oC for 10 minutes. Then the 
optical density of the first adhesion assay was measured and compared between early 
adherent and unsorted cells.  
The remaining early adherent and unsorted cells were transferred into separated 
uncoated flasks. Afterwards, both flasks were incubated for 48 hrs. In the second part 
of the experiment, another adhesion assay was performed using both flasks separately 
with cells seeded for 10 minutes to determine the stability of the early adherent 
phenotype.  
 
2.5 Chemoresistance assay 
Cells were seeded in triplicate wells for each dose of cisplatin (cis-Diammineplatinum 
(II) dichloride, Sigma-Aldrich, UK) in a 96 well plate at a density of 100,000 cells per 
well in their growth medium and incubated for 24 hours 37oC. 10μM of fresh cisplatin 
was prepared for each experiment by dissolving of 3mg of cisplatin powder in 1mL of 
SFM followed by filter sterilization. The cisplatin stock solution was diluted to a 
range of final concentrations in SFM (0.5, 2.5, 5, 10, 15, 20, 30 and 50μM). SFM 
alone acted as a positive control. Wells were washed with SFM before adding 
cisplatin to each triplicate wells and incubating for 24 hours 37oC. Then, wells were 
washed in SFM and 100μl of growth medium was added to each well and incubated 
for 5 days at 37oC. The final steps were similar to that in adhesion assay and involved 
washing wells twice in SFM as well as 3 empty wells were as negative control 
followed by the addition of 100μL SFM and 20μl of MTS solution and incubating for 
1hour 37oC. Then, the absorbance at 492nm was measured using an Infinite® M200 
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Pro Series spectrophotometer (Tecan UK Ltd) and the data analysed using Magellan 
TM Software (Tecan UK Ltd). Thereafter, drug inhibitory response curve was plotted 
using Graphpad prism software and IC90 was calculated. 
 
2.6 Determination of the stability of the chemoresistant phenotype 
A semi confluent flask of cells was treated with 15μM cisplatin in SFM and was 
incubated for 24 hours at 37oC. The flask was washed twice with PBS, growth 
medium was added and the flask incubated for 5 days at 37oC. After that, the treated 
cells were seeded as 2 rows of triplicates along with untreated cells at 100,000 cells 
per well in 100μL of growth medium and the plate was incubated for 24 hours 37oC. 
The wells were washed twice with SFM and 100μL of 15μM cisplatin solution was 
added to one row of both previously treated and untreated cells, while 100μL of SFM 
was added to the other row in triplicate wells of just SFM as a control and the plate 
was incubated for 24 hours 37oC. Then, the wells were washed twice with SFM and 
100μL of growth medium was added and incubated for 5 days at 37oC. Afterward, 
growth medium was removed and replaced with 100μL SFM and the absorbance was 
measured following addition of 20μL MTS for 1hour 37oC. Cell viability was 
expressed as percentage of optical density of treated wells related to their untreated 










Figure 2.2: Diagram summarizing the steps for the determination of the stability 
of the chemoresistant phenotype. 
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2.7 Chemoresistance of early adherent cells 
A T75 cm2 flask was coated with 1mL of (75μg/mL) fibronectin and incubated for 1 
hour at 37oC and then the non-specific binding sites were blocked with 1% BSA for 1 
hour at 37oC.  After that, unsorted cells were seeded for 10 minutes at 37oC. The non-
adherent cells were removed by washing twice with PBS, while the early adherent 
cells were collected by trypsinisation and seeded into 96 well plate in 2 triplicates at 
density of 100,000 cells per well as well as unsorted cells at the same density in 2 
triplicates. The well plate was incubated for 24 hours at 37oC. Afterwards, the growth 
medium was removed and one triplicate of both early adherent and unsorted cells 
were treated with100μL of 15μM cisplatin in SFM, while SFM only has added to the 
other triplicate of both conditions as control for 24 hours at 37oC. Wells were washed 
twice with PBS and 100μL of SFM was added to each well followed by addition of 
20μL MTS solution and incubated for 1 hour at 37oC. Finally, the absorbance at 
492nm was measured using of an Infinite® M200 Pro Series spectrophotometer 
(Tecan UK Ltd) and analysed using MagellanTM Software (Tecan UK Ltd) and the 
percentage of cell viability was calculated and compared between early adherent and 
unsorted. 
 
2.8 Adhesion of chemoresistant cells 
A semi-confluent flask of unsorted cells was treated with 15μM cisplatin in SFM and 
incubated overnight at 37oC. Then, the flask was washed twice with PBS and growth 
medium added for 5 days at 37oC. A 96 well plate was coated with 100μL of 
(75μg/mL) fibronectin and incubated for 1 hour at 37oC and then the non-specific 
binding sites were blocked with 1% BSA for 1 hour at 37oC. The collected chemo-
resistant cells and unsorted cells were seeded in triplicate at a density of 40,000 cells 
per well for 10 minutes at 37oC. Wells were washed twice with PBS, 100μL of SFM 
is added to each well followed by addition of 20μL MTS solution and incubation for 1 
hour at 37oC. The absorbance was then measured at 492nm as described above. 
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2.9 Proliferation assay 
The isolated cells (early adherent cells or chemoresistant cells) and the unsorted cells 
were seeded in triplicate wells of 4 separate 96 well plates at a density of 10,000 cells 
in 100μL of their growth medium per well and were incubated at 37°C. After every 24 
hours (i.e. 24 hrs, 48 hrs, 72 hrs and 96 hrs) one of the plates was removed from 
incubator. Medium was removed from wells and they were washed twice with 
DMEM. Afterwards, fresh 100μL DMEM was added to each well followed by 20μL 
MTS solution and the plate was incubated for 1 hour at 37°C. The absorbance of each 
well was measured and growth curves were drawn using the means from each 
triplicate wells of different days.  
 
2.10 Colony forming assay 
Early adherent cells were plated at 1000 cells in 2mL of their growth medium per well 
in the upper row of a 6 well plate and the same number of unsorted cells per well in 
the lower row. The 6 well plate was incubated for 14 days at 37°C. Medium were 
changed every 3 days. After 14 days, the medium was removed and wells were 
washed with PBS twice. Colonies were fixed in 4% paraformaldehyde in PBS for 30 
minutes at room temperature. The fixed colonies were stained with methylene blue 
stain (5mg/mL) in distilled water for 1 minute. The well plate was washed with 
distilled water to remove excess stain and the plate was left to dry for 30 minutes at 
room temperature. Photos were captured and numbers of colonies were counted for 
each well. 
 
2.11 Flow cytometry for stem cell surface marker expression  
 
Both isolated cells (early adherent or chemoresistant cells) and unsorted cells were 
detached from flasks using Accutase (BioLegend, UK) for 20 minutes at 37°C. 
Growth medium was then added and cell suspensions were centrifuged at 179 g for 5 
minutes. Cell pellets were re-suspended in flow buffer (PBS containing 10% Foetal 
bovine serum) and were adjusted to a density of 1x106 cells/1mL. Afterward, samples 
were prepared by putting 100μL (1x105 cells) in each Eppendorf tube on ice. Three 
direct conjugated antibodies were used in this assay, which were: FITC conjugated 
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mouse mono-clonal anti- human CD24 (BD Pharmingen™, UK), FITC conjugated 
mouse mono-clonal anti- human CD29 (integrin-β1) (Life Technologies Ltd., USA) 
and PE conjugated mouse mono-clonal anti-human CD44 antibody (BD 
Pharmingen™, UK). Each antibody was added to one sample of isolated cells and one 
of unsorted cells. In addition, one sample from both types had no antibody added and 
were used as controls. Amounts of antibodies were added for each sample as the 
following: CD24 and CD44 were 20μL per 100μL, while CD29 was 5μL per 100μL 
for 1 hour and the samples on ice in the dark. Ice prevents the antibody complex being 
internalised into the cells. Then, cells were washed by adding 1mL cold flow buffer to 
each sample and they were centrifuged at 200 g for 5 minutes. Supernatant was 
removed and the pellet re-suspended in 200μL of cold flow buffer on ice. In the final 
step, cell surface expression of CD24, CD44 and CD29 was quantified using a FACS 
Calibur machine (BD Biosciences, Oxford, UK). In each run 10,000 live cells were 
assessed and in order to avoid false positive results, gating was performed so that only 
viable cells were analysed. CellQuestPro Software (BD Biosciences) was used to 
determine the median fluorescence expression of each stem cell marker. 
Subsequently, levels were compared between the isolated cells (early adherent or 
chemoresistant cells) and unsorted cells. 
 
 
2.12 RNA extraction from isolated and unsorted cells 
Extraction of RNA was performed using a RNeasy mini kit (Qiagen) according to 
manufacturer’s instructions.  The first step involved lysing the cell pellet in lysis 
buffer with thorough mixing using a pipette. Afterwards, the lysate was transferred to 
spin column and 70% ethanol was added and mixed well by pipetting up and down. 
The lysate was then loaded onto new spin column which contain a silica membrane 
that binds RNA and this was centrifuged at 11000 g for 30 seconds. Genomic DNA 
was digested by adding of RNase free DNase 27 K unit/sample to the centre of silica 
membrane and this was incubated for 15 minutes at room temperature. The membrane 
was washed for 3 times to remove any impurities such as cellular components and salt 
metabolites. Finally, the purified RNA was eluted with 50μL RNase-free water by 
centrifuging at 8000 g for 1 minute and the samples were stored at -80oC.  
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2.13 cDNA synthesis 
Isolated RNA from cells was used to synthesise cDNA using a high capacity cDNA 
reverse transcription kit (Applied biosystem, Life Technologies Ltd., UK). At first, 
the concentration of each RNA sample was measured using a NanoDrop 1000 
spectrophotometer (ThermoScientific, USA) at 260/280nm and RNA volume was 
calculated to give 500ng RNA /10μL. Reaction master mix was prepared from the kit 
reagents in accordance with manufacturer’s instruction, as shown in the table 2.1. 
10μL of master mix was added and mixed with each RNA sample. In addition, a 
negative control sample was prepared by mixing 10μL Nuclease free water and 10μL 
master mix. Then, tubes were placed into a thermal cycler (engine DYAD, BIO-RAD, 
USA) to run a set programme which involved: initially 25oC for 10 minutes, then 
37oC for 2 hours and finally at 85oC for 5 minutes. After that, all cDNA samples were 
stored at -20oC. 
 
Table 2.1: The master mix components used for reverse transcription-







Kit without RNase inhibitor 
 
Kit with RNase inhibitor 
 


































Total per Reaction 
 
10 10 
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2.14 Real time- Polymerase chain reaction (qPCR) 
Two qPCR techniques were used in this study to quantify expression of target genes. 
First technique was performed using SYBR green probes. The components of the 
reaction mix are shown in table 2.2.A. The following genes were targeted using 
primers from Sigma: CD24, CD44 and CD29 for isolated and unsorted cells of oral 
cancer cell lines and α-smooth muscle actin (α-SMA) for fibroblasts, while the U6 
gene was used as an endogenous control. Sequences of these genes for forward and 
reverse primers are illustrated in the table 2.3. Assays were performed in triplicate on 
a Rotor-Gene Q real-time PCR machine (QIAGEN, Germany). The thermal cycle 
consisted of 3 stages: 95oC for 10 seconds, 60oC for 15 seconds and 72oC for 20 
seconds for 40 cycles.  
The second technique involved using TaqMan probes. The components of reaction 
mix are shown in the table 2.2.B. This technique was used in this study to investigate 
the levels of IL-6 (TaqMan, assay ID: Hs00985639_mL, ThermoFisher, USA) gene 
expression in fibroblasts, whilst the B2M primer (TaqMan, assay ID: Hs00982282, 
Applied Biosystems, UK) was used as an endogenous control. The same qPCR 
machine was used as above however, the thermal cycle was different and was 
composed of 2 stages (95oC for 10 seconds and 60oC for 45 seconds) for 40 cycles.  
Rotor-Gene 2.1.0.9 software programme (QIAGEN, Germany) was used to analyse 
cycle threshold (Ct) values for all samples in both SYBR and TaqMan methods.  
The qPCR data was quantified using ΔΔCt method (Livak and Schmittgen, 2001; 
Schmittgen and Livak, 2008). The relative expression levels of both sorted (early 
adherent and chemoresistant) and unsorted samples were calculated and compared. At 
first, the ΔCt of target gene in each sample was calculated in comparison to its 
relevant reference housekeeping gene (that reflects the amount of cDNA existed in 
each sample) to normalize the variation in individual samples, as in the following 
equations: 
ΔCt sample sorted (early adherent or chemoresistant) = ΔCt target sorted - ΔCt reference sorted  
ΔCt sample unsorted = ΔCt target unsorted - ΔCt reference unsorted 
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Afterwards, ΔCt values were used for calculation of ΔΔCt values as in the following 
equation:  
ΔΔCt sample sorted= ΔCt sample sorted - ΔCt sample unsorted 
 
Finally, target gene expression fold change for each sorted sample was calculated as 
the following: 
Relative Quantification (RQ)=2- ΔΔCt 
Fold difference= log2(RQ)= - ΔΔCt 
Table 2.2: The components of reaction mixes used in analysis of the gene 
























 SYBR Green Master 
mix 
10 
TaqMan Master mix 
5 
Nuclease - free water 
 


















Total 20 Total 10 
                                                                           
                                                                                     (A) SYBR green reaction mix                (B) TaqMan reaction mix 
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Table 2.3: Sequences of the nucleotide of gene expression primers used for real 
time-PCR. 
                         Forward   5’ ACAGCCAGTCTCTTCGTGGT 3’ 
  CD24 
                     Reverse    5’ CCTGTTTTTCCTTGCCACAT 3’ 
                     Forward   5’ CTGCCGCTTTGCAGGTGTA 3’ 
 CD44 
 Reverse    5’ CATTGTGGGCAAGGTGCTATT 3’ 
         Forward   5’ AATGAATGCCAAATGGGACACGGG 3’ 
 CD29 
Integrin-β1    Reverse    5’ TTCAGTGTTGTGGGATTTGCACGG 3’ 
                        Forward   5’ GAAGAAGAGGACAGCACTG 3’ 
 α-SMA 
                     Reverse    5’ TCCCATTCCCACCATCAA 3’ 
                     Forward   5' CTCGCTTCGGCAGCACA 3' 
   U6 




2.15 Immunohistochemical staining  
 
Section slides (4μm thickness) of 10 cases of various oral squamous cell carcinoma 
were obtained from Oral and Maxillofacial Pathology unit, School of Clinical 
Dentistry under the ethical approval number (07/H1309/150) granted by the Sheffield 
Research Ethics Committee. The procedure was performed over two days.  
On the first day, sections were de-waxed by washing them twice for 5 minutes in 
xylene (Fisher Scientific, Leicestershire, UK) and they were re-hydrated by putting 
them in 100% ethanol (Fisher Scientific) twice for 5 minutes each time. Then, slides 
were incubated for 20 minutes in 3% (v/v) hydrogen peroxide (Fisher Scientific) in 
100% methanol (Fisher Scientific). Slides were rinsed with stirring in PBS and 
antigen retrieval was undertaken by putting slides in 0.01M sodium citrate solution 
and were subjected to high power in microwave (Panasonic NN-E252W) for 8 
minutes. After that they were washed and cooled in PBS. Slides were transferred to a 
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tray filled with water and blocking of sections was performed using of 100% horse 
serum at room temperature for 30 minutes afterwards the serum was tipped off. The 
last step of the first day involved application of diluted primary mouse monoclonal 
antibodies in horse serum 1/100 v/v (the optimised concentration) and each antibody 
was added to 3 sections for each case with one section without primary antibody as 
control. Then slides were incubated a humidified atmosphere overnight at 4°C. The 
primary antibodies that used in this study:  
1. Monoclonal human anti-CD24 antibody 2μg/mL (ab31622, Abcam, UK) 
2. Monoclonal human anti-CD44 antibody 0.5μg/mL (ab9524, Abcam, UK) 
3. Monoclonal human anti-alpha smooth muscle actin (α-SMA) antibody 10μg/mL 
(ab7817, Abcam, UK). 
 
On the second day, slides were washed twice in PBS with stirring (using magnet bead 
at 400 rpm) for 5 minutes each time. Mouse biotinylated secondary antibody 
VECTASTAIN® Elite ABC-Peroxidase Kits (Vector Laboratories, Peterborough, 
UK) was prepared by diluting of 1 drop in 10mL of PBS. Secondary antibody was 
added to slides and incubated for 30 minutes at room temperature. Meanwhile, Avidin 
Biotinylated enzyme Complex (ABC) reagent (Vector Laboratories) was prepared 
according to manufacturer’s instructions and was left for 30 minutes prior to use. 
After that, the secondary antibody was tipped off and ABC reagent was added to 
slides for 30 minutes to enable binding to the secondary antibody. Then slides were 
washed twice in PBS for 5 minutes each time.  
DAB 3,3’-diaminobenzidine tetrahydrochloride (Vector Laboratories) substrate was 
prepared according to manufacturer’s instruction and was added to slides until a dark 
brown precipitate appeared. The slides were transferred to distilled water to stop the 
reaction. After that slides were counterstained with haematoxylin using a Leica 
ST4020 Small Linear Stainer (Leica Microsystems, Milton Keynes, UK) and the steps 
of this procedure are shown in the table 2.4. The final stage involved mounting slides 
with cover slips using DPX non-aqueous mounting medium (Thermo Fisher 
Scientific, UK). 
Slides were digitally scanned using Aperio ScanScop (Leica Biosystem, USA) and 
were archived and viewed in the dentalmicroscopy.shef.ac.uk website using e.slide 
manager Digital Pathology software (Leica Biosystem, USA). Six images of same 
magnification were captured for selected equal sized regions of interest (ROI) of the 
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tumour invasive front regions in each tumour section slide using the Aperio 
ImageScope software (Leica Biosystem, USA) and a free hand tool of ImageJ 
software was used to select and analyse the specific ROI in the images to determine 
the percentage contribution of high, moderate and low density of antibody staining in 
each image and an average of them was calculated. Antibody staining density for each 
slide was determined by calculating the average value of the three positive densities 
for the six images for a specific slide. 
 
Table 2.4: The protocol for counterstaining using a small liner stainer. The 
duration of each step was 1 minute. 
Step Process 
1 Harris’s haematoxylin (x2) 
2 Running tap water 
3 
1% (v/v) acid alcohol 
(1% HCl in 70% isopropanol) 
4 Running tap water 
5 
Scott’s tap water substitute 
(3.5g/L sodium bicarbonate & 20g/L magnesium sulphate) 
6 Running tap water 
7 95% ethanol (x2) 
8 100% ethanol (x2) 




Cells were seeded at a density of 5,000 cells on a glass coverslip (Fisher Scientific, 
USA) in 1mL of their growth medium in a 24 well plate for 48 hours at 37oC. 
Medium was removed from wells of a 24 well plate that containing cells seeded on 
coverslips and were washed gently with PBS to avoid removing of cells. Coverslips 
were fixed with 100% methanol (Fisher Scientific, UK) for 15 minutes, permeabilised 
with 4mM sodium deoxycholate in PBS for 15 minutes followed by incubation with 
blocking buffer (2.5mg Bovine Serum Albumin in 100mL PBS) for 30 minutes at 
room temperature. Coverslips were incubated with 0.2mL of FITC conjugated anti-
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alpha smooth muscle actin (α-SMA) antibody (1:100 dilution, Clone A.4, Sigma, UK) 
for 1 hour at room temperature. They were washed 3 times with PBS. Before 
mounting using ProlongTM Diamond Antifade Mountant with DAPI (ThermoFisher, 
USA). Slides were viewed using a fluorescent microscope (Zeiss Axioplan 2 and the 
image-ProPlus 7.0.1 imaging software Zeiss, Ltd). 
 
2.17 Activation of NOFs by early adherent and chemo-resistant cells  
 Cells isolated either by adhesion (described in 2.3) or chemo-resistance (described in 
2.5) and their relevant unsorted cells were seeded with 1mL of their growth medium 
in a 24 well plate in triplicate at a density of 200,000 cells per well and incubated at 
37oC for 24 hours (figure 2.3). The following day, medium was removed and cells 
were washed in DMEM twice and 1mL low serum containing medium (0.5% FCS 
and DMEM: F12 3:1 with antimicrobials) was added and incubated at 37oC for 48 
hours. Meanwhile, glass coverslips were placed in a 12 well plate and were sterilised 
with 70% ethanol. Normal oral fibroblasts (NOFs) were plated on the coverslips 
containing wells with 1mL of their growth medium and their density was dependent 
on which assay was used (i.e. 5000 cells per well for immunofluorescence and 
100,000 cells per well for qPCR). Following incubation at 37oC for 24 hours, 
conditioned medium was transferred to labelled Eppendorf tubes which were 
centrifuged at 300 g for 10 minutes. Meanwhile, medium was removed from the 
NOFs seeded on coverslips and 1mL conditioned medium from isolated and unsorted 
cells was added to triplicate NOFs seeded coverslips wells. In addition, low serum 
medium containing 10ng/mL TGF-β1 (Human recombinant TGF-β1, R&D System) 
was added to triplicate NOFs seeded coverslips wells as a positive control as well as 
triplicate wells with just low serum medium as a negative control. Afterward the 



















Figure 2.3: Diagram summarizing the steps of the method of activation of NOFs 
by early adherent and chemo-resistant cells. 
 
2.18 Secretion of extracellular vesicles by early adherent and chemo-
resistant cells 
Isolated cells (early adherent or chemoresistant cells) and unsorted cells were seeded 
in 6 well plates with 2mL of their growth medium at 500,000 cells per well and 
incubated at 37oC for 24 hours. The next day, medium was removed and 1mL low 
serum containing medium was added and incubated at 37oC for 24 hours. Conditioned 
medium were transferred from isolated and unsorted cells to labelled Eppendorf tubes 
and placed on ice. The wells were washed with PBS and 500μL trypsin were added to 
each well and the 6 well plate was incubated at 37oC for 10 minutes followed by 
adding of 500μL of low serum medium to each well. The cell suspension was 
transferred into Eppendorf tubes for centrifugation (300 g, 5 mins). Cells were re-
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suspended in 1mL low serum medium and counted using a haemocytometer slide. 
Serial centrifugations were then performed on the collected condition medium 
samples. Firstly, they were centrifuged at 300 g for 10 minutes and supernatant of 
each sample were transferred to fresh labelled Eppendorf tubes. After that they were 
centrifuged at 2000 g for 15 min, followed by the last spin at 10000 g for 30 minutes. 
Samples were filtered using a 0.22μm centrifugal filter immediately before Tunable 
resistive pulse sensing (TRPS). An IZON Qnano machine (IZON Science Ltd., New 
Zealand) was used to perform TRPS and data analysed using iZON Control Suite 
software (IZON Science Ltd., New Zealand) to identify the concentration, size and 
distribution of vesicles in each sample. Finally, the exact number of vesicles per cell 
that produced by each sample were calculated according to the following equation: 
Number of extracellular vesicles of each sample =
vesicles raw count per mL 
number of cells for each sample per mL
 
 
2.19 Statistical analysis 
GraphPad Prism, version 7 software was used for analysis of all comparisons. Testing 
of statistical was performed using an unpaired two tailed Student’s t-test with P value 
< 0.05. Whereas, liner regression of scatter and Pearson’s coefficient were used to test 
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As described earlier, oral cancer is a heterogeneous disease (Mannelli and Gallo, 
2011), with poor prognosis due to failure of conventional anticancer therapies and a 
high recurrence rate as well as developing of metastasis and generating of secondary 
tumours at distant sites (Daniela et al., 2012). All these mentioned causes could be 
attributed to a small population of cells within a tumour which are called cancer stem 
cells (Prince and Ailles, 2008). Therefore, developing accurate and effective methods 
for isolation of CSCs is a crucial step for better understanding of the biological 
behaviour of these cells in cancer research (Beck and Blanpain, 2013) and 
subsequently, developing of novel strategies of targeting them (Zhou et al., 2009). 
Currently, various techniques are used for isolation of CSCs which are based on: cell 
sorting, image, molecular, functional and filtration approaches (Milne et al., 2009; 
Lianidou and Markou, 2011; Tirino et al., 2012; Podberezin, Wen and Chang, 2012). 
However, fluorescent activated cell sorting analysis (FACS) is considered the most 
common method that is used to identify and isolate CSCs on the basis of their 
expression of specific surface markers (Li et al., 2007; Vermeulen et al., 2012). 
However, FACS has several limitations that influence the accuracy of results. For 
instance, some extrinsic factors such as calibration of machine, compensation/gating 
protocol and use of appropriate controls as well as intrinsic factors such as cell 
confluence and clonal variations. In addition, expression of surface antigens does not 
necessarily reflect the behaviour of CSCs (Chen et al., 2014). Moreover, it has been 
reported that interactions of the tumour stroma with cancer cells have a great 
influence on the stemness properties of CSCs (Chaffer et al., 2011). On the other 
hand, some recent studies reported that functional methods of CSCs isolation based on 
their unique intrinsic features such as rapid adhesiveness to ECM proteins represented 
effective alternatives to FACS (Ling et al., 2014). 
Therefore, in this study we aimed to develop non-invasive, highly functional methods 
to form alternatives to FACS in order to isolate oral CSCs from oral cancer cell lines 
on the basis of the rapid adherence ability of CSCs to ECM proteins as well as their 
capability to resist conventional chemotherapies. Furthermore, we investigated the 
stability of the isolated cell phenotypes in culture several days after their isolation. In 
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addition, we explored if there is a phenotypic correlation between the populations of 
cells isolated by the two methods. 
 
3.2 The aims of the chapter 
1. To assess the factors that affect the adhesion of cells to ECM proteins in order 
to develop an effective adhesion assay by which we could isolate the most 
purified subpopulation of cells with CSC-like properties.   
2. To investigate the stability of the adherent phenotype in culture 2 days after 
the isolation. 
3. To assess the required IC90 (the conc. of cisplatin that kill approximately 90% 
of the total number of seeded cells) and isolate approximately 10% viable cells 
(chemoresistant cells) which are suspected to have CSC-like properties. 
4. To investigate the stability of the isolated chemoresistant phenotype after 
exposing to cisplatin for a second time compared to unsorted cells. 
5. To investigate if there is a phenotypic correlation between the isolated 





3.3 Methods  
The following methods were used in this chapter: 
• Cell culture (section 2.2) 
• Adhesion assay (section 2.3) 
• Cell counting (section2.3)  
• Determination the stability of the early adherent phenotype (section 2.4) 
• Chemoresistance assay (section 2.5) 
• Determination the stability of the chemoresistant phenotype (section 2.6) 
• Chemoresistance of early adherent cells (section 2.7) 
• Adhesion of chemoresistant cells (section 2.8) 
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3.4 Results  
3.4.1 Assessment of the effects of time, ECM proteins and oral cancer 
cell line on the adhesion rate and isolation of early adherent cells. 
The adhesion of both H357 and SCC4 oral cancer cell lines (OCCL) to collagen I and 
fibronectin was investigated at different incubation time points from 10 minutes to 60 
minutes at 10 minutes intervals.  
The results show that adhesion of both oral cancer cell lines is less to fibronectin than 
that to collagen I at all time points and it is considerably less at 10 minutes. The 
adhesion to both ECM proteins increases with incubation time (figure 3.1 and 3.3). 
Maximum adhesion of H357 cells to collagen I was achieved after 30 minutes. 
H357 cells adhere to both collagen I and fibronectin at a significantly higher level 
compared to the control (uncoated wells) at all-time points. Moreover, significantly 
more H357 cells attached to collagen I than to fibronectin at all-time points figure (3.1 
and figure 3.2). 
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Figure 3.1: Adhesion of H357 cell line to collagen I (blue line), fibronectin (red line) and 
control (green line) at different time points. All the assays were performed in triplicate and 
repeated three times. The error bar represents SEM. (p-value <0.0001) indicates the statistical 
difference of adhesion of H357 cell line to collagen I compared to fibronectin as well as the 
adhesion to both collagen I and fibronectin compared to control at all time points. 
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Figure 3.2: Photomicrographs showing the difference in adhesion of the H357 
cell line to collagen I, fibronectin and control at different time points. The 
adhesion of H357 cells to fibronectin is noticeably less than that to collagen I at 10 
minutes and the adhesion to both ECM is increased with incubation time. Maximum 
cell adhesion occurs to collagen I after 30 minutes. No noticeble cell adhesion to 
control (uncoated wells) was seen at all time points. 
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The adhesion of the SCC4 oral cancer cell line to both collagen I and fibronectin was 
significantly higher than control. However, more SCC4 cells adhere to collagen I 
compared to fibronectin at all-time points (figure 3.3). In addition, the findings 
demonstrated that SCC4 cell line adheres significantly higher to collagen I and 
fibronectin than H357 cell line at all-time points. 
Our findings showed that the average number of early adherent cells of both oral 
cancer cell lines to fibronectin at 10 minutes represented less than 10% of the average 
number of the seeded cells (H357= 4.49% and SCC4= 5.51%), figures 3.4 and 3.5. 
Therefore, we selected the adhesion of OSCC cell lines to fibronectin at 10 minutes to 
isolate CSCs in order to obtain a more purified population of CSC-like cells.  
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Figure 3.3: Adhesion of SCC4 cell line to collagen I (blue line), fibronectin (red 
line) and control (green line) at different time points. All the assays were 
performed in triplicate and repeated three times. The error bar represents SEM. (p-
value <0.0001) indicates a statistical difference of adhesion of SCC4 cell line to 
collagen I compared to fibronectin as well as the adhesion to both collagen I and 
fibronectin compared to control at all-time points. 
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Figure 3.4: The number of early adherent H357 cells to fibronectin at 10minutes 
time point compared to the total number of seeded cells. The early adherent cell 
number (light grey column) = 4.49% of the total number of seeded unsorted H357 
cells (dark grey column). The error bar represents SEM. P value < 0.0001. 
























Figure 3.5: The number of early adherent SCC4 cells to fibronectin at 10minutes 
time point compared to the total number of seeded cells. The early adherent cell 
number (light grey column) = 5.51% of the total number of seeded unsorted SCC4 
cells (dark grey column). The error bar represents SEM. P value < 0.0001.  
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3.4.2 Effect of cell detachment solution on the adhesion rate 
This experiment was performed to investigate if there is an influence of the different 
types of cell detachment solution on subsequent the cell adhesion. The result showed 
no significant difference in cell adhesion of the H357 cell line to both collagen I and 
fibronectin proteins, whether trypsin/EDTA or Accutase was used as a cell 
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Figure 3.6: The effect of two different cell detachment solutions trypsin and Accutase on 
the adhesion of H357 cell line to ECM proteins (collagen I and fibronectin). The black 
columns represent the adhesion of cells detached by using trypsin. The grey columns 
represent the adhesion of the H357 cell detached by using Accutase. For collagen I (P value = 
0.88), Fibronectin (P value = 0.51). 
 
3.4.3 Stability of early adherent phenotype 
 In these experiments the stability of early adherent phenotype of the two oral cancer 
cell lines (H357 and SCC4) was assessed by measuring their early adhesion rate to 
fibronectin after incubation at 37oC for 48 hours.  
The early adherent phenotype of  both cell lines H357 and SCC4, was conserved to 
fibronectin after incubation for 48 hours and was significantly higher compared to 
unsorted cells, (figures 3.7 and 3.8). 
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Figure 3.7: Stability of early adherent phenotype of H357 cell line to fibronectin. The 
dark grey columns represent the adhesion of unsorted cells phenotype, while the light grey 
columns represent the adhesion of early adherent phenotype. The first adhesion assay was 
performed by measuring the adhesion after 10 minutes on the same day of cell isolation while 
the second adhesion assay represented a repeating of adhesion for 10 minutes after 48 hours 
incubation of both early adherent and unsorted cells in culture. The error bar represents SEM. 
P value = 0.03 in the first adhesion assay and P = 0.01 in the second adhesion.  
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Figure 3.8: Stability of early adherent phenotype of SCC4 cell line to fibronectin. The 
dark grey columns represent the adhesion of unsorted cells phenotype, while the light grey 
columns represent the adhesion of early adherent phenotype. The first adhesion assay was 
performed by measuring the adhesion after 10 minutes on the same day of cell isolation while 
the second adhesion assay represented a repeating of adhesion for 10 minutes after 48 hours 
incubation of both early adherent and unsorted cells in culture. The error bar represents SEM. 
P value = 0.0008 in the first adhesion assay and P = 0.001 in the second adhesion.  
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3.4.4 Assessment of sensitivity of oral cancer cell lines to cisplatin and 
isolation of chemoresistant cells. 
Cytotoxicity assays were performed using a range of cisplatin concentrations on both 
OSCC cell lines (H357 and SCC4) and drug inhibtory response curves were ploted to 
determine the values of IC90 (drug inhibtory concentration 90) which is the 
concentration of drug that kills 90% of cells, the remaining 10% of cells which were 
viable were then subjected to further characterisation.   
The findings demonstrated that the IC90 of H357 cell line was 15μM (figure 3.9), 
whereas for SCC4 cell line was 17.5μM (figure 3.10). Overall there was no 
significance difference in the sensitivity between the 2 cell lines. 
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Figure 3.9: Drug inhibitory response curve of H357 cell line to cisplatin. 
Concentrations of cisplatin were represented by Logarithms and the drug inhibitory 
curve and IC90 were generated using GraphPad prism software. IC90= 15μM. 
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IC 9 0 =  1 7 .5 M
Figure 3.10: Drug inhibitory response curve of SCC4 cell line to cisplatin. Concentrations 
of cisplatin were represented by Logarithms and the drug inhibitory curve and IC90 were 
generated using GraphPad prism software. IC90= 17.5μM.  
The average number of viable H357 cells after treatment using the previously 
determined IC90 concentrations represented 8.7% of the average total number of 









Figure 3.11: The number of chemoresistant H357 and SCC4 cells compared to the total 
number of seeded cells before treatment. The light grey columns represent the number of 
chemoresistant cells which presented for H357= 8.7% and for SCC4=10.2% of the total 
number of seeded unsorted cells which are represented by the dark grey columns. The error 
bar represents SEM. P value < 0.0001.  
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3.4.5 Stability of chemoresistant phenotype 
The stability of the chemoresistant phenotype was determined by exposing previously 
treated chemoresistant cells to the same concentration of cisplatin again and 
comparing their viability to that of untreated cells that had not been previously 
exposed to the drug. 
The results showed that was significantly higher levels of viability of chemoresistant 
cells of both OSCC cell lines (H357 and SCC4) in comparison to untreated cells, 
figures 3.12 and 3.13.  
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Figure 3.12: Stability of the chemo-resistant phenotype of H357 cell line after re-
treatment compared to untreated unsorted cells. The dark grey columns represent 
the cell viability of untreated unsorted cells phenotype, while the light grey columns 
represent the cell viability of chemoresistant phenotype. The error bar represents 
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Figure 3.13: Stability of the chemo-resistant phenotype of SCC4 cell line after re-
treatment compared to untreated unsorted cells. The dark grey columns represent 
the cell viability of untreated unsorted cells phenotype, while the light grey columns 
represent the cell viability of chemoresistant phenotype. The error bar represents 
SEM. P value < 0.0001.  
 
3.4.6 Determination the chemoresistance of early adherent cells 
In order to investigate the chemoresistance capability of early adherent cells, they 
were treated with 15μM cisplatin. Then cell viability was calculated and compared of 
both adherent cells and unsorted cells. 
The early adherent H357 and SCC4 cells exhibited higher levels of resistance to the 
chemotherapy with significantly increased levels of viability than unsorted cells. 
(figures 3.14 and 3.15). 
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Figure 3.14: The chemoresistance of early adherent H357 cells after treatment with 
15μM cisplatin compared to that of unsorted cells. The dark grey column represents the 
cell viability of unsorted cells phenotype, while the light grey column represents the cell 









Figure 3.15: The chemoresistance of early adherent SCC4 cells after treatment with 
15μM cisplatin compared to that of unsorted cells. The dark grey column represents the 
cell viability of unsorted cells phenotype, while the light grey column represents the cell 
viability of early adherent phenotype. The error bar represents SEM. P value = 0.0002. 
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3.4.7 Determination the adhesion of the chemoresistant cells 
Adhesion assays were performed on the isolated chemoresistant cells from OSCC cell 
lines to identify their adhesion to fibronectin and compare it to that of unsorted cells. 
The results demonstrate significantly higher adhesion of the isolated chemoresistant 
cells of both cell lines H357 (P value <0.0001) and SCC4 (P value = 0.0002) 
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Figure 3.16: The adhesion of chemoresistant H357 cells and unsorted cells to the 
fibronectin. The light grey column represents the adhesion rate of the chemoresistant 
phenotype, while the dark grey column represents the adhesion rate of unsorted cells 
phenotype. The error bar represents SEM. P value < 0.0001. 
 

























































Figure 3.17: The adhesion of chemoresistant SCC4 cells and unsorted cells to the 
fibronectin. The light grey column represents the adhesion rate of the chemoresistant 
phenotype, while the dark grey column represents the adhesion rate of unsorted cells 












3.5.1 Assessment of the effects of time, ECM protein and oral cancer 
cell line on cell adhesion and isolation of early adherent cells.  
Collagen I is one of the most common extracellular matrix molecules and is arranged 
as fibrils in the connective tissue of different body tissues particularly that are exposed 
to pressure, tensile or shear forces. It is formed by mesenchymal cells such as 
fibroblasts and myofibroblasts (Bosman and Stamenkovic, 2003). Whereas, 
fibronectin is a matrix glycoprotein occurs in cell matrix throughout body tissues 
(Kosmehl et al., 1999) and has an important role in cell proliferation, adhesion and 
migration (Ioachim et al., 2005). Both collagen I and fibronectin are considered as 
chemoattractants for oral cancer cell lines (Bitu et al., 2012). They provide anchorage 
to oral cancer cells facilitating their growth, spread and subsequent migration and 
invasion (Radisky, 2005). Attachment of cells to ECM proteins such as collagens, 
fibronectin and laminin are mediated by integrin family of surface receptors. Integrins 
are heterodimers consisting of 2 transmembrane glycoproteins which are non-
covalently associated called α and β subunits. There are many possible combinations 
of these subunits which define the substrate binding specificity. For example, α2β1 
(receptor of collagen), α3β1 (receptor of laminin), α5β1 (receptor of fibronectin) and 
αvβ6 (receptor for tenascin and fibronectin) (Watt and Hertle, 1994). There are 
variations in integrin receptor expression with the highest levels confined to basal cell 
layer including stem cells and their levels are inversely related to cell differentiation. 
In addition, to their role in adhesion and migration of cells, integrins can regulate the 
differentiation of cells through signals transduction between the cells and extracellular 
microenvironment (Watt, 2002).  
Our data showed a significant rapid adhesion of OSCC lines H357 and SCC4 to both 
collagen I and fibronectin compared to the adherence of controls. This might 
attributed to the high expression and increased functional activity of β1 integrin 
receptors (Jones and Watt, 1993; Jones et al., 1995). Furthermore, several studies 
found a strong correlation between cell adhesion to ECM proteins and the levels of β1 
integrins, i.e. significant reduction of β1 integrins levels and/or down-regulating of 
functional activity of pre-existing β1 integrins leads to a significant decrease in 
adhesiveness of cells to ECM proteins (Adams and Watt, 1989; Hotchin and Watt, 
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1992; Jones and Watt, 1993). Therefore, to confirm that rapid adherence of isolated 
early adherent cells was due to the high expression of α5β1 integrin, we could use an 
antibody specifically block it and see this reduces and inhibits rapid adhesion of these 
cells.  
Our results showed that adhesion of both cell lines (H357 and SCC4) to collagen I 
was significantly higher at all time points compared to fibronectin and reached a 
maximum after 30 minutes compare to fibronectin (section 3.4.1). This could be due 
to the fact that collagen receptors (α2β1) are constitutive receptors and considered as 
the most abundant epithelial integrin receptors (Watt and Hertle, 1994) while 
fibronectin receptors (α5β1 and αvβ6) are induced in culture or in certain pathological 
condition such as upon wounding (Watt and Hertle, 1994; Breuss et al., 1995; 
Zambruno et al., 1995; Häkkinen et al., 2000). 
Therefore, the large number of rapidly adhering cells to collagen I could render it 
unsuitable for sorting of CSCs and this in consistent with studies by Kaur and Li 
(2000) who considered collagen I and IV inappropriate for isolation of keratinocyte 
stem cells from basal layer cells due to the expression of functionally active α2β1 
(collagen receptors) by most cells of this layer. As a result, we used fibronectin to 
isolate CSCs in order to obtain a more purified population of cells and this is in 
agreement with a number of other studies (Jones and Watt, 1993; Dowthwaite et al., 
2003; Hall et al., 2006). Moreover, David and her colleagues (2010) used differential 
adhesion to fibronectin to isolate adult stem cells from oral mucosa lamina properia.     
Many studies predict that the percentage of stem cells is less than 10% of the total 
unfractionated keratinocytes (Withers, 1967; Potten and Morris, 1988; Bickenbach 
and Chism, 1998; Clausen and Potten, 1990; Jones et al., 1995). This is in accordance 
with our study (section 3.4.1), in that we found the number of rapidly adhering cells 
(the isolated cells) using fibronectin from both oral cancer cell lines was less than 
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3.5.2 Effect of cell detachment solution on cell adhesion  
Our results showed that there was no difference in the adhesion rate of oral cancer cell 
lines to ECM proteins when either trypsin/EDTA or Accutase cell detachment 
solutions were used. Therefore, we suggest that trypsin/EDTA does not disturb cell 
surface integrin expression. However, we used Accutase as detachment solutions for 
cells in flow cytometry experiments due to the fact that it is thought to preserve 
maximally cell surface proteins (Harper et al., 2007).  
 
 
3.5.3 Stability of the isolated phenotype (early adherent and 
chemoresistant phenotype) 
 
In the current study, the stability of the phenotypes isolated using the two functional 
methods (adhesion and chemoresistance) from the both OSCC cell lines (H357 and 
SCC4) was investigated. The findings showed that the early adherent phenotypes 
from H357 and SCC4 exhibited significant higher levels of rapid adhesion to 
fibronectin after two days incubation in culture compared to unsorted cells, section 
(3.4.3). Furthermore, the results demonstrate that isolated chemoresistant populations 
from H357 and SCC4 cell lines expressed significantly less sensitivity to 
chemotherapeutic agent compared to untreated cells section (3.4.5).    
To our knowledge there are no previous reports that have investigated the stability of 
the early adherent phenotype, whilst our findings on stability of the chemoresistant 
phenotype is in accordance with that reported by Kim, Roopra and Alexander, (2012) 
and Bertolini et al., (2009). Kim and his colleagues (2012) found an increased mitotic 
index of CSC-like cells after a second administration of chemotherapeutic drug and 
that these cells were able to regenerate tumours after serial passages. Furthermore, 
Bertolini and his colleagues (2009) revealed that an isolated subpopulation of CD133 
positive cells expressed high levels of stemness-associated genes and were resistant to 
cisplatin exposure, establishing a stable chemoresistant phenotype in vitro. 
Several reports show that heterogeneous tumour populations have a tendency over 
time to maintain a fixed equilibrium of phenotypic proportions called a phenotypic 
equilibrium and that this has been shown in vivo as well as in cell lines in vitro (Gupta 
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et al., 2011; Iliopoulos et al., 2011; Zapperi and La Porta, 2012). In addition, CSC 
have the ability to change their stem cell status through reversible fluctuations and this 
known as phenotypic plasticity (Chaffer et al., 2011; Gupta et al., 2011; Yang et al., 
2012). It has been reported that acquiring or losing stem-like characteristics by cancer 
cells in phenotype plasticity can be induced either by signals from the 
microenvironment or in response to anticancer therapy (Junttila and Sauvage, 2013; 
Lacina et al., 2015). 
Gupta and his colleagues (2011) reported that the phenotypic state of cancer cells is 
stable and the phenotypic equilibrium is maintained over time through inter-
conversions between cancer cell phenotypic states under fixed conditions. Therefore, 
they proposed a model of cell-state dynamics (Markov chain) to explain the transition 
of phenotypes in breast cancer cell lines. Iliopoulos and his colleagues (2011) 
revealed in their study that the CSCs proportion in many cell lines is retained and 
stable over multiple generations due to switching between CSCs and cancer cells in a 
dynamic equilibrium. 
Zapperi and La Porta, (2012) provided other explanations to the phenotypic 
equilibrium and stability of the CSC phenotype. They proposed two models: the 
phenotypic switching model and the imperfect CSC biomarker model. In the first 
model they suggest reversible transformation of cancer cells to a CSC state in order to 
retain the same discrimination between CSCs and cancer cells. On the other hand, the 
imperfect markers model was based on the inaccuracy of FACS sorting and suggests 
that the subpopulation with positive CSC markers is rich CSCs, while the 
subpopulation with negative CSC markers is low but not entirely devoid of CSCs. As 
a consequence, the CSCs (within the negative marker subpopulation) will re-establish 
the subpopulation with positive markers and subsequently drive tumourgenesis. 
Moreover, they found that there was no significance difference in the outcomes of the 
two models and both of them were in accordance with the Markov chain model 
reported by Gupta and his colleagues (2011).  
Yang and his colleagues (2012) investigated two human cancer cell lines (colon and 
breast cell lines) in normal and irradiated conditions and found that there is an 
intrinsic homeostasis between CSCs and cancer cells. In addition, the stability of the 
CSC proportion was maintained due to the balance between the transition of cancer 
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cells to CSCs and the self-renewal, differentiation and asymmetric division of CSCs 
on the other side.  
Liu and his colleagues (2013) examined the dynamic interaction between cancer cells 
and CSCs by developing a mathematical model to determine the proportion of CSCs. 
They found that the balance of CSC and cancer cell phenotypes and the maintenance 
of CSC proportion was controlled by negative feedback mechanisms of non-linear 
growth kinetics of CSCs.  
 
3.5.4 Assessment of the sensitivity of oral cancer cell lines to cisplatin 
and isolation of chemoresistant cells. 
Cisplatin is a well-known and potent anticancer agent, used in the treatment of a range 
of solid tumors including head and neck squamous cell carcinoma (Siddik, 2003). The 
cytotoxic action of cisplatin is mainly targeted to the DNA of cells (Eastman, 1983) 
leading to the formation of DNA adducts (Eastman, 1987). As a result of these 
adducts, many cellular functions controlled by DNA are affected such as suppression 
of DNA replication and RNA transcription as well as arresting of cell cycle 
(Zdraveski et al., 2002; Vogelstein, Lane and Levine, 2000). In addition, apoptosis 
activating signals are mediated by DNA damage that result primarily from intrastrand 
crosslinks due to drug-DNA interactions (Eastman, 1987). Furthermore, the binding 
of damage recognition proteins (DRPs) which form part of the mismatch repair 
(MMR) complex with DNA physical distortions mediate the initiation of sequential 
events that extend from DNA adduct formation to the completion of apoptosis 
(Siddik, 2003). 
As previously described, CSCs are more resistant to chemotherapeutic agents 
including cisplatin (section 1.2.4). Furthermore, because DNA is the main target of 
cisplatin, the chemoresistance of CSCs is attributed to the inhibition of signal 
propagation from DNA damage to apoptosis activation. Also there is increased repair 
of DNA adducts by several mechanisms such as: repair of DNA crosslinks by 
overexpression of topoisomerase II and activation of the NER pathway which is 
considered a crucial pathway in removal of platinum adducts (Siddik, 2003). 
Chapter 3 Isolation and Stability of CSCs Phenotype 
90 
 
In our study, a wide range of cisplatin concentrations on both H357 and SCC4 cell 
lines were investigated from 0.5μM- 50μM (section 3.4.4) for 24 hours treatment and 
5 days recovery time during which time cells continued to die. We selected an 
inhibitory concentration of 90% (IC90) that yielded 10% of viable cells from the total 
number of treated cells which represents the chemoresistant cells (CSCs) and this in 
agreement with many studies that reported the percentage of CSCs in the total number 
of keratinocytes was equal or less than 10% (Withers, 1967; Potten and Morris, 1988; 
Bickenbach and Chism, 1998; Clausen and Potten, 1990; Jones et al., 1995). 
Recent studies have been conducted to isolate CSCs from different cancer cell lines 
using cisplatin and reported a variety of cisplatin concentrations and duration of 
treatment. For instance, Ma et al., (2010) isolated CSCs from the SKOV3 ovarian 
cancer cell line using cisplatin at a concentration 40μM for 7 days, while Lopez-
Ayllon et al., (2014) reported in their study 2 concentrations of cisplatin to isolate 
CSCs from 2 different lung cancer cell lines H460 and A549 which were 1.7μM and 
8.3μM respectively for 72 hours. However, our findings showed that the appropriate 
concentrations of cisplatin for isolation of CSCs from oral cancer cell lines were 
15μM for the H357 cell line and 17.5μM for the SCC4 cell line for 24 hours. The 
wide variation of cisplatin concentrations and duration of treatment was attributed to 
the difference in cisplatin sensitivity and drug inhibitory responses between cancer 
cell lines (Carmichaell et al., 1988; Barr et al., 2013). The critical parameters in the 
isolation of CSCs using a chemoresistance assay are the concentration of 
chemotherapeutic agent, duration of treatment and the period of time during which the 
isolated cells stay viable after isolation (Cole et al., 2014). Therefore, in this study we 
considered these parameters carefully in the assessment of the required concentration 
of cisplatin, period of treatment and viability of isolated cells during the recovery 
period.   
Furthermore, the main limitation we faced in this experiment was the slow and 
continuous dying of cells during the recovery period that affected the final percentage 
of viable cells. Therefore, to overcome this problem we decided to reduce the time of 
treatment and selected the appropriate concentration of the drug as well as leaving the 
cells for 5 days for recovery in order to obtain 10% of viable cells. Similar issues were 
faced by Cole and his colleagues (2014) when they used the same protocol of Ma et 
al., (2010) for isolation of CSCs from the SKOV3 ovarian cancer cell line. 
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Modifications of the protocol were made by reducing the cisplatin concentration from 
40μM for 7 days to 20μM for 72 hours. 
 
3.5.5 Determination the chemoresistance of early adherent cells and 
the early adhesion of the chemoresistant cells 
These experiments were performed to investigate if there is a correlation between the 
phenotypes of cell populations isolated using the two different functional methods. 
This was considered a novel approach because almost all previous reported studies 
focused on isolation of CSCs either by FACS analysis or single functional assay and 
then further characterized by more functional assays. 
Our findings showed that early adherent cells of both cancer cell lines (H357 and 
SCC4) expressed significantly higher levels of viability after cisplatin treatment in 
comparison to unsorted cells (section 3.4.6). This finding is in agreement with that 
reported by several studies that found enhanced cisplatin chemoresistance in cancer 
cells with increased adhesion to fibronectin (Sethi et al., 1999; Matter and Ruoslahti, 
2001; Nakahara et al., 2003; Hartmann et al., 2005). Several mechanisms have been 
suggested to explain this phenomenon. Sethi et al., (1999) found that cancer cell 
adhesion to fibronectin activates α5β1 integrin to mediate survival signals that trigger 
activation of tyrosine kinases that inhibit apoptosis induced by chemotherapy. Matter 
and Rouslahti, (2001) showed in their study that adhesion to fibronectin modulates 
chemoresistance by activation of survival signal pathway resulting in overexpression 
of the anti-apoptotic bcl-2 protein. The pathway mediated by α5β1 integrin activates 
focal adhesion kinase (FAK) which in turn activates Ras and the PI3K-AKT pathway 
which enhances transcription of the bcl-2 protein. Nakahara and his colleagues (2003) 
revealed that adhesion to fibronectin mediated by a α5β1 integrin in a head and neck 
squamous cell line activates phosphorylation of FAK that initiates a survival signaling 
pathway leading to increased chemoresistance to cisplatin. Furthermore, they found 
that treating cells with a neutralizing antibody to α5β1 integrin leads to a complete 
abolishment of cisplatin-resistance rendering cells highly sensitive to cisplatin 
chemotherapy. 
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 Our results revealed that the isolated chemoresistant cells of H357 and SCC4 cell 
lines demonstrated increased levels of rapid adherence to fibonectin compared to 
unsorted cells (section 3.4.7). This is in accordance with the study of Vallo et al., 
(2017) who showed up-regulating levels of β1 integrin expression in cisplatin-
resistant urethral cancer cell lines and functional suppression of β1 integrin leads to a 
significant reduction in the adhesion of these cells compared to untreated control cells. 
 
3.6 Conclusions  
We can conclude that cell adhesion is higher to collagen I than to fibronectin and 
maximal cell adhesion occurred after 30 minutes. Rapid adhesion to fibronectin at 10 
minutes and chemoresistance to 15μM cisplatin isolate less than 10% of the average 
total number of the seeded cells for both oral cancer cell lines (H357 and SCC4). In 
addition, the increased chemoresistance of early adherent cells and the increased 
adherence of cisplatin-resistant cells suggest that these two methods are isolating 
phenotypically overlapping populations of CSCs. The isolated phenotype (early 
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4.1 Introduction  
Characterisation of the biological and molecular properties of the cancer stem cells 
isolated in chapter (3) was considered a crucial step to verify the ‘stemness’ of the 
population in order to study their characteristics accurately with the aim of subsequent 
specific targeting and eradicating of these cells (Ailles and Weissman., 2007).  
It has been reported that CSCs have distinctive characteristics discriminating them 
from other cancer cells within tumor which are: they form a minor population of cells, 
they are capable of self-renewal and differentiation to multiple non-tumourigenic cell 
lineages and they express of specific surface cell markers according to type of cancer 
(Clarke et al., 2006; Dalerba et al., 2007) as well as they are tumourigenic and resist 
to conventional anticancer therapy (Reya et al., 2001). In addition, there is a 
distinctive gene expression profile reflecting the biology of these CSCs that drives the 
progression of tumour (Sgroi et al., 1999; Leethanakul et al., 2001).  
In general, two approaches were used to characterise CSCs: investigation of specific 
protein expression and functional assays (Dobbin and Landen, 2014). 
In the current study, we characterised the sorted cells from the two functional methods 
(adhesion and chemoresistance) using FACS analysis and gene-expression profile of 
the three common head and neck squamous cell carcinoma cancer stem markers 
(CD24, CD44 and CD29). In addition, proliferation and colony forming assays were 
performed as functional measures of ‘stemness’ as well as examination of capability 
of the isolated cells to secrete extracellular vesicles. This was performed as EVs have 
roles in communication between various cells in tumour microenvironment, as well as 
mediation of different signalling pathways that enhance proliferation, survival and 
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4.2 The aims of the chapter  
1. To investigate the expression of stem cell surface markers in the isolated cells.  
2. To investigate the expression of stem cell associated genes in the isolated 
cells. 
3. To compare the proliferation capacity of the isolated cells to that of unsorted 
cells.  
4. To investigate the clonogenic potential of the isolated cells. 
5. To investigate the capability of isolated cells to secrete extracellular vesicles in 
comparison to that of unsorted cells. 
 
4.3 Methods 
The following methods were used in this chapter: 
• Cell culture (section 2.2) 
• Isolation of early adherent cells by adhesion assay (section 2.3) 
• Isolation of chemoresistant cells by chemoresistance assay (section 2.5) 
• Flow cytometry for stem cell surface markers expression (section 2.11) 
• RNA extraction from isolated and unsorted cells (section 2.12) 
• cDNA synthesis (section 2.13) 
• Real time –Polymerase chain reaction (qPCR) (section 2.14) 
• Proliferation assay (section 2.9) 
• Colony forming assay (section 2.10) 
• Determination of extracellular vesicles produced by early adherent and 










4.4.1 Stem cell surface markers analysis by flow cytometry 
In this experiment, the expression of three well-known head and neck squamous cell 
carcinoma specific stem cell surface markers (CD24, CD44 and CD29) were 
investigated using FACS analysis in the isolated cells from both oral cancer cell lines 
using rapid adhesion and chemoresistance and the levels compared to that of unsorted 
cells. 
The results showed that isolated early adherent cells of the both cell lines H357 and 
SCC4 expressed significantly higher levels of all the examined stem cell surface 
markers (CD24, CD44 and CD29) compared to the unsorted cells, as illustrated in 
figures 4.1 and 4.2 respectively.   
The enhanced expression of CD29 marker in particular by the early adherent cells of 
both examined oral cancer cell lines compared to unsorted cells was expected because 
β1 integrins are the main receptors that bind cells to the ECM proteins. Moreover, this 
finding could explain and support our results in previous (chapter 3), that showed 
early adherent cells rapidly attached to fibronectin compared to unsorted cells. 
The chemoresistant cells isolated from H357 and SCC4 oral cancer cell lines also 
exhibited significantly increased levels of CD24, CD44 and CD29 in comparison to 
unsorted cells, as shown in figures 4.3 and 4.4. 
However, our data showed that the biggest difference in expression of stem cell 
markers between early adherent H357 cells and unsorted cells was in CD44 
expression. Whereas, CD24 was expressed by both early adherent SCC4 cells and 
chemoresistant H357 with biggest differences compared to unsorted cells. Finally, 
CD29 represents the stem cell marker with biggest difference in expression between 
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Figure 4.1: Expression of stem cell surface markers by early adherent and 
unsorted H357 cells. (A, B, C) Representative histograms of the median fluorescence 
value were plotted against the number of CD24, CD44 and CD29 positive cells; 
respectively, early adherent cells (red), unsorted cells (blue) early adherent unstained 
–negative control- (green) and unsorted unstained– negative control- (brown). The 
graphs represent one of at least 3 independent experiments. (D, E, F) Histogram bars 
represent means ± SD of three independent experiments of expression of CD24, CD44 
and CD29 respectively by early adherent cells (light grey) and unsorted cells (dark 
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Figure 4.2: Expression of stem cell surface markers by early adherent and 
unsorted SCC4 cells. (A, B, C) Representative histograms of the median 
fluorescence value were plotted against the number of CD24, CD44 and CD29 
positive cells; respectively, early adherent cells (red), unsorted cells (blue) early 
adherent unstained –negative control- (green) and unsorted unstained –negative 
control- (brown). The graphs represent one of at least 3 independent experiments. (D, 
E, F) Histogram bars represent means ±SD of three independent experiments of 
expression of CD24, CD44 and CD29 respectively by early adherent cells (light grey) 
and unsorted cells (dark grey). *, **, **** Indicate statistically significant differences 
at (P< 0.05), (P<0.001) and (P<0.0001) respectively.  
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Figure 4.3: Expression of stem cell surface markers by chemoresistant and 
unsorted H357 cells. (A, B, C) Representative histograms of the median fluorescence 
value were plotted against the number of CD24, CD44 and CD29 positive cells; 
respectively, chemoresistant cells (red), unsorted cells (blue) unstained chemoresistant 
–negative control- (green) and unstained unsorted–negative control- (brown). The 
graphs represent one of at least 3 independent experiments. (D) Histogram bars 
represent means ± SD of three independent experiments of expression of CD24, CD44 
and CD29 respectively by early adherent cells (light grey) and unsorted cells (dark 
grey). *, **, *** Indicate statistically significant differences at (P< 0.05), (P<0.001) 
and (P<0.0001) respectively.  
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Figure 4.4: Expression of stem cell surface markers by chemoresistant and 
unsorted SCC4 cells. (A, B, C) Representative histograms of the median 
fluorescence value were plotted against the number of CD24, CD44 and CD29 
positive cells; respectively, chemoresistant cells (red), unsorted cells (blue) unstained 
chemoresistant –negative control- (green) and unstained unsorted–negative control- 
(brown). The graphs represent one of at least 3 independent experiments. (D) 
Histogram bars represent means ± SD of three independent experiments of expression 
of CD24, CD44 and CD29 respectively by early adherent cells (light grey) and 
unsorted cells (dark grey). *, ** Indicate statistically significant differences at (P< 
0.05) and (P<0.001) respectively. 
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4.4.2 Genetic characterisation of isolated CSCs 
The RNA expression of stem cell associated genes was determined in isolated CSCs 
(early adherent and chemoresistant) and compared with that of unsorted cells using 
quantitative real time-PCR (qPCR) analysis. Three of commonly used head and neck 
squamous cell carcinoma ‘stemness’ related genes were selected to be investigated in 
this experiment which were CD24, CD44 and CD29 (Han et al., 2009; Ling et al., 
2014). 
Our findings of qPCR analysis revealed that all examined genes (CD24, CD44 and 
CD29) were significantly up-regulated in the isolated early adherent cells from both 
cancer cell lines (H357 and SCC4) compared to that in unsorted cells. The fold 
increase of the early adherent cells of the H357 cell line in comparison with that of 
unsorted cells were as follows: 6 fold for CD24, 4 fold for CD44 and 2 fold for CD29 
respectively (figure 4.5). Whereas, the elevated fold change in early adherent cells of 
SCC4 cell line were: 2 fold for CD24 and 1.5 fold for both CD44 and CD29 compared 
to that in unsorted cells (figure 4.6).  
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Figure 4.5: The mean fold change in CD24, CD44 and CD29 stem associated gene 
expression by the early adherent cells (light grey) of H357 cell line relative to the 
unsorted control (dark grey), ±SD of at least 3 independent experiments performed in 
triplicate. *, **, **** Indicate statistically significant differences at (P<0.05), (P<0.001) and 
(P<0.0001) respectively. 
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Figure 4.6: The mean fold change in CD24, CD44 and CD29 stem cell associated 
gene expression by the early adherent cells (light grey) of SCC4 cell line relative 
to the unsorted control (dark grey), ±SD of at least 3 independent experiments 
performed in triplicate. **, *** Indicate statistically significant differences at 
(P<0.001) and (P<0.0001) respectively. 
 
The isolated chemoresistant cells from H357 showed significant up-regulation of the 
investigated genes as follows: 55 fold for CD24, 12 fold for CD44 and 2 fold for 
CD29 expression compared to unsorted control as illustrated in the figures 4.7 A, B 
and C respectively. At the same time, qPCR analysis of the chemoresistant and 
unsorted cells of SCC4 cell line delineated that chemoresistant cells expressed 11 fold 
higher levels of CD24 and CD44 genes as well as 3 fold higher CD29 compared to 






























Figure 4.7: The mean fold change in (A) CD24, (B) CD44 and (C) CD29 stem cell 
associated gene expression by the chemoresistant cells (light grey) of H357 cell 
line relative to the unsorted control (dark grey), ±SD of at least 3 independent 
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Figure 4.8: The mean fold change in CD24, CD44 and CD29 stem cell associated 
gene expression by the chemoresistant cells (light grey) of SCC4 cell line relative 
to the unsorted control (dark grey), ±SD of at least 3 independent experiments 
performed in triplicate. **, *** Indicate statistically significant differences at 
(P<0.001) and (P<0.0001) respectively. 
 
4.4.3 Proliferation assay 
This assay was performed as it has been previously shown that stem cells are slow 
cycling and have a proliferation rate which is lower than normal cells (Roesch et al., 
2010; Pece et al., 2010). Therefore, growth curves were plotted on the basis of 
proliferation rate of both isolated and unsorted cells over a period of 96 hours after 
isolation. 
The study identified a significant reduction in the proliferation rate of cells isolated by 
rapid adherence of both H357 and SCC4 cell lines over time in comparison to the 
highly elevated growth rate of unsorted cells, figure 4.9 and 4.10. 
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Figure 4.9: The growth curves of H357 cells showing the proliferation of 
unsorted cells (blue line), early adherent cells (red line) and control (green line) 
at different time points. All the assays were performed in triplicate and repeated 
three times. The error bar represents SEM. (p-value<0.0001). 
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Figure 4.10 : The growth curves of SCC4 cells showing the proliferation of 
unsorted cells (blue line), early adherent cells (red line) and control (green line) 
at different time points. All the assays were performed in triplicate and repeated 
three times. The error bar represents SEM. (p-value<0.0001). 
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Meanwhile, the isolated chemoresistant cells from both OSCC cell lines (H357 and 
SCC4) exhibited a minimal growth rate while the unsorted cells showed highly 
increasing proliferation rate over time. There was a significant difference between the 
growth rate of chemoresistant and unsorted cells in the both cancer cell lines, figures 
4.11 and 4.12.  
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Figure 4.11: The growth curves of H357 cells showing the proliferation of 
unsorted cells (blue line), chemoresistant cells (red line) and control (green line) 
at different time points. All the assays were performed in triplicate and repeated 
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 Figure 4.12: The growth curves of SCC4 cells showing the proliferation of 
unsorted cells (blue line), chemoresistant cells (red line) and control (green line) 
at different time points. All the assays were performed in triplicate and repeated 
three times. The error bar represents SEM. (p-value<0.0001). 
 
 
4.4.4 Colony forming assay 
This assay was performed in order to assess the clonogencity of the early adherent and 
unsorted cells by seeding at a low density and allowing them to grow for 14 days after 
isolation.  
The early adherent cells of H357 and SCC4 oral cancer cell lines demonstrated 
significantly higher clonogenic capacity in their ability to form a large number of 
colonies compared to unsorted cells, figures 4.13 and 4.14. 
On the other hand, this assay was repeated 3 times on chemoresistant cells of both cell 
lines H357 and SCC4 and showed no colonies were formed after 14 days. 
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Figure 4.13: Colony forming ability of early adherent and unsorted H357 cells. 
(A) Photograph of a well showing the colonies formed by unsorted cells after seeding 
of 1000 cells and incubation for 14 days. (B) Photograph of a well showing the 
colonies formed by early adherent cells after seeding of 1000 cells and incubation for 
14 days. (C) Histogram showing the number of colonies formed by unsorted (dark 
grey column) and early adherent H357cells (light grey column) after 14 days. All the 
assays were performed in triplicate and repeated three times. The error bar represents 
SEM. (p-value<0.05). 



























Figure 4.14: Colony forming ability of early adherent and unsorted SCC4 cells. 
(A) Photograph of a 6 well plate showing the colonies formed by early adherent cells 
(upper row wells) and unsorted cells (lower row wells), after seeding of 1000 cells 
and incubation for 14 days. (B) Histogram showing the number of colonies formed by 
unsorted (dark grey column) and early adherent H357cells (light grey column) after 
14 days. All the assays were performed in triplicate and repeated three times. The 
error bar represents SEM. (p-value<0.001).  
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4.4.5 Determination of extracellular vesicles derived from early 
adherent and chemoresistant cells 
In current experiment, the number of EVs derived from isolated cells by the two 
methods (rapid adhesion to fibronectin and chemoresistance to cisplatin) were 
investigated and compared with that derived from unsorted cells. 
Analysis of our results showed that the number of EVs in the conditioned media 
collected from early adherent cells for both examined cell lines (H357 and SCC4) 
were significantly higher than that derived from unsorted, figures 4.15 and 4.16. 
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Figure 4.15: The number of extracellular vesicles EVs (50-150nm in diameter) 
were counted using an IZON Qnano machine of the conditioned media collected 
from unsorted (dark grey column) and early adherent H357 cells (light grey 
column). All the assays were performed in triplicate and repeated three times. The 
error bar represents SEM. (P≤0.05).  
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Figure 4.16: The number of extracellular vesicles EVs (50-150nm in diameter) were 
counted using an IZON Qnano machine of the conditioned media collected from 
unsorted (dark grey column) and early adherent SCC4 cells (light grey column). All the 
assays were performed in triplicate and repeated three times. The error bar represents SEM. 
(P≤0.05).  
 
Chemoresistant cells isolated from H357 and SCC4 cancer cell lines exhibited a much 
larger increase in the levels of secreted extracellular vesicles in comparison to that of 
unsorted cells, figure 4.17 and 4.18. 
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Figure 4.17: The number of extracellular vesicles EVs (50-150nm in diameter) counted 
using an IZON Qnano machine of the conditioned media collected from unsorted (dark 
grey column) and chemoresistant H357 cells (light grey column). All the assays were 
performed in triplicate and repeated three times. The error bar represents SEM. (P≤0.0001). 
Chapter 4 Characterisation of The Isolated Cells 
112 
 
U n s o r te d T r e a te d  
0
1 0 0 0 0
2 0 0 0 0

















Figure 4.18: The number of extracellular vesicles EVs (50-150nm in diameter) 
counted using an IZON Qnano machine of the conditioned media collected from 
unsorted (dark grey column) and chemoresistant SCC4 cells (light grey column). 
All the assays were performed in triplicate and repeated three times. The error bar 
















It has been established that a tumour consists of a heterogeneous population of cells 
with CSCs representing a minor subset of specialised cells with unique biological 
characteristics and distinct cell surface protein and gene expression that have a 
significant role in the enhancement of pro-malignant features. Characterisation 
approaches of CSCs generally are based on investigation of unique functional 
properties as well as particular surface markers that differentiate them from non CSCs 
(Dobbin and Landen, 2014). Although, many in vitro and in vivo assays have been 
developed to characterise CSCs, there is no method that can exclusively isolates or 
verifies CSCs (Tirino et al., 2012) and there are advantages and disadvantages of each 
experimental method (Islam, Gopalan et al., 2015). It has been reported that FACS 
analysis represents an advanced, sensitive and specific technique of sorting and 
characterising of CSCs (Clarke et al., 2006). However, it has some disadvantages 
such as; it is an expensive method and requires a high skilled and well trained user 
(Walia and Elble, 2010). Moreover, there are several technical limitations that affect 
the accuracy of FACS results. For instance the process of the preparing cell 
suspension (especially for solid tumours), setting of the gates and the quality of 
antibodies used in different procedures (Clarke et al., 2006). However, it has been 
established that utilisation of a set of specific phenotypic and functional cell surface 
markers is crucial to obtain an unequivocal characterisation of CSCs (Tarnok, Ulrich 
and Bocsi, 2010). CSCs in many tumour types share several specific cell surface 
markers (Mannelli and Gallo, 2011). 
On the other hand, many reports emphasise that the xenotransplantation assay is a 
gold standard assay for identifying and characterising of CSCs. This is because of it is 
a functional assay based on the tumourigenic characteristics of CSC and their ability 
to initiate a secondary tumour when transplanted into immunodeficient host with a 
phenotypic heterogeneity similar to that of original tumour (Tirino et al., 2012; 
Dobbin and Landen, 2014). Although, this assay is considered a very sensitive in vivo 
assay for detection of CSCs (Biddle and Mackenzie, 2012), it is influenced by several 
factors that should be considered. For instance: number of injected cells i.e. tumour 
are formed at a higher frequency with fewer CSCs, the mouse strain and lack of 
immune response (immune system completely knocked-out) (Rosen and Jordan, 
2010; Dobbin and Landen, 2014). In addition, the site of injection i.e. if the cells are 
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directed to a niche which might preferable than subcutaneous xenografts (O’Brien, 
Kreso and Jamieson, 2010). Several studies have been conducted on HNSCC cell 
lines that using an in vivo xenotransplantation assay to characterise oral CSCs (Prince 
et al., 2007; Chen et al., 2009; Zhang et al., 2009; Liang et al., 2014). 
It is evident that most literature recommends that the most reliable method to 
characterise an isolated CSC population should examine a combination of surface cell 
markers and gene profile followed by investigation of functional characteristics 
(Dangles-marie et al., 2007; Masahiko et al., 2012; Ray et al., 2012; Rao et al., 2013). 
Therefore, in this chapter we firstly investigated the expression of the most common 
CSC surface markers in head and neck squamous cell carcinoma and their related 
genes as well as the most important in vitro functional assays of the isolated 
population of cells using both isolation methods. 
FACS analysis was the first step in the characterisation of our sorted population of 
cells after isolation using early adhesion to fibronectin and chemoresistance to 
cisplatin. Selection of appropriate markers for characterisation of sorted population of 
cells in  CSCs studies is mainly depended on the specific tumour type (Dobbin and 
Landen, 2014). Therefore, we selected a set of three of the most common head and 
neck squamous cell carcinoma cell surface markers CD44 (hyaluronate receptor), 
CD24 (specific ligand of P-selectin receptor) and CD29 (integrin-β1 receptor). Our 
selection of multiple markers is due to the fact that there is no universal or single 
specific marker for CSCs and there is variation between tumour types as to the 
markers which best distinguish CSCs from non-CSCs populations (Tirino et al., 
2012). In addition, CSCs can not be discriminated using a single cell surface marker 
because the patterns of marker expression partly overlap between cell lineages 
(Tarnok, Ulrich and Bocsi, 2010). Furthermore, sorting and / or characterising of 
CSCs using a combination of stem cell surface markers was considered more reliable 
method yielding a more purified population of CSCs than using a single marker alone 
(Han et al., 2014). Our findings of FACS analysis of sorted and unsorted cells of the 
both tested oral cancer cell lines (H357 and SCC4) isolated by the two different 
functional methods (adhesion and chemoresistance) showed that the isolated cells 
expressed significantly increased levels of all investigated stem cell surface markers 
(CD24, CD44 and CD29) compared to that of unsorted cells. This is consistant with 
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studies by Han et al., (2014) which showed a population of CD24+/CD44+ head and 
neck squamous cell carcinoma cells expressed higher levels of CD29 and possessed 
‘stemness’ characteristics. Other studies on colon cell lines reported that sorted CSCs 
populations expressed significantly higher levels of CD24, CD44 and CD29 
(Vermeulen et al., 2008; Kemper, Grandela and Medema, 2010). In addition, many 
studies reported at least two markers from the panel of surface markers used in our 
work (CD24, CD44 and CD29), were highly expressed by CSCs. For instance, some 
studies showed CSCs with increased levels of CD24 and CD44 (Li et al., 2007; Han 
et al., 2009;  Dembinski and Krauss, 2009; Abubaker et al., 2013). Moreover, Harper 
et al., (2007) isolated CSCs from HNSCC cell lines and Geng et al., (2013) from skin 
SCC using high expression levels of a combination of CD44 and CD29. Whereas, 
some studies identified that CSCs exhibited overexpression levels of both CD24 and 
CD29 (Shackleton et al., 2006; Vassilopoulos et al., 2008). The H357 cell line 
showed the biggest difference in the expression of CD44 stem cell marker between 
the isolated cells (early adherent and chemoresistant) and unsorted cells, while SCC4 
cell line exhibited the biggest difference in expression of CD29 between isolated and 
unsorted cells in the two isolation methods (adhesion and chemoresistance). Variation 
in expression of stem cell markers between studies could be interpreted by individual 
differences among various cell lines or differences in the functional properties or 
composition of the CSC population (Barr et al., 2013). 
In the second experiment of our characterisation, qPCR was performed to investigate 
the expression of stem cell associated genes (CD24, CD44 and CD29), the cell surface 
protein expression of which was examined in the first set of experiments. The results 
of qPCR analysis demonstrated a significant up-regulation in the expression levels of 
all investigated genes (CD24, CD44 and CD29) in the both isolated populations of 
cells (early adherent and chemoresistant) of the both tested OSCC cell lines (H357 
and SCC4). These results are consistent with the findings in the first experiment and 
suggest that these cells have the same pattern of surface protein and gene expression. 
This strong correlation that was found between expression of stemness associated 
genes and cell surface proteins of the isolated cell populations in this study confirms 
the ‘stemness’ features of the sorted early adherent and chemoresistant cells. 
Although previous literature did not investigate expression of CD24, CD44 and CD29 
genes together in the characterisation of CSCs, some studies reported an up-regulation 
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of combination of CD24 and CD44 with other stemness associated genes such as: Han 
et al., (2009) in their characterising of CSCs in HNSCC cell lines and this in 
agreement with our findings. However, there are many CSC characterising studies 
which identified increased levels of various stemness associated genes in CSC 
subpopulations and they reported up-regulation of at least one of the genes 
investigated in our study. For instance, Zhang et al., (2009), Yeung et al., (2010) and 
Abubaker et al., (2013) demonstrated high levels of CD44 expression was associated 
other stem cell genes in sorted CSCs. Whereas, Gao et al. (2010) found  an up-
regulation level of CD24 in liver CSCs. In addition, Li et al., (2005) and Liang et al., 
(2014) reported increased levels of CD29 in CSCs . 
Proliferation assays were performed as the third set of experiments in our 
characterisation of sorted cells. It was considered as one of important in vitro 
functional assays for characterising of CSCs, based on the CSCs hallmark of being as 
relatively quiescent cells with low mitotic activity (Roesch et al., 2010). The low 
growth rate of CSCs was considered an important conventional anticancer therapy 
mechanism that plays a crucial role in avoiding the effects of treatment (Maugeri-
Saccà, Zeuner and De Maria, 2011). The results of proliferation assays in current 
study indicated a significant reduced growth rate of sorted cell subpopulations (early 
adherent and chemoresistant) compared to unsorted cells of both examined OSCC cell 
lines (H357 and SCC4). These findings in accordance with that established in 
previous studies (Dallas et al. 2009; Gao et al., 2010; Barr et al., 2013; Han et al., 
2014). 
The other functional assay that was conducted in this study to characterise the cell 
populations after isolation by early adhesion and chemoresistance was a colony 
forming assay. This assay is based on the enhanced ability of CSCs to form a colony 
from single cell, which is considered one of unique intrinsic properties of CSCs 
(Rodermond et al., 2006). In general, the size and number of the colonies originate 
from CSCs are greater than those formed from non-CSCs (Tirino et al., 2012). 
Furthermore, Locke et al., (2005) and Harper et al., (2007) indicated in their studies 
that clonogencity was limited to a CSC population within the total population of cells 
from HNSCC cell lines and that these were also associated with specific cellular 
morphology and distinct surface markers expression as well as cellular heterogeneity 
which reflected the pattern of stem cell hierarchy within HNSCC cell lines. Our 
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evidence from colony forming assays revealed that early adherent cells of both tested 
OSCC cell lines showed a significantly higher clonogenic potential through formation 
of more colonies compared to that formed by the same number of unsorted cells. This 
is in agreement with previous studies on HNSCC cell lines (Locke et al., 2005; 
Harper et al., 2007; Zhang et al., 2009; Han et al., 2014; Liang et al. 2014). In 
addition, studies of other tissues show that this is also the case for skin squamous cell 
carcinoma (Geng et al., 2013), lung CSCs (Barr et al., 2013), pancreatic CSCs 
(Collins et al., 2005), colon CSCs (Dalas et al., 2009) and breast CSCs (Vassilopoulos 
et al., 2008). On the other hand, the failure of formation of colonies by chemoresistant 
cells after incubation for 14 days might be attributed to the delayed action of cisplatin 
and the fact that such cells carry on dying sometime after the drug has been removed.  
The last step of experiments was conducted to quantify the number of EVs derived 
from both isolated cells (early adherent and chemoresistant) and unsorted cells. It is 
evident that crosstalk between heterogeneous population of cells within a tumour are 
mediated by soluble molecules like: growth factors, cytokines, chemokines and 
proteinases (Hanahan and Coussens, 2012). However, recent studies report that 
extracellular vesicles (EVs) could be a major mechanism of mediation of cellular 
interactions in the tumour microenvironment (Roma-rodrigues, Fernandes and 
Baptista, 2014).   
Our findings revealed that chemoresistant cells of both examined cell lines (H357 and 
SCC4) secreted significantly enhanced number of EVs compared to that released by 
unsorted cells. This result is in agreement with that reported by Samuel et al., (2018) 
in their study on ovarian cancer cell where it was established that treatment with 
20µM cisplatin for 3 hours and after 3 days recovery time was enhanced secretion of 
cancer cells derived EVs. Whilst early adherent cells here shown to be CSC like, there 
are no previous reports of early adherent cells secreting enhanced levels of EVs.  
 
4.6 Conclusions 
The consistency of results of all characterisation experiments that were performed on 
early adherent and chemoresistant cells of the both tested oral cancer cell lines (H357 
and SCC4) which showed expression of enhanced levels of stem associated genes 
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with their related stem cell surface marker proteins, low proliferation rate, high 
clonogenic potential and secretion of EVs confirms the ‘stem-like’ characteristics of 
both isolated populations of cells. In addition, our findings in previous chapter of the 
strong correlation between the isolated populations suggest the two methods isolate 
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The tumour microenvironment of solid tumours consists mainly of two fundamental 
elements which are the neoplastic epithelial cells and several types of host stromal 
cells that have great influence on the growth and invasion of cancer cells (Liotta and 
Kohn, 2001; Kalluri and Zeisberg, 2006; Joyce and Pollard, 2009) .  
 
Although, fibroblasts are considered the most abundant cells within a stroma that 
provide niches and mechanical support for cancer cells. Cancer associated fibroblasts 
(CAFs) represent an activated fibroblast phenotype and the most common and 
important one in the tumour playing pivotal roles in tumourgenesis. These roles 
include: stimulation of tumour cell proliferation, modulation of immune responses, 
resistance to therapies as well as promotion of angiogenesis, metastasis and invasion 
(Ishii et al., 2016). This may occur as a result of their secretion of ECM proteins and 
their proteases as well as soluble factors such as inflammatory cytokines and growth 
factors (Ilzle et al., 2004; Kalluri and Zeisberg, 2006). 
 
It has been reported that normal fibroblasts in the tumour stroma acquire a CAF 
phenotype and are activated due to signals released from cancer cells as a part of what 
is known stromal-tumour crosstalk (Elenbaas and Weinberg, 2001; Wever and 
Mareel, 2003; Kalluri and Zeisberg, 2006).  
TGF-β1 is a well-studied potent activating factor of normal fibroblasts transforming 
them into a myofibroblast phenotype with enhanced expression of α-SMA (Honda, 
Yoshida and Munakata, 2010). In addition, previous work in our lab established that 
normal fibroblasts treated with 10ng/mL TGF-β1 for 48 hours is a good model of 
activating fibroblasts and as a consequence we used this as positive control. 
Therefore, in this chapter we examined the influence of the conditioned media derived 
from the early adherent and chemoresistant cells on the activation of normal oral 
fibroblasts (NOFs). This was performed through investigating CAF characteristics 
features and gene profile in NOFs activated by isolated and unsorted cells and 
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5.2 The aims of the chapter 
1. To investigate the expression of α- smooth muscle actin protein fibres (α-
SMA) in NOFs incubated with conditioned media from isolated (early 
adherent and chemoresistant) and unsorted cells using immunofluorescence. 
As a result of abundant expression of α-SMA by activated fibroblasts this is 
considered a crucial hallmark discriminating them from quiescent fibroblast  
(Pourreyron et al., 2003; Kalluri and Zeisberg, 2006; Kellermann et al., 2008). 
2. To investigate the expression of some CAF associated genes (α-SMA and IL-




The following methods were used in this chapter: 
• Cell culture (section 2.2) 
• Isolation of early adherent cells by adhesion assay (section 2.3) 
• Isolation of chemoresistant cells by chemoresistance assay (section 2.5) 
• Activation of NOFs by early adherent and chemoresistant cells (section 2.17) 
• Immunofluorescence (section 2.16)  
• RNA extraction from isolated and unsorted cells (section 2.12) 
• cDNA synthesis (section 2.13) 












5.4.1 Effects of conditioned media from isolated cells on normal oral 
fibroblast expression of α- smooth muscle actin fibres. 
In this experiment, immunofluorescence staining using anti- alpha smooth muscle 
actin antibody was used to investigate the expression of α- smooth muscle actin (α-
SMA) protein fibres in normal oral fibroblasts (NOFs) after their incubation for 48 
hours with condition media derived from sorted (early adherent or chemoresistant) 
and unsorted cells. 
Our results showed that the NOFs that were incubated in conditioned media collected 
from early adherent cells of both tested oral cancer cell lines (H357 and SCC4) 
stimulated and exhibited significantly more intense α-SMA staining compared to the 
NOFs incubated with conditioned media derived from unsorted cells, figures 5.1 and 
5.2. 
Similarly, significant more intense α-SMA staining was observed in NOFs when they 
were grown in conditioned media derived from chemoresistant H357 and SCC4 oral 
cancer cell lines in comparison to that expressed by NOFs incubated with conditioned 
media of unsorted cells, figures 5.3 and 5.4.  
In addition, in all our immunofluorescence experiments the NOFs exposed to media 
alone showed very low α-SMA staining, while NOFs treated with 10ng/mL TGF-β1 
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Figure 5.1: Representative photomicrographs of α-SMA immunofluorescence in 
normal oral fibroblasts (NOFs). NOFs were treated for 48 hours and the treatment 
consisted of (A) conditioned media derived from early adherent H357 cells (B) 
conditioned media derived from unsorted cells of H357 cell line (C) with 10 ng/mL of 
TGF-β1 (D) without treatment. The cell nucleus is stained in blue (DAPI) and the α-

























                               (C)                                                                      (D) 
Figure 5.2: Representative photomicrographs of α-SMA immunofluorescence in 
normal oral fibroblasts (NOFs). NOFs were treated for 48 hours and the treatment 
consisted of (A) conditioned media derived from early adherent SCC4 cells (B) 
conditioned media derived from unsorted cells of SCC4 cell line (C) with 10 ng/mL 
of TGF-β1 (D) without treatment. The cell nucleus is stained in blue (DAPI) and the 

























                               (C)                                                                      (D) 
Figure 5.3: Representative photomicrographs of α-SMA immunofluorescence in 
normal oral fibroblasts (NOFs). NOFs were treated for 48 hours and the treatment 
consisted of (A) conditioned media derived from chemoresistant H357 cells (B) 
conditioned media derived from unsorted cells of H357 cell line (C) with 10 ng/mL of 
TGF-β1 (D) without treatment. The cell nucleus is stained in blue (DAPI) and the α-

























                               (C)                                                                      (D) 
Figure 5.4: Representative photomicrographs of α-SMA immunofluorescence in 
normal oral fibroblasts (NOFs). NOFs were treated for 48 hours and the treatment 
consisted of (A) conditioned media derived from chemoresistant SCC4 cells (B) 
conditioned media derived from unsorted cells of SCC4 cell line (C) with 10 ng/mL 
of TGF-β1 (D) without treatment. The cell nucleus is stained in blue (DAPI) and the 
α-SMA fibres in green (FITC). (Magnification: 200×). 
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5.4.2 Assessment of α- smooth muscle actin gene expression in 
normal oral fibroblasts. 
In order to quantify the increase in α-SMA observed by immunofluorescence 
experiments, qPCR analysis were performed to investigate the level of α- smooth 
muscle actin gene (α-SMA) expression in normal oral fibroblasts exposed to 
conditioned media derived from cells sorted by adhesion and chemoresistance from 
both oral cancer cell lines and compared to that of unsorted cells. 
The levels of α-SMA expressed by NOFs treated with 10 ng/mL TGF-β1 was used as 
positive control, while that of those treated with media alone as negative control. 
Our results indicated that NOFs stimulated with conditioned media derived from both 
isolated cells (early adherent and chemoresistant cells) of both tested oral cancer cell 
lines (H357 and SCC4) expressed significantly up-regulated levels of α-SMA which 
were 2-3 fold higher compared to that expressed by untreated NOFs and NOFs 
stimulated by conditioned media from unsorted cells, figures 5.5 and 5.6.  
On the other hand, NOFs treated with conditioned media derived from unsorted cells 
of both OSCC cell lines (H357 and SCC4) exhibited less levels of α-SMA than that of 
untreated NOFs, figures 5.5 and 5.6. 
In addition, NOFs treated with 10 ng/mL TGF-β1 showed very obviously raised levels 
of α-SMA gene expression (8-9 fold) compared to that from NOFs stimulated by 
conditioned media from sorted or unsorted cells as well as untreated NOFs in all 
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(B) SCC4 cell line 
Figure 5.5: The mean fold change in α-SMA gene expression by normal oral fibroblasts 
(NOFs) treated with conditioned media derived from early adherent cells (red bars) 
relative to the non-treated NOFs control (black bars) (A) H357 cell line (B) SCC4 cell 
line. NOFs treated with conditioned media derived from unsorted cells (blue bars), NOFs 
treated with 10 ng/mL of TGF-β1 (green bars). ±SD of at least 3 independent experiments 
performed in triplicate. *, ** Indicate statistically significant differences at P≤ 0.05 and 
P≤0.001 respectively. 
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Figure 5.6: The mean fold change in α-SMA gene expression by normal oral fibroblasts 
(NOFs) treated with conditioned media derived from chemoresistant cells (red bars) 
relative to the non-treated NOFs control (black bars) (A) H357 cell line (B) SCC4 cell 
line. NOFs treated with conditioned media derived from unsorted cells (blue bars), NOFs 
treated with 10 ng/mL of TGF-β1 (green bars). ±SD of at least 3 independent experiments 
performed in triplicate. *, **, **** Indicate statistically significant differences at P≤ 0.05, 
P≤0.001 and P≤0.0001 respectively. 
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5.4.3 Assessment of interleukin-6 (IL-6) gene expression in stimulated 
normal oral fibroblasts. 
Further assessment of the normal oral fibroblast gene expression profile using qPCR 
was performed in cells stimulated with conditioned media derived from early adherent 
and chemoresistant cells to investigate the expression of IL-6 which is considered one 
of common up-regulated proinflammatory genes in CAFs (Erez et al., 2010).  
Expression was compared with that of untreated NOFs as well as with NOFs 
incubated with conditioned media of unsorted cells. 
Our findings revealed a significant up-regulation of IL-6 expression levels in NOFs 
exposed to conditioned media collected from isolated cells from both OSCC cell lines 
(H357 and SCC4) whether they were sorted by rapid adhesion or by chemoresistance.  
The fold changes were nearly 5 fold in the expressions of IL-6 by NOFs triggered by 
conditioned media derived from early adherent and chemoresistant cells of H357 cell 
line in comparison to the levels of IL-6 expressed by NOFs grown in conditioned 
media of unsorted cells and untreated NOFs. Whereas, it was 2 fold higher in NOFs 
incubated in conditioned media of early adherent and chemoresistant cells of SCC4 
cell lines compared to the levels of IL-6 expressed by NOFs grown in conditioned 
media of unsorted cells and untreated NOFs, figures 5.7 and 5.8. 
Furthermore, IL-6 levels expression of NOFs incubated in conditioned media from 
unsorted SCC4 cells showed down-regulation in levels compared to that expressed by 
non-treated NOFs, figures (5.7 B) and (5.8 B).  
 NOFs treated with 10 ng/ml TGF-β1 showed very obviously down-regulated levels of 
IL-6 gene expression compared to that from NOFs stimulated by conditioned media 
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(B) SCC4 cell line 
Figure 5.7: The mean fold change in IL-6 gene expression in normal oral 
fibroblasts (NOFs) treated with conditioned media derived from early adherent 
cells (red bars) relative to the non-treated NOFs control (black bars) (A) H357 
cell line (B) SCC4 cell line. NOFs treated with conditioned media derived from 
unsorted cells (blue bars), NOFs treated with 10 ng/mL of TGF-β1 (green bars). ±SD 
of at least 3 independent experiments performed in triplicate. ***, **** Indicate 
statistically significant differences at P≤0.0001. 
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(B) SCC4 cell line 
Figure 5.8: The mean fold change in IL-6 gene expression in normal oral 
fibroblasts (NOFs) treated with conditioned media derived from chemoresistant 
cells (red bars) relative to the non-treated NOFs control (black bars) (A) H357 
cell line (B) SCC4 cell line. NOFs treated with conditioned media derived from 
unsorted cells (blue bars), NOFs treated with 10 ng/mL of TGF-β1 (green bars). ±SD 
of at least 3 independent experiments performed in triplicate. **, *** Indicate 
statistically significant differences at P≤0.001 and P≤0.0001 respectively.  




In the 1880s, Paget proposed the ‘seed and soil theory’ which considered that the 
tumour microenvironment was basically composed from seeds ‘the cancer cells’ and 
soil ‘stromal cells and ECM’ (Paget, 1889). Currently, it has been understood that 
tumour cells were modified genetically or epigenetically due to thorough molecular 
analysis of cancer cells which resulted in identification and characterisation of many 
oncogenes and tumour suppressor genes. On the contrary, there is no full 
characterisation for ‘soil’ of tumour microenvironment that is formed by both tumour 
and host stromal cells, probably due to its functional and structural complexity. 
Recently, there is increasing evidence that host stromal cells characteristics have great 
influence on the biological behaviour of tumour cells (Bhowmick et al., 2004).  
The tumour microenvironment consists of extracellular matrix (ECM) including 
mainly collagen, fibronectin, tenascin and laminin as well as different types of cells 
such as mesenchymal stem cells (George,, Singh and Nirmala, 2012) and vasculature 
which includes endothelial cells, pericytes and smooth muscle cells  (Polyak, Haviv 
and Campbell, 2009). In addition, inflammatory and immune cells are present 
recruited by cytokines and chemokines (Müller-hübenthal et al., 2009) as well as 
various types of fibroblasts (Lorusso and Rüegg, 2008).  
Head and neck squamous cell carcinoma is derived from epithelial cells, which are 
normally separated from the underlying connective tissue by a basal lamina 
(Weinberg, 2007). During tumour development, basement membrane is degraded and 
cancer cells invade into the connective tissue and become directly in contact with the 
stromal cells (Akashi et al., 2005).  
It has been reported that the growth of a tumour relies mainly on its genetic 
exclusivity and the interaction between cancer cells with stromal cells in tumour 
microenvironment (Galiè et al., 2005; Kellermann et al., 2008). In addition, stromal 
cells acquire a specific biological phenotype through their interaction with tumour 
cells (Bhowmick et al., 2004). In turn, the activated stromal cells induce tumour cells 
through release of biological agents to promote growth and acquisition of an invasive 
phenotype as well as breakdown of the normal barrier created by the ECM (Hsu, 
Meier and Herlyn 2002; Wever and Mareel, 2003). Therefore, the crosstalk between 
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tumour cells and stromal cells plays a dynamic role in tumour initiation, survival, 
progression, invasion and resistance to conventional anticancer therapies (Patten et 
al., 2008; Buggins et al., 2010; Pepper et al., 2011). This crosstalk is concentrated in 
two main interactive pathways: firstly, an efferent pathway by which cancer cells 
activate and/or modify the tumour leading to a reactive response. Whereas, the second 
pathway is an afferent one whereby modified and/or activated stromal fibroblasts cells 
in the tumour microenvironment affects the behaviour and responses of cancer cells 
(Wever and Mareel, 2003), as illustrated in figure 5.9.  
Many soluble mediators have been reported to be involved in intercellular 
communication between tumour and stromal cells, such as: vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor-β 
(TGF-β), hepatocyte growth factors (HGF), platelet derived growth factor (PDGF), 
insulin-growth factor-1 (IGF-1), stromal derived factor-1 (SDF-1) and ligands of the 
Wnt, Notch and Hedgehog pathways. In addition, these factors have important roles in 
tumour progression through induction of CSC self-renewal, tumour growth, 
angiogenesis, recruitment of stromal cells, invasion and metastasis (Molloy et al., 
2009; Qian et al., 2012). Recently, reports established that cell derived exosomes are 
potent mediators of direct communication between cancer and stromal cells and that 
this can influence cancer cell survival, proliferation, invasion and metastasis (Camp et 
al., 2011; Luga et al., 2012). 
Although evidence shows that fibroblasts form the most common stromal cell within 
tumour microenvironment, cancer associated fibroblasts (the activated phenotype of 
fibroblasts) are considered a key player in tumourigenesis (Cirri and Chiarugi, 2011; 
Öhlund, Elyada and Tuveson, 2014). One of the important hallmarks that 
discriminates CAFs from quiescent fibroblasts is the common expression of smooth 
muscle actin fibres (α-SMA) (Pourreyron et al., 2003; Kalluri and Zeisberg, 2006; 
Kellermann et al., 2008). It has been widely accepted that CAFs are histologically 
defined as plump, spindle shaped cells which positively expressed α-SMA, and are 
usually located at the tumour periphery (Thode et al., 2011). Many studies have 
established that expression of α-SMA fibres as a myofibroblast ultra-structure within 
activated tumour stroma is considered the most prominent feature indicating 
phenotypic switching of quiescent fibroblasts into CAFs (Tuxhorn, Ayala and 
Rowley, 2001; Kunz-Schughart and Knuechel, 2002).   
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Our first finding that might suggest the activation of normal oral fibroblasts (NOFs) 
into CAFs when they were exposed to conditioned media from isolated cells (early 
adherent and chemoresistant) from the both tested OSCC cell lines (H357 and SCC4) 
was obtained from experiments assessing the immunofluorescent expression of 
smooth muscle actin fibres (α-SMA). The results showed highly intense staining of α-
SMA in fibroblasts stimulated by media from isolated cells compared to no noticeable 
change in expression in those exposed to conditioned media from unsorted cells. This 
is in accordance with the findings of many studies which reported that CAFs were 
identified through their expression of α-SMA (Sugimoto et al., 2006; Erez et al., 
2010; Wang et al., 2013). Although, the very obvious difference in expression of α-
SMA stain in NOFs activated by isolated and unsorted cells was observed by 
immunofluorescent microscopy, we could quantify this in future experiments using 
ImageJ software or extract protein from NOFs and perform western blotting for α-
SMA.  
CAFs promote and enhance cancer progression in different ways through secretion of 
various factors. CAFs mediate ECM remodelling through their abundant secretion and 
deposition of variety of ECM proteins such as collagen type I and IV, fibronectin, and 
tenascin-C leading to increased tumour growth. In turn, their secretion of proteases 
such as matrix metalloproteinases (MMPs) that digest ECM and have crucial roles in 
tumour progression, invasion and subsequent metastasis (Sato, Maehara and Goggins, 
2004; Wever et al., 2008; Kessenbrock, Plaks and Werb, 2010). CAFs secrete many 
pro-inflammatory cytokines and chemokines that recruit inflammatory cells and 
promote sustained inflammation in the tumour stroma as well as inducing 
neoangiogenesis through stimulation of pericytes and endothelial cells (Hanahan and 
Coussens, 2012). Moreover, they suppress recruitment of immune cells that results in 
modulation of the immune response (Misra et al., 2008; Xiang et al., 2009). Cancer 
cell proliferation is induced and regulated by growth factors such as hepatocyte 
growth factor (HGF) released from CAFs, as a result of the direct interaction and 
communication of cancer cells with CAFs (Tyan et al., 2011; Jia et al., 2013; Wu et 
al., 2013; Saito et al., 2015). Furthermore, EMT is induced in cancer cells by TGF-β 
secreted from CAFs (Yu et al., 2014). In addition, the oncogenic potential of 
epithelial cells was modulated by TGF-β secreted from CAFs (Puisieux et al., 2006). 
CAFs regulate CSC plasticity during tumour progression via a Nanog dependent 
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mechanism (Chen et al., 2014). Although, the crucial role of CAFs in tumourigenesis 
and their obvious biological and clinical impacts in tumour microenvironments have 
been clearly recognised, the mechanism of activation of normal fibroblast to CAFs 
remains unclear (Lee et al., 2015).         
Previously, it was considered that CAFs just altered phenotypically but remained 
genetically similar to normal host derived cells. However, recent literature 
emphasised that CAFs were their genetic profile distinct from normal fibroblasts 
(Kurose et al., 2001; Sugimoto et al., 2006; Erez et al., 2010). Moreover, it has been 
reported that α-SMA is a common marker for identifying CAFs (Tlsty, 2001; Tuxhorn 
et al., 2001; Kunz-Schughart and Knuechel, 2002; Gabbiani 2003; Sugimoto et al., 
2006). In addition, there are other markers were overexpressed by CAFs such as IL-6 
(Giannoni et al., 2010; Osuala et al., 2015; Yeh et al., 2015), fibroblast-activating 
protein (FAP), vimentin (Gabbiani 2003; Liu et al., 2006) and fibroblast specific 
protein-1 (FSP-1) (Sugimoto et al., 2006).  
Therefore, we performed qPCR assays using two most commonly up-regulated 
markers in CAFs (α-SMA and IL-6) for further confirmation that normal oral 
fibroblasts were activated and transformed to CAFs upon exposed to condition media 
from isolated cells. Our results revealed a high significantly up-regulation of both 
investigated markers (α-SMA and IL-6) when fibroblasts were incubated with 
conditioned media collected from isolated cells (early adherent and chemoresistant) 
for the both examined oral cancer cell lines (H357 and SCC4) in comparison to their 
levels exhibited by fibroblasts subjected to conditioned media of unsorted cells. These 
results are consistent with many reports that showed increased levels of expression of 
α-SMA by CAFs (Tuxhorn, Ayala and Rowley, 2001; Kunz-Schughart and Knuechel, 
2002; Gabbiani, 2003; Huang et al., 2010; Shintani et al., 2016). In addition, several 
studies revealed up-regulation of IL-6 in CAFs which support our findings (Giannoni 
et al., 2010; Vicent et al., 2012; Osuala et al., 2015; Yeh et al., 2015; Lee et al., 2015; 
Shintani, Fujiwara and Kimura, 2016). However, our finding showed significantly 
down-regulated levels of IL-6 expressed by the NOFs treated with TGF-β compared 
to that NOFs incubated with conditioned media from isolated cells (early adherent and 
chemoresistant) in all experiments. This could be attributed to variation in CAF 
phenotype which was identified by some studies that revealed despite these various 
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CAF phenotypes having the same common positive α-SMA protein expression, they 
possess divergent gene expression profiles (Mellone et al., 2017). 
Some literature suggests that cancer cells secrete cytokines and growth factors that 
mediate fibroblast activation into CAFs, which is considered an early and important 
event in tumourgenesis (Liotta and Kohn, 2001; Beacham and Cukierman, 2005; 
Amatangelo et al., 2005). There are several stimuli and pathways reported to induce 
activation of quiescent fibroblasts into CAFs in tumour stroma. For instance, TGF-β, 
EGF, PDGF and FGF-2 secreted from injured epithelial cells as well as monocytes 
and macrophages provide support to the theory that tumours are non-healed wounds. 
Moreover, direct communication and contact via vascular cell adhesion molecule-1 
(VCAM-1) or intercellular adhesion molecule-1 (ICAM-1) between fibroblasts and 
leukocytes leads to activation of fibroblasts into CAFs. Furthermore, reactive oxygen 
species, alteration in composition of ECM and complement factor C1 were reported to 
contribute to the activation of fibroblasts to CAFs (Kalluri and Zeisberg, 2006). Many 
studies consider TGF-β as the main mediator in altering the stromal responses of the 
tumour microenvironment in early stromagenesis through activating of fibroblasts to 
CAFs (Wever et al., 2008; Sridhara et al., 2013; Rao et al., 2014). Such processes are 
maintained as a result of continuous TGF-β secretion by cancer cells and maintaining 
of increased levels of TGF-β receptors in CAFs (Wever and Mareel, 2003). In 
addition to the role of TGF-β in activation of CAFs, it plays a significant role with 
other factors such as PDGF and tumour necrosis factor (TNF-α) in maintaining CAFs 
within the tumour microenvironment (Orimo et al., 2006; Shimoda, Mellody and 
Orimo, 2010). Moreover, literature reports additional roles of TGF-β in 
tumourgenesis, such as induction of EMT in CSCs and chemoattraction of infiltrating 
macrophages into the stroma of tumours (Wang et al., 2007). However, increasing 
evidence on several types of tumours indicated that IL-6 induced transdifferentiation 
of fibroblasts to CAFs (Paland et al., 2009; Giannoni et al., 2010; Sanz-moreno et al., 
2011; Doldi et al., 2015).  Paland et al., (2009) and Sanz-moreno et al., (2011) 
revealed that activation of fibroblasts mediated by IL-6 has been through the IL-
6/STAT3 pathway. Giannoni et al., (2010) found in their study on prostate cancer that 
cancer cells released IL-6 which induced activation of normal prostate fibroblasts and 
the resultant CAFs in turn secreted IL-6, which mediated EMT in cancer cells that 
enhanced tumour invasiveness. In addition, Schauer et al., (2011) showed that ovarian 
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cancer cells activated normal fibroblasts in tumour stroma through secretion of IL-6, 
IL-8, and IL-1β cytokines. Furthermore, some reports found that aggressive growth of 
tumours was mediated through the TGF-β – IL-6 axis due to raised secretion of IL-6 
and TGF- β in several types of cells as a result of IL-6 signalling (Aoki et al., 2006; 
Luckett-Chastain and Gallucci, 2009). In turn, CAFs in activated stroma induce EMT 
in cancer cells through production of IL-6 (Orimo et al., 2006;  Shimoda, Mellody and 
Orimo, 2010). Moreover, Yamada et al., (2013) found in their study a vicious cycle 
was formed due to the crosstalk between TGF-β and IL-6, which enhances tumour 
growth. Whereas, Doldi et al., (2015) showed a close relation between TGF-β and IL-
6 signalling and that either one of them can induce activation of fibroblasts in the 
stroma of prostate cancer.  
We could interpret the activation of normal oral fibroblast subjected to conditioned 
media of isolated cells into CAFs using several explanations. Lygoe and her 
colleagues (2007) found in their study on oral and dermal fibroblasts that integrin 
pathways specifically α5β1 (fibronectin receptor) and αvβ6 (vitronectin receptor) 
regulate and induce TGF-β1. Moreover, they showed when these integrin receptors 
were functionally blocked this lead to down-regulation of TGF-β1 and subsequent 
inhibition of activation and differentiation of oral and dermal fibroblast into 
myofibroblasts. Our findings in chapter (4) from both FACs and qPCR analysis 
revealed that both isolated population of cells (early adherent and chemoresistant) 
from the both tested oral cancer cell lines (H357 and SCC4) expressed significantly 
high levels of integrin-β1 (CD29) as well as up-regulated levels of integrin-β1 gene 
expression compared to unsorted cells. Therefore, one of the mechanisms that might 
explain the activation of fibroblasts incubated with condition media of early adherent 
and chemoresistant cells could be attributed to their high expression of integrin-β1 
receptors that may result in higher production of TGF-β1 which in turn increases 
activation of normal oral fibroblasts into CAFs. On the other hand, integrin-β1 
receptors mediate costimulatory signals that required for persistent inflammatory 
cytokine gene expression and subsequent production of inflammatory cytokines 
(Miyake et al., 1993). Several studies reported that some inflammatory cytokines are 
secreted by cancer cells induce the activation of stromal fibroblasts into CAFs (Paland 
et al., 2009; Giannoni et al., 2010; Sanz-moreno et al., 2011; Doldi et al., 2015). 
Therefore, we could suggest another mechanism for activation NOFs exposed to 
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conditioned media from isolated cells is due to overproduction of proinflammatory 
cytokines such as IL-6, IL-8, and IL-1β by isolated cells compared to that by unsorted 
cells (Schauer et al., 2011). 
Shintani and his colleagues (2016) conducted a study on lung cancer and they found 
that normal lung fibroblasts incubated with condition media of cancer cells treated 
with cisplatin showed an increase activation of these fibroblasts into CAFs compared 
to the normal fibroblasts that subjected to conditioned media from untreated cancer 
cells. Furthermore, they revealed that addition of a TGF-β1 inhibitor to the 
conditioned media of cisplatin treated cells reduced the activation of normal 
fibroblasts into CAFs. Therefore, they inferred that treatment with cisplatin increases 
secretion of TGF-β1 in cancer cells that could result in increased activation and 
differentiation of normal fibroblasts. This could explain our findings that normal oral 
fibroblasts incubated with conditioned media collected from chemoresistant cells were 
activated and expressed intense α-SMA staining as well as upregulated CAF markers. 
Recent studies indicate the emerging and increasing role of cancer cell derived 
exosomes in triggering differentiation of normal fibroblasts into CAFs and activation 
of the tumour stroma. Webber and his colleagues (2010) revealed that normal 
fibroblasts differentiated into their fully activated phenotype (myofibroblasts) through 
the TGF-β1 signalling pathway initiated by TGF-β1 delivered from cancer-derived 
exosomes. They found that the myofibroblast phenotype resulting from activation by 
exosomal TGF-β1 resembled but was not identical to that obtained through activation 
initiated by soluble TGF-β1.  Other studies attributed the effects of cancer-derived 
exosomes in the activation of normal stromal fibroblasts to some miRNAs that were 
transmitted through these exosomes. For instance, Pang et al., (2015) reported that 
miR-155 delivered from pancreatic cancer-derived exosomes initiated 
transdifferention of normal murine pancreatic fibroblasts to CAFs. A similar study 
was conducted on ovarian cancer by Mitra et al., (2012) and found that 
reprogramming of normal fibroblasts into CAFs was due to the effects of three 
miRNAs (miR31-miR-214 and miR-155) delivered by EVs secreted from cancer 
cells. Our data in chapter (4) demonstrated that the OSCC cells isolated by the two 
isolation methods (rapid adhesion and chemoresistance) secreted significantly 
elevated levels of EVs compared to unsorted cells. Therefore, we could attribute the 
activation of normal oral fibroblast subjected to conditioned media from isolated cells 
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(early adherent and chemoresistant) to the high concentrations of EVs secreted from 
these cells in their conditioned media in comparison to that of unsorted cells. 
Figure 5.9: Activation of normal oral fibroblasts into cancer associated 
fibroblasts, and crosstalk between cancer cells and cancer associated fibroblasts 
within tumour stroma. TGF-β: transforming growth factor, IL-6: interleukin 6, EGF: 
endothelial growth factor, PDGF: platelet derived growth factor, FGF2: fibroblast 
growth factor 2, HH: Hedgehog ligand, TNF-α: tumour necrosis factor, HGF: 
hepatocyte growth factor, Wnt: Wnt ligand, Notch ligand, IGF-1: insulin-growth 
factor-1, α-SMA:  smooth muscle actin fibres, FAP: fibroblasts activating protein. 
 
5.6 Conclusions  
We can deduce that NOFs are activated by factors in the conditioned medium secreted 
by isolated stem cells (early adherent and/or chemoresistant) leading to significantly 
higher expression of both α-SMA and IL-6 genes compared to the unsorted cells. 
However, the identity of activating factor(s) has not been identified during this study 
and further investigation is needed in the future to characterise them. 
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Oral cancer is classified as one of top ten malignancies worldwide with more than 
300,000 new cases diagnosed each year (Ferlay et al., 2015). Oral squamous cell 
carcinoma is considered the most common type of oral cancer and represents more 
than 90% of oral cancer cases (Choi and Myers, 2008). Although, recent reports 
indicate an overall reduction in mortality rate of cancer due to advances in treatment, 
the high mortality and low survival rates of oral squamous cell carcinoma remain 
unchanged because of its poor prognosis due to the high rates of local recurrence and 
distant metastasis (Michael et al., 2008). 
Recent studies proposed that initiation, development as well as the recurrence of 
tumours can be attributed to cancer stem cells (Oliveira, Jeffrey and Ribeiro-Silva, 
2010; Papagerakis et al., 2014). These cells form a small subpopulation of cells within 
tumour that possess unique characteristics such as self-renewal, ability of 
differentiation into diverse types of cells and resistance of anticancer therapies (Reya 
et al., 2001; Nguyen et al., 2012; Yua et al., 2013). CSCs have been identified and 
characterised in various tumour types through expression of a variety of specific cell 
surface markers (Al-Hajj et al., 2003; Mannelli and Gallo, 2011; Yua et al., 2013; 
Routray and Mohanty, 2014). There is increasing evidence that CD24 and CD44 are 
key markers of CSCs in oral squamous cell carcinoma (Han et al., 2014). Both CD24 
and CD44 are cell surface molecules that play different roles in cancer. CD24 is 
glycosylated mucin protein, while CD44 is a glycoprotein (Kristiansen et al., 2003; 
Collins et al., 2005; Prince et al., 2007; Sagiv et al., 2008) 
It has been reported that activation of host stromal cells by cancer cells is a crucial 
step in solid cancer progression. Despite this, the mechanisms of activation of the 
tumour stroma is not fully understood. In addition, the scientific literature indicates 
that cancer associated fibroblasts (CAFs) are the most prominent hallmark of the 
activated stroma.  These CAFs are characterised by their expression of alpha smooth 
muscle actin (α-SMA) (Barth et al., 2004; Kojc et al. 2005).   
In this chapter we performed immunohistochemical analysis of samples of oral 
squamous cell carcinoma to examine the expression of CSC markers (CD24 and 
CD44) as well as a CAFs marker (α-SMA) to investigate if there is a correlation 
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between their expression and therefore whether there is a link between presence of 
CSCs and activated stroma. 
 
6.2 The aims of the chapter 
To investigate the concomitant expression of CSC specific markers (CD24 and CD44) 
with the a CAFs specific marker (α-SMA) in oral squamous cell carcinoma using 
immunohistochemistry. 
 
6.3 Materials and methods 
• The study sample consisted slides from 10 patients with squamous cell 
carcinoma in Sheffield. All the cases have a moderate grade of differentiation 
with various size and depth. Although all the cases are metastatic (invaded one 
or more of regional lymph nodes), some of them have extracellular spread 
(spread through the full thickness of the capsule of lymph node). Moreover, 
they vary in the degree of host response (represented by lymphocytes 
infiltrating through margin of tumour) ranging from poor to moderate and 
strong. Full clinical and histopathological data of patients and tumours in the 
selected study samples illustrated in table 6.1. 
• Immunohistochemistry staining method (section 2.15). 
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Perineural Vascular Margin Metastasis 
Extracapsular 
spread 
1 88 Female Moderate 34 10 Discohesive Moderate No No Close Yes Yes 
2 68 Male Moderate 18 5.5 Cohesive Poor No No Clear Yes No 
3 63 Male Moderate 30 23 Discohesive Moderate No Yes Involved Yes No 
4 79 Male Moderate 30 17 Discohesive Poor Yes No Close Yes No 
5 55 Female Moderate 12 1.5 Cohesive Poor No No Involved Yes No 
6 42 Female Moderate 30 12.5 Discohesive Poor Yes No Close Yes Yes 
7 70 Female Moderate 49 11.5 Discohesive Moderate No Yes Close Yes Yes 
8 71 Male Moderate 62 20 Cohesive Moderate No No Involved Yes Yes 
9 91 Male Moderate 14 6 Discohesive Strong No No Clear Yes Yes 
10 72 Female Moderate 50 8 Discohesive Moderate Yes No Close Yes Yes 






6.4.1 Assessment of the correlation of immunohistochemical 
expression of CSC and CAF markers in OSCC. 
 Immunohistochemical analysis was conducted on slides from 10 cases of various oral 
squamous cell carcinoma (table 6.1) using human anti-CD24, anti-CD44 and anti- 
alpha smooth muscle actin (α-SMA) antibodies to investigate the expression of CSC 
markers (CD24 and CD44) as well as a CAF marker (α-SMA). The 
immunohistochemical stained slide were quantified and an average of stain intensity 
of each tested marker was calculated for all examined cases, as illustrated in table 6.2. 
Table 6.2: Immunohistochemical stain intensity averages for CSC markers (CD24 and 
CD44) and the CAF marker (α-SMA) for each case of oral squamous cell carcinoma. 
Case number 
Marker stain intensity (pixels) 
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Our data showed an increased intensity of α-SMA stain in the cases that exhibited 
concomitant high intensities of both CD24 and CD44 such as case number 1, 2 and 5, 
as shown in table 6.2. The microscopic photos of these cases show an abundance of α-
SMA stain in the stroma concentrated close to the basal cell layer of tumour 
epithelium at the tumour invasive front. In addition, intense α-SMA staining can be 
seen directly adjacent and surrounding islands of the epithelial tumour cells in the 
stroma, distributed either in a network or reticular pattern that demarcates the tumour 
invasive front, as illustrated in figures 6.4, 6.5 and 6.6. 
Furthermore, our results indicated highly significant positive correlations between the 
expressions of both CD24 and CD44 stain in tumours and the expression of α-SMA 
stain in the stroma. Pearson’s coefficient of the correlation between CD24 and α-SMA 
was r = 0.91 and P value = 0.0006, whereas for the correlation of CD44 with α-SMA r 
= 0.89 and P value = 0.001, figures 6.1 and 6.2. 
Similarly, expression of CSC markers CD24 and CD44 in tumours of the examined 
OSCC cases revealed a strong positive correlation between them (r = 0.83, P= 0.005), 
figure 6.3. 



























Figure 6.1: Scatter plot showing the significant positive correlation between 
expression of CD24 stem cell marker in the tumour and expression of a CAF 
marker (α-SMA) in the tumour stroma, (r =0.91, P =0.0006). 































Figure 6.2: Scatter plot showing the significant positive correlation between the 
expression of CD44 stem cell marker in the tumour and expression of a CAF 
marker (α-SMA) in the tumour stroma, (r =0.89, P =0.001). 
 
 



























Figure 6.3: Scatter plot showing the significant positive correlation between the 
expression of the stem cell markers CD24 and CD44 in tumour sections, (r =0.83, 
P =0.005). 































Figure 6.4: Representative photomicrographs of case number 1. Primary oral 
squamous cell carcinoma invading the underlying connective tissue. (A) CD24 
staining is seen throughout the tumour epithelium (B) CD44 staining is seen 
throughout the tumour epithelium. (C) α-SMA staining is seen throughout stroma at 
the invasive front of the tumour. (Magnification: 100×). The brown stain indicates the 
expression of markers. 
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Figure 6.5: Representative photomicrographs of case number 2. Primary oral 
squamous cell carcinoma invading the underlying connective tissue. (A) CD24 
staining is seen throughout the tumour epithelial islands. (B) CD44 staining is seen 
throughout the tumour epithelial islands. (C) α-SMA staining is seen throughout the 
stroma at the invasive front of the tumour surrounding tumour epithelial islands. 
(Magnification: 100×). The brown stain indicates the expression of markers. 




























Figure 6.6: Representative photomicrographs of case number 5. Primary oral 
squamous cell carcinoma invading the underlying connective tissue. (A) CD24 
staining is seen throughout the tumour epithelial islands. (B) CD44 staining is seen 
throughout the tumour epithelial islands. (C) α-SMA staining distributed throughout 
the stroma at the tumour invasive front surrounding tumour epithelial islands. 
(Magnification: 100×). The brown stain indicates the expression of markers. 

























Figure 6.7: Representative photomicrographs of case number 4. Primary oral 
squamous cell carcinoma invading the underlying connective tissue. (A) CD24 very 
low staining is seen throughout the tumour epithelium. (B) CD44 low staining is seen 
throughout the tumour epithelium. (C) No noticeable α-SMA staining in the stroma. 
(Magnification: 100×). The brown stain indicates the expression of markers. 
 




The increasing importance of CSCs in the development and progression of many 
cancer types has been proposed recently (O'Connor et al., 2014; Kreso and Dick 
2014; Borah et al., 2015). However, little is known about the behaviour and biology 
of CSC in oral squamous cell carcinoma. Currently, CSC studies are considered a 
promising area in OSCC oncology that might result in better understanding of 
tumourgenesis (Oliveira et al., 2011).   
It has been established that stem cell surface markers can be used to identify CSCs in 
various tumours (Singh et al., 2003; Kristiansen et al., 2003; Collins et al., 2005; 
Ricci-Vitiani et al., 2007). Furthermore, several studies reported using 
immunostaining analysis of the expression of stem markers as a potent method to 
evaluate the existence of CSC phenotype in some tumours including OSCC (Lim and 
Oh, 2005; Graziano et al., 2008). We used the co-expression of CD24 and CD44 stem 
cell markers for immunohistochemical analysis as an indicator to evaluate the 
existence of CSCs in OSCC. A number of studies highlighted that cells with co-
expression of CD24 and CD44 were confirmed as CSCs in different types of cancer 
(Fang et al., 2005; Li et al., 2007; Ricci-Vitiani et al., 2007), and including head and 
neck squamous cell carcinoma (Han et al., 2009; Han et al., 2014). In addition, our 
findings in chapter (4) showed increased expression of both CD24 and CD44 markers 
in CSCs isolated from oral cancer cell lines using functional assays (early adhesion 
and chemoresistance).   
CD44 is a trans-membrane glycoprotein receptor for hyaluronate. Normally, it 
coordinates cell-cell adhesion, motility of cells, activation of lymphocyte and cell 
migration (Shtivelma and Bishop, 1991; De Marzo et al., 1998). Moreover, it plays a 
key role in cellular interaction with hyaluronate, osteopontin, serglycin and ECM 
proteins such as fibronectin, collagen I and IV. On the other hand, it has been reported 
that CD44 is a pivotal CSCs marker which overexpressed in most of solid tumours 
(Assimakopoulos et al., 2002). Furthermore, oral squamous cell carcinoma is 
considered as the second epithelial tumour type after breast cancer in which CD44 is 
the most frequent marker expressed by the CSC population (Hocwald et al., 2001). 
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CD24 is a glycosated cell surface protein for P selectin receptor (the adhesion 
receptor of activated endothelial cells and platelets) (Weichert et al., 2005; Lim, 
2005). Normally, CD24 is expressed by keratinocytes, regenerating muscles, renal 
tubules and the developing pancreas and brain (Weichert et al., 2005), as well as 
being a B cell marker (Weichert et al., 2005; Lim, 2005). Previous studies have 
indicated that CD24 could be a key marker of CSCs in various cancers including oral 
squamous cell carcinoma (Han et al., 2009; Han et al., 2014).  It has been suggested 
that the CD24 is a factor involved in regulation of cell adhesion, proliferation and 
apoptosis (Weichert et al., 2005). Therefore, down- regulation of CD24 leads to 
inhibition of tumour cell proliferation and induction of their apoptosis, whilst up- 
regulation results in increased of tumour growth and enhancement of metastasis due 
to its activation of P selectin receptors on platelets and activated endothelial cells 
(Lim and Oh, 2005; Sagiv et al., 2008). 
Our results revealed a significant positive correlation between the expression of CD24 
and CD44 markers in the study samples of oral squamous cell carcinoma. These 
results are consistent with the findings from other immunohistochemistry studies of 
CSCs in oral squamous cell carcinoma which reported increased levels of expression 
of both CD24 and CD44 (Han et al., 2009; Oliveira et al., 2011; Han et al., 2014). 
However, there are no previous reports correlating expression of these two CSC 
markers.  
Oral squamous cell carcinoma like other solid tumour types is described as a 
composite of cells due to the presence of cancer cells as well as various types of 
stromal cells such as fibroblast, inflammatory and endothelial cells. These cells 
interact in concert leading to tumour progression, local invasion and distant metastasis 
(de Vicente et al., 2005).  Therefore, there is coordination between transformation of 
normal epithelial cells into cancer cells and activation of normal stromal cells into 
cancer associated (Beacham and Cukierman, 2005; Amatangelo et al., 2005). So, 
alteration and remodelling of stroma is initiated by cancer cells, whereas 
stromagenesis is a process induced by activated stroma (Beacham and Cukierman, 
2005). The most distinctive feature of the activated stroma is the activation of normal 
stromal fibroblasts into myofibroblasts or CAFs (Giatromanolaki, Sivridis and 
Koukourakis, 2007). These cells show a phenotype between smooth muscle cells and 
fibroblasts that is characterized by the expression of alpha smooth muscle actin fibres 
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(α-SMA) (Desmouliere, Chaponnier and Gabbiani, 2005). It is evident that α-SMA 
immunostaining is not present in normal oral mucosa and premalignant oral lesions 
except by smooth muscle cells lining the blood vessel walls (Kellermann et al., 2007). 
Therefore, we selected α-SMA antibody in our immunohistochemical analysis to 
evaluate the existence of CAFs in the stroma of oral squamous cell carcinoma.  
Our findings demonstrated significant positive correlation between the expression of 
both CSC markers CD24 and CD44 in the tumour and the expression of α-SMA in 
stroma. This correlation has not been previously reported. Although, we have not 
investigated a potential mechanism for this link, it agrees with the data obtained from 
previous chapter (5). These data that found activation of normal oral fibroblasts into 
CAFs upon incubation with conditioned media of early adherent and chemoresistant 
cells (CSCs) isolated from OSCC cell lines. However, several immunostaining studies 
conducted on OSCC indicate that epithelial cancer cells induced the activation of 
stroma and increased expression of stromal α-SMA (Etemad‐Moghadam et al., 2009; 
Prasad et al., 2016). Furthermore, Marsh and his colleagues (2011) highlighted in 
their study the strong positive correlation between the high stromal α-SMA 
immunostaining expression with the increased aggressiveness and the mortality rate in 
OSCC patients regardless the stage of the disease and they consider stromal α-SMA 
rather than other tumour features as a crucial prognostic factor in OSCC.  Kellermann 
et al., (2007) found a significant positive link between the increased 
immunohistochemical expression of α-SMA in the tumour stroma and the increasing 
invasiveness and subsequent poor prognosis of OSCC. Similarly, many studies 
correlated the elevated concomitant immunostaining expression of CD24 and CD44 
stem cell markers in oral squamous cell carcinoma with clinicopathological increasing 
of tumour progression, aggressiveness, invasion and metastasis (Han et al., 2009; 
Oliveira et al., 2011; Koukourakis et al., 2012; AbdulMajeed, Dalley and Farah, 
2013; de Moraes et al., 2017). Han et al., (2009) reported CD24 and CD44 
immunostaining expression as important diagnostic markers for OSCC.  Koukourakis 
et al., (2012) revealed immunostaining overexpression of CSCs markers CD44, CD24 
and CD29 correlated with the increased growth rate and resistance to radiotherapy in 
head and neck squamous cell carcinoma. AbdulMajeed, Dalley and Farah, (2013) 
considered that increased immunostaining expression of CD24 a potent diagnostic 
marker for detection of oral epithelial dysplasia and OSCC. de Moraes et al., (2017) 
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established a correlation between immunohistochemical overexpression of CSC 
markers CD24, CD44 and CD29 with the poor overall survival outcomes in patients 
with OSCC. Whereas, in our study we could not correlate the co-expression of CD24 
and CD44 with clinicopathological features of selected OSCC samples because of our 
small sample size.  
There are many quantification methods used to assess the immunostaining, ranging 
from manual to automated computer-assisted methods. Manual methods of 
immunohistochemical (IHC) staining assessment are performed with the naked eye 
using light microscopy. This method has drawbacks of high subjectivity and 
variability between individuals leading to errors as well as being time consuming 
(Schüffler et al, 2013). The automated computer-assisted methods are developed 
software programs used to analyse the IHC staining. The scoring of IHC staining 
analysis is calculated on the basis of modern cellular imaging system (Mane, Kale and 
Belaldavar, 2017). Many software programs were developed to use for IHC analysis 
such as:  VORSTAIN (Guillaud et al., 1997), CellProfiler (Carpenter et al., 2006), 
KNIME (Berthold et al., 2007), Vaa3D (Peng et al., 2010), BioImageXD, Icy (de 
Chaumont et al., 2011), AQU Analysis (Klimowicz et al., 2012), ImageJ (Schindelin 
et al., 2012), TMARKER (Schüffler et al., 2013), Multiplex IHC and Multispectral 
Image Analysis (Oguejiofor et al., 2015). However, most of these software are 
expensive and need additional hardware attachments either for capturing images or 
for analysis (Mane, Kale and Belaldavar, 2017). Therefore, we selected ImageJ 
software system to quantify our IHC staining analysis. It is characterised by its simple 
free software, easily installed and run on all operating systems and can be used by 
researcher with minimal computer skills as well as several plugins which are 
additional software components could be installed to increase its applications 
(Schindelin et al., 2012). Furthermore, there is very minimal interobsever variability 
reported during using of ImageJ in IHC marker staining analysis that performed on 
formalin-fixed tissue (Mane, Kale and Belaldavar, 2017). ImageJ has been widely 
used in cancer research to investigate several diagnostic and prognostic markers in 
various cancer types (Kolenda et al., 2011; Hirata et al., 2013; Takemura et al., 2014; 
Okabe et al., 2014; Pietras et al., 2014). In addition, many immunohistochemical 
analysis were conducted in recent oral squamous carcinoma research using ImageJ 
software. For instances: Sun et al (2010) investigated the expression of CD44 and 
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ABGG2 markers in OSCC. Grimm et al (2012) examined the link between the co-
expression of CD44 and ABCB5 with tumour progression and recurrence. 
Spiegelberg et al (2014) investigated CD44 variant expression in head and neck 
squamous cell carcinoma. Sawant et al (2016) investigated the expression of CD44, 
Oct4 and c-Myc prognostic factors in OSCC patients who received radio or 
chemotherapy. Finally, Ghuwalewala et al (2016) analysed the immunohistochemical 
expression of CD24 and CD44 CSCs markers in OSCC samples. 
 
6.6 Conclusions 
We could conclude that the correlation between CSC and fibroblast activation 
markers in vivo suggests that CSCs in vivo induce activation of the tumour stroma in 









































 GENERAL DISCUSSION, 














7.1 General discussion 
The cancer stem cells (CSCs) hypothesis suggests the existence of a small population 
of undifferentiated cells within a tumour, characterised by unique intrinsic features 
such as their ability of self-renewal, unlimited proliferation and driving of 
tumourgenesis (Islam, Qiao, et al., 2015). In addition, they are considered tumour 
initiating cells that have distinct genetic and epigenetic heterogeneity and ability of 
resistance to conventional chemo and radiotherapies leading to relapse of a tumour 
and later initiation of metastasis (Zhou et al., 2009; Frank, Schatton and Frank, 2010; 
Islam, Qiao, et al., 2015). Furthermore, it has been reported in several cancer types 
the existence of a clinical correlation between the aggressive nature of CSCs and 
increasing recurrence and metastasis of tumour as well as the overall poor patient 
outcome (Prince and Ailles, 2008). Therefore, there is an increased demand to find 
effective methods to isolate and identify CSC populations within different tumours 
including the head and neck squamous cell carcinoma in order to thoroughly analyse 
their biological behaviour and develop novel therapies to targeting and eradicate them 
(Zhou et al., 2009; Beck and Blanpin, 2013).  
It has been established that the existence of CSCs (which are immortal) is not limited 
to patient tumour samples, but their presence is also found and persisted under 
different conditions for years and decades in many cancer cell lines derived from a 
wide range of tumour types (Singh et al., 2003; Al Hajj et al., 2003; Kondo, 
Setoguchi and Taga, 2004; Patrawala et al., 2005), including head and neck squamous 
cell carcinoma (Locke et al., 2005; Mackenzie, 2006). Therefore, we used two oral 
cancer cell lines (H357 and SCC4) in our methodology to develop functional 
approaches to isolate and characterise CSCs in oral squamous cell carcinoma.  
Isolation of a purified population of CSCs from tumours still a challenging issue, 
although it is a fundamental aim for most cancer stem cell studies. Many studies have 
been conducted to identify and isolate cancer stem cells from various tumours and 
most of them are dependent on the detection of several stem cell surface markers 
(antigens) using flow cytometry (Vermeulen et al., 2012). In spite of FACS being 
considered the most common approach for CSCs isolation, several drawbacks have 
been reported. For instance, it is costly, good quality antibodies are required and the 
user should be well-trained and highly skilled (Walia and Elble, 2010). In addition, 




there are several technical factors influencing the accuracy of results, such as:  
modifications of the cell phenotype upon antibody binding, subjectivity and 
inconsistencies of gate setting as well as cell preparation (type and concentration of 
the sorting cells) (Li et al., 2005; Igarashi et al., 2008). Chen et al., (2014) reported 
that expression of CSC surface markers does not necessarily reflect the clinical 
manifestations or behaviours of cancer stem cells. Furthermore, several stem cell 
surface markers are expressed by non-CSCs as well as CSCs. Therefore, in our study 
we developed two functional assays to sort CSCs from oral cancer cell lines on the 
basis of two intrinsic characteristic features of CSCs which are the rapid adherence to 
ECM proteins and chemoresistance to conventional chemotherapy agents.    
It is evident that the percentage of CSCs forms approximately 0.1-10% of all tumour 
cells within any tumour or cancer cell line (Deonarain, Kousparou and Epenetos, 
2009). Both functional assays (adhesion and chemoresistance) developed in this study 
robustly and effectively yielded an average number of sorted cells from the both 
examined oral cancer cell lines (H357 and SCC4) of less than 10% of the total number 
of seeded unsorted cells.  
Our study is considered the first study that isolated CSCs using two functional 
approaches and at the same time found a correlation between the two sorted cell 
populations since cells that were rapidly adherent to fibronectin from both examined 
cell lines were more chemoresistant to cisplatin and the chemoresistant cells showed 
enhanced rapid adherence to fibronectin. As a consequence, this significant 
correlation indicates that the two developed functional methods isolated the 
overlapping population of cells and suggests that the two methods sorted a highly 
purified population of CSCs.  
The phenotype of isolated cells from the adhesion assay from the both oral cancer cell 
lines showed a stability and continuation of rapid adherence after incubation in culture 
for 48 hours. At the same time, the phenotype of chemoresistant cells from both oral 
cancer cell lines was stable with increased viability and growth rate following 
exposing to cisplatin treatment for the second time. The stability of CSCs phenotype 
is attributed mainly to tumour phenotypic equilibrium in which the various cell 
populations in a tumour tend to maintain their proportions overtime (Gupta et al., 
2011; Iliopoulos et al., 2011; Zapperi and La Porta, 2012). This study is the first study 




to investigate the stability of sorted early adherent cells phenotype after isolation and 
whilst some studies used other ECM protein (collagen IV) for sorting of CSCs they 
did not examine the stability of the rapid adherent phenotype afterwards (Lia, 2005; 
Ling et al., 2014). However, some previous studies examined the stability of the 
chemoresistant cell phenotype by exposing them to chemotherapeutic drugs again 
following isolation and found that chemoresistant cells continue to be less sensitive 
with high viability (Bertolini et al., 2009; Kim et al., 2012), and the results of our 
study are consistant with them. 
A tumour is defined as heterogenous mass that is composed of a variety of cells which 
vary in their phenotypic and genetic characteristics, such as cellular morphology, 
proliferation rate, metabolism, metastatic potential and gene expression (Islam, 
Gopalan et al., 2015). Therefore in any study, characterisation is considered an 
essential step to confirm the validity of isolated CSCs populations from a tumour. 
Characterisation includes investigating the stem cell characteristics of the sorted cells. 
Benchaouir et al., (2004) reported some stem cell criteria that should be present in any 
sorted cells population to validate them as CSCs. These criteria are: they represent a 
small population within tumour, have the ability of self-renewal and differentiation to 
non-tumourigenic cells as well as possess a distinctive gene profile and cell surface 
antigens. However, CSCs can be identified based on specific molecular, biological 
and functional features. For instance, differential and positive expression of stem cell 
surface markers and mRNA profile as well as functional properties such as colony 
formation, regeneration of tumour in immunodeficient animals, chemoresistance and 
aldehyde dehydrogenase activity (Milne et al., 2009; Lianidou and Markou, 2011; 
Tirino et al., 2012; Podberezin, Wen and Chang, 2012). Therefore in our study, we 
selected both molecular and functional assays for characteristion of the isolated cells 
from both functional methods (early adherent and chemoresistance) that we used in 
chapter (3) to ensure the presence of various ‘stemness’ features in the sorted cells. 
It has been reported that expression of stem cell surface markers remains the most 
common assay for characterising cells with ‘stemness’ proprieties (Shah et al., 2014). 
However, there is no universal marker identifying cancer stem cells and there may be 
tumour type specific variation of some markers. Moreover, it has been recommended 
that a combination of markers be used to get high specificity in characterising CSCs 
from a specific tumour (Karsten and Goletz, 2013). Therefore, we selected multiple 




stem cell surface markers that were commonly reported in head and neck squamous 
cell carcinoma studies as markers for identifying CSCs in OSCC which are CD44, 
CD24 and CD29. Our results showed increased protein and gene expression of all 
these markers by the isolated cells (early adherent and chemoresistant) from both 
investigated oral cancer cell lines (H357 and SCC4). This strong correlation between 
stem associated genes and cell surface proteins of the sorted cells in our study 
indicates that these cells have the same pattern of gene and surface protein expression 
and support their ‘stemness’ characteristics. In addition, in vitro functional assays 
(proliferation and colony forming assays) performed during characterisation of sorted 
cells using the two isolation methods for both cancer cell lines used in this study 
confirmed their ‘stemness’ characteristics as the isolated cells expressed low growth 
rate and high clonegenic potential. Subsequently, the results of the both molecular and 
biological assays conducted for characterisation of the early adherent and 
chemoresistance cells established them as cancer stem cells.  
Our results showed an increased ability of the sorted cells (CSCs) to secrete EVs 
compared to unsorted cells which may suggest a role for EVs as one of mechanisms 
of CSCs communication with other cancer and stromal cells within a tumour. In 
addition, it is might support the role of CSCs as key players in modulation of tumour 
progression.  Several molecules are transferred between various cells in the tumour 
microenvironment by EVs including: mRNA, microRNA, proteins and lipids 
(Hannafon and Ding, 2013). Evidence from the current literature suggests that CSC-
derived EVs are transferred to surrounding stromal and non-cancer cells and may 
have a key role in the modulation of tumour progression (Hannafon and Ding, 2015). 
Gross et al., (2012) and Lin, Wang and Zhao, (2013) established in their studies the 
presence of Wnt protein ligand in exosomes derived from human cancer cell lines that 
induce the Wnt signalling pathway in the recipient cells. In addition, several studies 
report that TGF-β proteins are transferred through cancer cells derived EVs. For 
instance, Cho et al., (2012) and Chowdhury et al., (2015) indicated in their studies 
that TGF-β released from cancer cells derived exosomes induces the TGF-β signalling 
pathway in mesenchymal stem cells with subsequent mediation of their differentiation 
to a myofibroblast like phenotype. Whereas, Webber et al., (2015) showed in their 
study that TGF-β in cancer cell derived exosomes triggered differentiation of 
fibroblasts to myofibroblasts in the prostate tumour microenvironment. Moreover, 




some studies reported the influence of microRNA carried by cancer cell derived 
exosomes. Abd Elmageed et al., (2014) identified several oncogenic microRNAs in 
prostate cancer cell derived exosomes such as miR-155, miR-130b and miR-125b that 
cause reprogramming and transformation of adipose stem cells to CSCs. In addition, 
two studies conducted on prostate CSC revealed that microRNAs expressed in CSC 
derived exosomes significantly enhanced EMT and pre-metastatic niche formation 
and subsequent metastasis compared to that expressed in exosomes released by non-
CSCs (Sánchez et al., 2015; Rana and Malinowska, 2013).  It has been suggested that 
cancer derived EVs play a role in cancer cells escaping from the immune response 
through different mechanisms (Naito et al., 2017). Wieckowski et al., (2009) and 
Szajnik et al., (2010) indicated a role for exosomes released from cancer cells in the 
suppression of anticancer immunity through induction of apoptosis of CD8+ T cell 
and promotion expansion of regulatory T cells. De Vrij et al., (2015) found that 
cancer cell derived EVs enhanced evasion of immunity via induction of differentiation 
of monocytes to immunosuppressive macrophages, while Chow et al., (2014) show in 
their study that EVs modulate anticancer immunity through induction of pro-
inflammatory cytokines such as TNF-α, CCL2 and IL-6 by activation of NF-kB 
signalling following internalization of EVs into macrophages. In addition, literature 
suggests CSC derived exosomes influence cancer progression. Grange et al., (2011) 
found that angiogenesis and premetastatic niche formation were triggered by renal 
CSC derived exosomes. Bourkoula et al., (2014) and Bronisz et al., (2014) reported 
in their studies on glioma CSC that gliomblastoma aggressiveness and invasion were 
promoted by glioma CSC derived EVs. The effects of EV secretion are bidirectional 
in that CSC do not only release EVs but they also receive EVs from other surrounding 
stromal cells in the tumour microenvironment. For example, stromal cells support 
self-renewal of CSC through exosomal signalling (Wu et al., 2014).   
Previous studies have highlighted the pivotal role of cancer associated fibroblast 
(CAFs) in promoting and enhancing of tumour progression. Such cells secrete 
abundant ECM proteins and proteases and many soluble factors such as cytokines and 
growth factors into the tumour stroma. As a result, they stimulate proliferation of 
tumour cells and modulate immune response and resistance to anticancer therapies. In 
addition, they induce angiogenesis, invasion and metastasis (Kalluri and Zeisberg, 
2006; Ishii et al., 2016). Literature reports that the activation of normal fibroblasts 




into CAFs in the tumour microenvironment is induced by signals from tumour cells 
(Elenbaas and Weinberg, 2001; Wever and Mareel, 2003; Kalluri and Zeisberg, 
2006). Moreover, it has been established that the cross-talk between cancer and 
stromal cells in a tumour microenvironment plays a dynamic role in tumour 
progression (Patten et al., 2008; Buggins et al., 2010; Pepper et al., 2011). Orimo and 
Weinberg, (2006) reported that the preferential residence of both CSCs and CAFs at 
the tumour-stroma interface leads to reciprocal support and interaction with each 
other. Therefore, in our study we investigated which population of tumour cells in 
particular activates the stromal fibroblasts into CAFs because of heterogeneity in the 
tumour cells population. Subsequently, we investigated in chapter (5) the effects of 
conditioned media collected from isolated cells (CSCs) on the normal oral fibroblasts. 
We found an intense expression of α-SMA fibres in the immunofluorescence analysis 
by the normal oral fibroblasts that were incubated in conditioned media from the 
CSCs (early adherent and chemoresistant). The resultant CAF phenotype was further 
confirmed by expression of significantly increased levels of CAF-associated genes (α-
SMA and IL-6) that were revealed by qPCR analysis. Therefore, we concluded that 
CSCs in the tumour cell population induce the activation of the stromal fibroblasts 
into CAFs in the tumour microenvironment and as a consequence they drive the 
tumourigenesis process through their cross-talk with CAFs which in turn promote and 
enhance the stromagenesis, tumour growth, invasion and metastasis. Therefore, 
developing approaches to target and block the cross-talk and the communication 
between CSCs and CAFs could be an effective approach in anticancer therapy in the 
future. 
It is well known that solid tumours including head and neck squamous cell carcinoma 
are identified as composite tumours, due to the existence of cancer cells and variety of 
stromal cells such as fibroblasts, inflammatory and endothelial cells within the tumour 
mass. Furthermore, there are dynamic interactions among these cellular elements of a 
tumour (de Vicente et al., 2005).  Due to our findings that showed the influence of 
CSCs conditioned media on the activation of stromal fibroblasts. We examined the in 
vivo correlation of CSC and CAFs in the tumour microenvironment of oral squamous 
cell carcinoma patient samples. This was performed by investigating of the 
immunohistochemical expression of two of most common reported CSC markers of 
head and neck squamous cell carcinoma which are CD24 and C44 and a marker of 




activated fibroblasts (α-SMA). Our results revealed an in vivo positive correlation 
between the immunohistochemical expression of CSC markers (CD24 and CD44) in 
tumour and the CAFs marker (α-SMA) in the stroma which confirms our previous 
finding of in vitro activation of stromal fibroblasts by CSCs. Additionally, it suggests 
a mechanism by which CSC drive tumour progression.  
The high mortality and recurrence rates of oral squamous cell carcinoma as well as 
the increasing importance for its early detection suggests more work is required on the 
basic understanding of disease progression. Our findings suggest the possibility of 
future studies using these CSC markers to develop new diagnostic and prognostic 
biomarkers which could improve the early detection and prevent recurrence of oral 


















7.2 General conclusions 
1. Rapid adhesion to fibronectin and chemoresistance to cisplatin are sensitive 
and effective functional methods to isolate CSC population in oral squamous 
cell carcinoma cell lines. 
2. The increased chemoresistance of early adherent cells and the increased 
adherence of cisplatin-resistant cells suggest that these two methods are 
isolating phenotypically overlapping highly purified populations of CSCs.  
3. The isolated phenotype (early adherent and/or chemoresistant) was stable at 
least 48 hours after isolation. 
4. The sorted cells by the two functional methods (early adhesion and 
chemoresistance) from the both examined oral cancer cell lines exhibited 
molecular and functional CSC-like characteristics. 
5. CSCs (early adherent and chemoresistance) secreted enhanced levels of EVs 
compared to other unsorted cancer cells. 
6. Normal oral fibroblasts (NOFs) are activated into CAFs by the factors released 
from isolated stem cells (early adherent and/or chemoresistant). 
7. As there is a positive correlation between CSC and activated fibroblasts in 
vivo, CSCs may drive tumourigenesis through the activation of stromal 


















7.3  Future perspectives 
1. Many studies report that xenotransplantation is the gold standard assay for 
charactering of CSCs (Tirino et al., 2012; Dobbin and Landen, 2014). 
Therefore, it would be important to investigate the tumourigenic potential of 
the isolated cells in vivo and examine their ability to initiate and generate 
tumours in immunodeficient animals. This could be performed through 
xenotransplantation after sorting CSCs using our developed functional methods 
(early adhesion and chemoresistance). Four groups of immunodeficient mice 
would be investigated for each oral cancer cell line. The first group would be 
injected with fresh early adherent cells after their isolation by adhesion assay 
from unsorted cells. The second group would be injected with chemoresistant 
cells following treating of the unsorted cells with 15µM cisplatin for 24 hours 
and after that the treatment is washed and incubated for 5 days with fresh 
growth medium. Whereas, the third group of mice are injected with isolated 
cells using both functional methods sequentially to increase the probability of 
getting high purified population of sorted CSCs. Therefore, the unsorted cells 
from both tested oral cancer cell lines are isolated firstly by rapid adherence to 
fibronectin 75µg/mL for 10 minutes. Then the early adherent cells are treated 
with cisplatin 15µM for 24 hours, then the drug is washed away with PBS and 
fresh growth medium is added for 5 days (the recovery period). Afterwards, the 
viable chemoresistant cells would be injected in immunodeficient mice. The 
last group of mice would be injected with unsorted cells. 
2. Since we found in our study that CSC drive the tumourgeniesis through 
activation of stromal fibroblasts. It would be useful to investigate other 
mechanisms by which these sorted CSCs could affect the tumourgenesis and 
cancer progression, such as the influence of CSCs on induction of EMT and 
acquiring an invasive phenotype in the other tumour cells. This could be 
studied by incubating unsorted cancer cells for 48 hours in the conditioned 
media collected from sorted cells (early adherent and chemoresistant) after 
their isolation. Then, the levels of EMT genes in the cancer cells incubated in 
conditioned media could be measured using qPCR analysis and compared with 
the levels of these genes in the cancer cells incubated in their normal growth 
media or in the conditioned media from unsorted cells. 




3. It has been established that several soluble growth factors and cytokines induce 
activation of normal fibroblasts into CAFs such as, TGF-β, IL-6, VEGF, FGF, 
HGF, PDGF and SDF-1 (Kalluri and Zeisberg, 2006; Molloy et al., 2009; Qian 
et al., 2012). Therefore, it would be interesting to analyse the conditioned 
media of the isolated CSCs (early adherent and chemoresistant) to identify the 
specific proteins secreted from these cells which initiate activation of normal 
oral fibroblasts into CAFs. This could be conducted by analysing the collected 
conditioned media from the isolated CSCs using enzyme-linked 
immunosorbent assays (ELISA). Many reports suggest that TGF-β is the key 
factor in activation of normal fibroblasts to CAFs. Therefore, we could detect 
TGF-β in the conditioned media using ELISA and confirm its effect by using a 
specific inhibitor to block its effects. Similarly, we could use the same method 
to identify other specific molecules in cell secretion using ELISA or western 
blotting and use specific inhibitor to block their effects for confirmation of their 
role. 
4. Our findings showed that isolated CSCs secreted high levels of EVs compare to 
unsorted cells. Therefore, it would be interesting to investigate if there is a role 
for secreted EVs in conditioned medium of isolated CSCs on activation of 
NOFs and what is their cargo. This could be performed through firstly isolation 
of the EVs from the conditioned medium of both isolated cells (early adherent 
and/ or chemoresistant) and unsorted cells using ultracentrifugation and then 
add them back to the fibroblast activation assay (in SFM) to confirm is it is the 
EVs having the effect. The proteins from the EVs could also be extracted and 
either the whole protein profile examined using proteomics or specific proteins 
levels investigated using western blotting. Nucleic acids could be analysed 
using sequencing or again specific micro RNAs could be analysed using qPCR. 
5. It would be valuable to increase the number of oral squamous cell carcinoma 
patient cases in the studies of the immunohistochemical expression of CSC and 
stromal markers in order to allow for further correlations of their expression 
with different clinicopathological conditions. Furthermore, it is worthwhile to 
investigate the degree of significance of the correlation between CSC and 
activated stroma in oral dysplasia and in various stages of differentiation of oral 
squamous cell carcinoma (from well to poor differentiated). As a consequence, 




it would allow for future developing of new diagnostic and prognostic 
biomarkers for oral squamous cell carcinoma. 
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